import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

# åˆå§‹åŒ– session_state ç”¨æ–¼è¯å‹•èˆ‡æŒä¹…åŒ–
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = "ğŸ“š RUBY (ENGOT-EN6)"

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === UI é«˜å°æ¯”åº¦èˆ‡è¦–è¦ºæ•‘æ´ === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F4F7F9; color: #1A1A1A;
        font-size: 19px !important; line-height: 1.1;
    }

    .main-title {
        font-size: 34px !important; font-weight: 900; color: #004D40;
        padding: 10px 0; border-bottom: 4px solid #4DB6AC; margin-bottom: 10px;
    }

    /* åœ–ä¸€ä¿®å¾©ï¼šå¤§éšæ®µ Header é£½å’Œæ¼¸å±¤èƒŒæ™¯ï¼Œç¢ºä¿ç™½è‰²æ–‡å­—æ¸…æ™° */
    .big-stage-card {
        border-radius: 12px; padding: 0px; box-shadow: 0 6px 25px rgba(0,0,0,0.15);
        border: 2.5px solid transparent; background: white; margin-bottom: 8px; overflow: hidden; height: auto !important;
    }
    .big-stage-header {
        font-size: 20px !important; font-weight: 900; color: white !important;
        padding: 14px; text-align: center; text-shadow: 1px 1px 3px rgba(0,0,0,0.5);
    }

    /* éšæ®µé…è‰²é£½å’ŒåŒ– */
    .card-p-tx { border-color: #1B5E20; }
    .header-p-tx { background: linear-gradient(135deg, #2E7D32, #1B5E20); } /* åˆæ²»: æ·±ç¶  */
    .card-p-mt { border-color: #0D47A1; }
    .header-p-mt { background: linear-gradient(135deg, #1565C0, #0D47A1); } /* ç¶­æŒ: æ·±è— */
    .card-r-tx { border-color: #BF360C; }
    .header-r-tx { background: linear-gradient(135deg, #E65100, #BF360C); } /* å¾©ç™¼: æ·±æ©˜ç´… */
    .card-r-mt { border-color: #4A148C; }
    .header-r-mt { background: linear-gradient(135deg, #6A1B9A, #4A148C); } /* å¾©å¾Œç¶­æŒ: æ·±ç´« */

    .sub-block {
        margin: 4px 8px; padding: 8px; border-radius: 10px; 
        background: #F8F9FA; border-left: 6px solid #455A64;
    }
    .sub-block-title {
        font-size: 16px; font-weight: 900; color: #263238;
        margin-bottom: 2px; border-bottom: 1.2px solid #CFD8DC; padding-bottom: 2px;
    }

    /* æŒ‰éˆ•æ¨£å¼ï¼šæ·±é»‘è‰²åŠ ç²— (#1A1A1A) */
    .stPopover button { 
        font-weight: 900 !important; font-size: 12px !important; 
        border-radius: 6px !important; margin-top: 3px !important;
        padding: 4px 10px !important; width: 100% !important; 
        text-align: left !important; color: #1A1A1A !important; 
        border: 1.5px solid rgba(0,0,0,0.2) !important;
        box-shadow: 0 2px 5px rgba(0,0,0,0.1) !important;
    }
    
    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 6px solid #455A64 !important; }
    .stPopover button[aria-label*="ğŸ“"] { background: #E1F5FE !important; border-left: 6px solid #0288D1 !important; } 

    .detail-section { background: white; border-radius: 24px; padding: 35px; border: 1.5px solid #CFD8DC; box-shadow: 0 15px 50px rgba(0,0,0,0.1); }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 34px !important; font-weight: 900; color: #D84315; }
    .regimen-box { background: #F1F8E9; border-left: 6px solid #689F38; padding: 15px; border-radius: 8px; font-size: 15px; margin: 10px 0; line-height: 1.4; }
    .results-box { background: #FFF8E1; border: 1px solid #FFE082; padding: 10px; border-radius: 8px; margin-top: 5px; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•æ•¸æ“šåº«ï¼šåˆ†å‹ã€éšæ®µèˆ‡è·¨çµ„å°èˆª ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "dMMR / MSI-H / MMRd", "content": "ä¸€ç·šé¦–é¸ï¼šå«é‰‘åŒ–ç™‚ + PD-1 (RUBY/GY018/AtTEnd)ã€‚"},
            {"title": "pMMR / NSMP / MSS", "content": "ä¸€ç·šç¶­æŒï¼šChemo + Durva/Ola (DUO-E)ã€‚äºŒç·šæ¨™é¶å…ç–« (KN775)ã€‚"},
            {"title": "POLE mutation (è¶…çªè®Šå‹)", "content": "é å¾Œæ¥µä½³ã€‚æ—©æœŸå¯è€ƒæ…®æ²»ç™‚é™éš (De-escalation)ã€‚"},
            {"title": "p53 mutation (é«˜æ‹·è²å‹)", "content": "ä¾µè¥²æ€§æœ€å¼·ã€‚å»ºè­°åŒ–æ”¾ç™‚ç©æ¥µä»‹å…¥ã€‚Serous å‹éœ€æª¢æ¸¬ HER2ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance Therapy", "content": "ä¸€ç·š IO æ²»ç™‚å¾Œå»¶çºŒç¶­æŒè‡³ PD (MK2870-033/DUO-E)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "æ¨™æº–äºŒç·šï¼šæ¨™é¶+å…ç–« (KN775) æˆ–å–®è—¥ IO (GARNET)ã€‚æ•‘æ´ ADC (SG)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "æ•‘æ´æ²»ç™‚å¾Œç¶­æŒç•¶å‰æœ‰æ•ˆæ–¹æ¡ˆç›´åˆ°ç–¾ç—…é€²å±•ã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Neoadjuvant Setting", "content": "NAC + IDS + HIPEC (van Driel)ã€‚"},
            {"title": "DDCT Setting", "content": "Dose-Dense Chemotherapyã€‚"},
            {"title": "IP Setting", "content": "NAC-IDS/PDS + IP chemoã€‚"},
            {"title": "HGSC / Endometrioid", "content": "æ‰‹è¡“ (PDS/IDS) + Carbo/Pacli Â± Bevã€‚"},
            {"title": "Clear Cell Carcinoma", "content": "OCCCã€‚"},
            {"title": "Low grade serous carcinoma", "content": "AI, MEK, CDK 4/6"},
            {"title": "Mucinous (MOC) é‘‘å®š", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚IA æœŸå¯ä¿å®ˆã€‚ä¾µè¥²å‹å»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutation", "content": "Olaparib å–®è—¥ç¶­æŒ 2å¹´ (SOLO-1)ã€‚"}, 
            {"title": "HRD positive (wt)", "content": "PAOLA-1 (Ola+Bev) æˆ– PRIMA (Nira)ã€‚"},
            {"title": "HRD negative (pHRD)", "content": "Niraparib ç¶­æŒ (PRIMA ITT) æˆ– Bevacizumabã€‚"},
            {"title": "Clear Cell Carcinoma", "content": "OCCCã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (Sensitive Recur)", "content": "PFI > 6mã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ (DESKTOP III) æˆ–å«é‰‘è¤‡æ–¹ã€‚"},
            {"title": "PROC (Resistant Recur)", "content": "PFI < 6mã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL)ã€‚"},
            {"title": "Low grade serous carcinoma", "content": "AI, MEK, CDK 4/6"},
            {"title": "Clear Cell Carcinoma", "content": "OCCCã€‚"},
            {"title": "Mucinous (MOC) é‘‘å®š", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚IA æœŸå¯ä¿å®ˆã€‚ä¾µè¥²å‹å»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [
            {"title": "PARPi Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒç”¨ PARPi (NOVA/ARIEL3/SOLO2)ã€‚"},
            {"title": "ADC/other Maint", "content": "å…¶ä»–è—¥ç‰©ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Locally Advanced (CCRT)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ Â± åŒæ­¥ IO (A18) æˆ– èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},
            {"title": "Locally Advanced (NIC)", "content": "MIC then Surgeryã€‚"},
            {"title": "Early Stage (Surgery)", "content": "æ ¹æ²»è¡“ (LACC) æˆ–å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "1L æ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒ (KEYNOTE-826)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurr / Metastatic", "content": "ä¸€ç·š KN826/BEATccã€‚äºŒç·š ADC (innovaTV 301) æˆ– IO (EMPOWER)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³ PDã€‚"}]}
    ],
    "Uterine Sarcoma": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "Primary Sarcoma", "content": "è¡“å¾Œè¼”åŠ©æˆ–è½‰ç§»æ€§ä¸å¯åˆ‡é™¤ã€‚"},
            {"title": "Carcinosarcoma", "content": "ç™Œè‚‰ç˜¤ã€‚"},
            {"title": "Low grade ESS", "content": "LGESS"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Maintenance", "content": "1L æ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurr / Metastatic", "content": "å¾©ç™¼æ²»ç™‚ã€‚"},
            {"title": "Carcinosarcoma", "content": "ç™Œè‚‰ç˜¤ã€‚"},
            {"title": "Low grade ESS", "content": "LGESS"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³ PDã€‚"}]}
    ],
}

# --- 2. å¯¦è­‰è³‡æ–™åº« (33 é …è©¦é©—å…¨é‡æ•¸æ“šæ¥µé‡åŒ–è£œå®Œ) ---
all_trials_db = [
    # ==========================
    # === Endometrial Published ===
    # ==========================
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š RUBY (ENGOT-EN6/GOG-3031)", "pharma": "GSK", "drug": "Dostarlimab + Carboplatin/Paclitaxel", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒdMMR/MSSï¼ˆpMMRï¼‰çš†é¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.28ï¼›å…¨é«”ï¼šHR 0.64ï¼‰ï¼Œä¸”æ›´æ–°åˆ†æé¡¯ç¤ºOSäº¦æ”¹å–„ï¼ˆdMMRï¼šHR 0.32ï¼›å…¨é«”ï¼šHR 0.69ï¼‰ï¼Œå¥ å®šä¸€ç·šã€Œå…ç–«ï¼‹åŒ–ç™‚ã€æ–°æ¨™æº–ã€‚",
     "rationale": "PD-1 é˜»æ–· (PD-1 blockade) èˆ‡å«é‰‘åŒ–ç™‚ (Carbo/Pacli) å…·å‚™å”åŒå…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ã€‚è—‰ç”±åŒ–ç™‚èª˜å°è…«ç˜¤æŠ—åŸé‡‹æ”¾ï¼Œé‡‹æ”¾å…ç–«å¾®ç’°å¢ƒå£“åŠ›ä¸¦é‡å° MMRd æ—ç¾¤é”æˆæ¥µé«˜æŒä¹…æ‡‰ç­”ç‡ã€‚",
     "regimen": "Arm 1 (Dostarlimab çµ„): èª˜å°æœŸ: Dostarlimab 500mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸï¼›ç¶­æŒæœŸ: Dostarlimab 1000mg Q6W (æŒçºŒ 3å¹´)ã€‚ Arm 2 (Placebo çµ„): ç”Ÿç†é¹½æ°´å°ç…§ + åŒåŠ‘é‡ CP åŒ–ç™‚ x6 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æˆ–é¦–æ¬¡å¾©ç™¼ä¹‹å­å®®å…§è†œç™Œ (EC)ã€‚", "ECOG 0-1ã€‚", "å« Carcinosarcoma / Clear cell / Serous ç­‰çµ„ç¹”å‹æ…‹ã€‚"],
     "exclusion": ["æ—¢å¾€æ¥å— PD-1/PD-L1 æ²»ç™‚ã€‚", "æ´»å‹•æ€§/éœ€ç³»çµ±æ€§æ²»ç™‚ä¹‹è‡ªé«”å…ç–«ç–¾ç—…ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "è‡¨åºŠä¸Šé¡¯è‘— CNS è½‰ç§»ç­‰ã€‚"],
     "outcomes": "dMMR æ—ç¾¤ 24å€‹æœˆ PFS ç‡: 61.4% vs 15.7% (HR 0.28, 95% CI 0.16-0.50); ITT å…¨äººç¾¤ mOS HR 0.64 (95% CI 0.46-0.87, P=0.0021)ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š RUBY (ENGOT-EN6/GOG-3031)", "pharma": "GSK", "drug": "Dostarlimab + Carboplatin/Paclitaxel", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒdMMR/MSSï¼ˆpMMRï¼‰çš†é¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.28ï¼›å…¨é«”ï¼šHR 0.64ï¼‰ï¼Œä¸”æ›´æ–°åˆ†æé¡¯ç¤ºOSäº¦æ”¹å–„ï¼ˆdMMRï¼šHR 0.32ï¼›å…¨é«”ï¼šHR 0.69ï¼‰ï¼Œå¥ å®šä¸€ç·šã€Œå…ç–«ï¼‹åŒ–ç™‚ã€æ–°æ¨™æº–ã€‚",
     "rationale": "PD-1 é˜»æ–· (PD-1 blockade) èˆ‡å«é‰‘åŒ–ç™‚ (Carbo/Pacli) å…·å‚™å”åŒå…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ã€‚è—‰ç”±åŒ–ç™‚èª˜å°è…«ç˜¤æŠ—åŸé‡‹æ”¾ï¼Œé‡‹æ”¾å…ç–«å¾®ç’°å¢ƒå£“åŠ›ä¸¦é‡å° MMRd æ—ç¾¤é”æˆæ¥µé«˜æŒä¹…æ‡‰ç­”ç‡ã€‚",
     "regimen": "Arm 1 (Dostarlimab çµ„): èª˜å°æœŸ: Dostarlimab 500mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸï¼›ç¶­æŒæœŸ: Dostarlimab 1000mg Q6W (æŒçºŒ 3å¹´)ã€‚ Arm 2 (Placebo çµ„): ç”Ÿç†é¹½æ°´å°ç…§ + åŒåŠ‘é‡ CP åŒ–ç™‚ x6 é€±æœŸã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æˆ–é¦–æ¬¡å¾©ç™¼ä¹‹å­å®®å…§è†œç™Œ (EC)ã€‚", "ECOG 0-1ã€‚", "å« Carcinosarcoma / Clear cell / Serous ç­‰çµ„ç¹”å‹æ…‹ã€‚"],
     "exclusion": ["æ—¢å¾€æ¥å— PD-1/PD-L1 æ²»ç™‚ã€‚", "æ´»å‹•æ€§/éœ€ç³»çµ±æ€§æ²»ç™‚ä¹‹è‡ªé«”å…ç–«ç–¾ç—…ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "è‡¨åºŠä¸Šé¡¯è‘— CNS è½‰ç§»ç­‰ã€‚"],
     "outcomes": "dMMR æ—ç¾¤ 24å€‹æœˆ PFS ç‡: 61.4% vs 15.7% (HR 0.28, 95% CI 0.16-0.50); ITT å…¨äººç¾¤ mOS HR 0.64 (95% CI 0.46-0.87, P=0.0021)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd", "pMMR / NSMP / MSS"], "name": "ğŸ“š NRG-GY018 (KEYNOTE-868)", "pharma": "MSD", "drug": "Pembrolizumab + Carboplatin/Paclitaxel", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒPembrolizumabï¼‹åŒ–ç™‚åœ¨ä¸€ç·šé¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.30ï¼›pMMRï¼šHR 0.54ï¼‰ï¼Œæ˜¯å¦ä¸€å€‹æ”¹è®Šè‡¨åºŠå¯¦å‹™çš„ä¸€ç·šå…ç–«ï¼‹åŒ–ç™‚é—œéµè©¦é©—ã€‚",
     "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) é‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼ŒPembrolizumab å¼·åŒ–ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„æŒä¹…æ€§ã€‚",
     "regimen": "Arm A: Pembrolizumab 200mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸ -> ç¶­æŒæœŸ: Pembrolizumab 400mg Q6W (æŒçºŒ 2å¹´)ã€‚ Arm B: Placebo + CP x6 é€±æœŸã€‚",
     "inclusion": ["Stage III/IV æˆ–å¾©ç™¼ ECã€‚", "æä¾› MMR æª¢æ¸¬ (IHC) å ±å‘Šï¼Œåˆ†ç‚º dMMR vs pMMR å…©å€‹ä¸»è¦åˆ†æ cohortã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["æ—¢å¾€ antiâ€“PD-(L)1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§åˆ¶å…±ç—…ï¼ˆæ„ŸæŸ“/å¿ƒè¡€ç®¡ç­‰ï¼‰ã€‚", "CNS æ´»å‹•æ€§ç—…ç¶ç­‰ã€‚"],
     "outcomes": "dMMR PFS HR 0.30 (95% CI 0.19-0.48); pMMR PFS HR 0.54 (95% CI 0.41-0.71, P<0.001)ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š NRG-GY018 (KEYNOTE-868)", "pharma": "MSD", "drug": "Pembrolizumab + Carboplatin/Paclitaxel", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒPembrolizumabï¼‹åŒ–ç™‚åœ¨ä¸€ç·šé¡¯è‘—å»¶é•·PFSï¼ˆdMMRï¼šHR 0.30ï¼›pMMRï¼šHR 0.54ï¼‰ï¼Œæ˜¯å¦ä¸€å€‹æ”¹è®Šè‡¨åºŠå¯¦å‹™çš„ä¸€ç·šå…ç–«ï¼‹åŒ–ç™‚é—œéµè©¦é©—ã€‚",
     "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) é‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼ŒPembrolizumab å¼·åŒ–ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„æŒä¹…æ€§ã€‚",
     "regimen": "Arm A: Pembrolizumab 200mg Q3W + Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) x6 é€±æœŸ -> ç¶­æŒæœŸ: Pembrolizumab 400mg Q6W (æŒçºŒ 2å¹´)ã€‚ Arm B: Placebo + CP x6 é€±æœŸã€‚",
     "inclusion": ["Stage III/IV æˆ–å¾©ç™¼ ECã€‚", "æä¾› MMR æª¢æ¸¬ (IHC) å ±å‘Šï¼Œåˆ†ç‚º dMMR vs pMMR å…©å€‹ä¸»è¦åˆ†æ cohortã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["æ—¢å¾€ antiâ€“PD-(L)1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§åˆ¶å…±ç—…ï¼ˆæ„ŸæŸ“/å¿ƒè¡€ç®¡ç­‰ï¼‰ã€‚", "CNS æ´»å‹•æ€§ç—…ç¶ç­‰ã€‚"],
     "outcomes": "dMMR PFS HR 0.30 (95% CI 0.19-0.48); pMMR PFS HR 0.54 (95% CI 0.41-0.71, P<0.001)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["pMMR / NSMP / MSS"], "name": "ğŸ“š DUO-E (ENGOT-EN9)", "pharma": "AZ", "drug": "Durvalumab + CP â†’ç¶­æŒ Â± Olaparib", 
     "pop_results": "ä¸€ç·šæ²»ç™‚ä¸­ï¼ŒDurvalumabï¼‹åŒ–ç™‚å¯æ”¹å–„PFSï¼ˆHR 0.71ï¼‰ï¼Œè€Œã€ŒDurvalumabï¼‹åŒ–ç™‚â†’ç¶­æŒåŠ ä¸ŠOlaparibã€æ•ˆç›Šæ›´å¤§ï¼ˆPFS HR 0.55ï¼‰ï¼›pMMRäº¦æœ‰PFSç²ç›Šï¼ˆDurva+Ola vs controlï¼šHR 0.57ï¼‰ï¼Œä¸”OSæœŸä¸­åˆ†ææ”¯æŒï¼ˆDurva+Ola vs controlï¼šHR 0.59ï¼‰ï¼Œä¸‰è—¥çµ„ pMMR PFS HR 0.57 (vs CP)",
     "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘ (PARPi) èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µçš„å”åŒæ•ˆæœï¼ŒPARPi èª˜å°çš„ DNA æå‚·å¯å¢åŠ æ–°æŠ—åŸè² è·ï¼Œå¼·åŒ–å…ç–«æ‡‰ç­”ã€‚",
     "regimen": "Arm 1: carboplatin/paclitaxel + placebo â†’ placebo maintenance åƒ…åŒ–ç™‚ (å°ç…§çµ„); Arm 2: CP+Durvalumab -> Durva 1500mg Q4W ç¶­æŒ; Arm 3: CP+Durvalumab -> Durva 1500mg Q4W + Olaparib 300mg bid ç¶­æŒç›´åˆ°ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["newly diagnosed advanced æˆ– recurrent endometrial cancerã€‚", "é©åˆ CPã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ / PARP inhibitorã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "å…¶ä»–ç ”ç©¶è€…åˆ¤å®šä¸é©åˆç­‰ã€‚"],
     "outcomes": ["pMMR Arm 3 (Ola+Durva) vs Arm 1: PFS HR 0.57 (95% CI 0.42-0.79); dMMR Arm 2 vs Arm 1: HR 0.42 (95% CI 0.22-0.80)ã€‚", 
                  "PFSï¼šdurvalumab vs control HR 0.71ï¼›durvalumab+olaparib vs control HR 0.55ã€‚", 
                  "AEï¼ˆè‡¨åºŠé‡é»ï¼‰ï¼šåŠ ä¸Š olaparib å¾Œï¼Œéœ€ç‰¹åˆ¥æ³¨æ„ è²§è¡€/è¡€çƒä¸‹é™ã€ç–²å€¦ ç­‰ PARP å…¸å‹æ¯’æ€§ç–ŠåŠ ã€‚"]},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd"], "name": "ğŸ“š AtTEnd (ENGOT-EN7)", "pharma": "Roche", "drug": "Atezolizumab + CP", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒAtezolizumabï¼‹åŒ–ç™‚åœ¨dMMRæ—ç¾¤PFSé¡¯è‘—æ”¹å–„ï¼ˆHR 0.36ï¼‰ï¼Œè¨Šæ¯é‡é»æ˜¯ã€Œæ•ˆç›Šä¸»è¦é›†ä¸­åœ¨dMMRã€ï¼ŒpMMRæ•´é«”æ•ˆç›Šç›¸å°ä¸æ˜é¡¯ï¼ŒdMMR PFS HR 0.36; ITT OS HR 0.82",
     "rationale": "é©—è­‰ä¸€ç·š PD-L1 æŠ‘åˆ¶åŠ‘ä½µç”¨åŒ–ç™‚å°æ™šæœŸæˆ–å¾©ç™¼æ‚£è€…ä¹‹ç”Ÿå­˜å„ªå‹¢ã€‚",
     "regimen": "Arm A: Atezolizumab 1200mg Q3W + CP x6-8 é€±æœŸ -> ç¶­æŒ Atezolizumab 1200mg Q3Wã€‚ Arm B: Placebo + CP x6-8 é€±æœŸã€‚",
     "inclusion": ["advanced æˆ– recurrent endometrial carcinomaã€‚", "ä¸€ç·šæ¥å— CPã€‚", "è©•ä¼° dMMR äºç¾¤ç²ç›Šã€‚"],
     "exclusion": ["æ—¢å¾€ PD-(L)1 æŠ‘åˆ¶åŠ‘ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "å…¶ä»–ç ”ç©¶è€…åˆ¤å®šä¸é©åˆç­‰ã€‚"],
     "outcomes": "dMMR PFS: æœªé”åˆ° vs 6.9m (HR 0.36, 95% CI 0.23-0.57); å…¨äººç¾¤ mOS HR 0.82 (P=0.048)ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š AtTEnd (ENGOT-EN7)", "pharma": "Roche", "drug": "Atezolizumab + CP", 
     "pop_results": "æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼è€…ï¼ŒAtezolizumabï¼‹åŒ–ç™‚åœ¨dMMRæ—ç¾¤PFSé¡¯è‘—æ”¹å–„ï¼ˆHR 0.36ï¼‰ï¼Œè¨Šæ¯é‡é»æ˜¯ã€Œæ•ˆç›Šä¸»è¦é›†ä¸­åœ¨dMMRã€ï¼ŒpMMRæ•´é«”æ•ˆç›Šç›¸å°ä¸æ˜é¡¯ï¼ŒdMMR PFS HR 0.36; ITT OS HR 0.82",
     "rationale": "é©—è­‰ä¸€ç·š PD-L1 æŠ‘åˆ¶åŠ‘ä½µç”¨åŒ–ç™‚å°æ™šæœŸæˆ–å¾©ç™¼æ‚£è€…ä¹‹ç”Ÿå­˜å„ªå‹¢ã€‚",
     "regimen": "Arm A: Atezolizumab 1200mg Q3W + CP x6-8 é€±æœŸ -> ç¶­æŒ Atezolizumab 1200mg Q3Wã€‚ Arm B: Placebo + CP x6-8 é€±æœŸã€‚",
     "inclusion": ["advanced æˆ– recurrent endometrial carcinomaã€‚", "ä¸€ç·šæ¥å— CPã€‚", "è©•ä¼° dMMR äºç¾¤ç²ç›Šã€‚"],
     "exclusion": ["æ—¢å¾€ PD-(L)1 æŠ‘åˆ¶åŠ‘ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶æ„ŸæŸ“ã€‚", "å…¶ä»–ç ”ç©¶è€…åˆ¤å®šä¸é©åˆç­‰ã€‚"],
     "outcomes": "dMMR PFS: æœªé”åˆ° vs 6.9m (HR 0.36, 95% CI 0.23-0.57); å…¨äººç¾¤ mOS HR 0.82 (P=0.048)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["p53 mutation (é«˜æ‹·è²å‹)", "pMMR / NSMP / MSS", "dMMR / MSI-H / MMRd"], 
        "name": "ğŸ“š KEYNOTE-B21 (ENGOT-en11)", "pharma": "MSD", "drug": "Pembrolizumab + Chemo Â± RT", 
        "pop_results": "é«˜é¢¨éšªè¼”åŠ©æ²»ç™‚æŒ‘æˆ°ï¼šæ‰‹è¡“æ¸…å®Œå¾Œè¼”åŠ©åŒ–ç™‚ï¼ˆÂ±æ”¾ç™‚ï¼‰ä¸­åŠ å…¥ Pembrolizumab ä¸¦æœªé¡¯è‘—æ”¹å–„ DFS (HR 1.02)ï¼Œç›®å‰ä¸å»ºè­°å¸¸è¦åŠ å…¥ã€‚",
        "rationale": "æ—¨åœ¨é©—è­‰å°æ–¼é«˜é¢¨éšªã€å·²æ‰‹è¡“åˆ‡é™¤çš„æ–°è¨ºæ–· EC æ‚£è€…ï¼Œåœ¨æ¨™æº–è¼”åŠ©åŒ–ç™‚åŸºç¤ä¸ŠåŠ ä¸Šå…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘æ˜¯å¦èƒ½é€²ä¸€æ­¥é™ä½å¾©ç™¼é¢¨éšªã€‚",
        "regimen": "è©¦é©—çµ„: Pembrolizumab (200mg Q3W x6 é€±æœŸ) ä½µç”¨åŒ–ç™‚ (CP) Â± æ”¾å°„æ²»ç™‚ï¼Œéš¨å¾Œ Pembrolizumab (400mg Q6W) ç¶­æŒè‡³ 14 é€±æœŸã€‚",
        "inclusion": [
            "æ–°è¨ºæ–·ã€é«˜é¢¨éšªä¸”å·²å®Œå…¨åˆ‡é™¤ä¹‹å­å®®å…§è†œç™Œ",
            "FIGO 2009 Stage I/II (Serous æˆ– Clear cell) æˆ– Stage III/IV (å·²åˆ‡é™¤è€…)",
            "ECOG 0-1"],
        "exclusion": [
            "å…ˆå‰å—éé‡å°æ­¤ç™Œç—‡ä¹‹å…¨èº«æ€§æ²»ç™‚",
            "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…",
            "å…·æœ‰å¤šç™¼æ€§åŸç™¼ç™Œç—‡ç—…å²"],
        "outcomes": "2yr DFS Rate: 75.2% (Pembro) vs 74.2% (Placebo); HR 1.02 (95% CI 0.79-1.32), P=0.57 (æœªé”é¡¯è‘—å·®ç•°)ã€‚"},
    
    {"cancer": "Endometrial", 
    "pos": "P-MT", 
    "sub_pos": ["Maintenance Therapy"], 
    "name": "ğŸ“š DUO-E (Maint)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab Â± Olaparib",
    "pop_results": "ä¸€ç·šæ²»ç™‚ä¸­ï¼ŒDurvalumabï¼‹åŒ–ç™‚å¯æ”¹å–„PFSï¼ˆHR 0.71ï¼‰ï¼Œè€Œã€ŒDurvalumabï¼‹åŒ–ç™‚â†’ç¶­æŒåŠ ä¸ŠOlaparibã€æ•ˆç›Šæ›´å¤§ï¼ˆPFS HR 0.55ï¼‰ï¼›pMMRäº¦æœ‰PFSç²ç›Šï¼ˆDurva+Ola vs controlï¼šHR 0.57ï¼‰ï¼Œä¸”OSæœŸä¸­åˆ†ææ”¯æŒï¼ˆDurva+Ola vs controlï¼šHR 0.59ï¼‰",
    "rationale": "æ¢ç´¢ PARP æŠ‘åˆ¶åŠ‘èˆ‡ PD-L1 æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µå° pMMR æ‚£è€…çš„å”åŒå¢æ•æ•ˆæ‡‰ã€‚",
    "regimen": "Arm 2: Durvalumab 1500mg Q4W ç¶­æŒ; Arm 3: Durvalumab + Olaparib 300mg bid ç¶­æŒã€‚",
    "inclusion": ["ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé” CR/PR ä¹‹æ™šæœŸ ECã€‚", "æä¾› MMR IHC ç‹€æ…‹ã€‚"],
    "exclusion": ["å…ˆå‰æ¥å—éç³»çµ±æ€§ IO æ²»ç™‚ã€‚"],
    "outcomes": "pMMR ä¸‰è—¥çµ„ (Ola+Durva) PFS HR 0.57 (95% CI 0.42-0.79)ã€‚"},

{"cancer": "Endometrial", 
        "pos": "P-MT", 
        "sub_pos": ["Maintenance Therapy"], 
        "name": "ğŸ“š SIENDO (ENGOT-EN5/GOG-3055)", 
        "pharma": "Karyopharm", 
        "drug": "Selinexor", 
        "pop_results": "TP53 wild-type æ—ç¾¤ç²ç›Šæ¥µä½³ï¼šç¶­æŒæ²»ç™‚é¡¯è‘—å»¶é•· PFS é” 5 å€ä»¥ä¸Š (27.4m vs 5.2m, HR 0.41)ã€‚",
        "rationale": "åˆ©ç”¨ XPO1 æŠ‘åˆ¶åŠ‘ Selinexor åœ¨ TP53 wild-type æ‚£è€…ä¸­èª˜å°ç´°èƒæ ¸å…§æŠ‘ç™Œè›‹ç™½è“„ç©ï¼Œé€²è€Œå¼•ç™¼è…«ç˜¤ç´°èƒå‡‹äº¡ã€‚",
        "regimen": "Selinexor 80 mg æ¯é€±å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ä¹‹æ¯’æ€§ã€‚",
        "inclusion": [
            "å®Œæˆä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé” CR æˆ– PR ä¹‹æ™šæœŸ/å¾©ç™¼æ€§å­å®®å…§è†œç™Œ",
            "ECOG 0-1",
            "éœ€æä¾›çµ„ç¹”å­¸æ¨£æœ¬é€²è¡Œ p53 ç‹€æ…‹åˆ¤å®š"],
        "exclusion": [
            "å…ˆå‰æ¥å—é XPO1 æŠ‘åˆ¶åŠ‘æ²»ç™‚",
            "æ´»å‹•æ€§è…¦è½‰ç§»",
            "ç„¡æ³•ååš¥å£æœè—¥ç‰©è€…"],
        "outcomes": "TP53 wild-type PFS: 27.4m (vs 5.2m, HR 0.41, 95% CI 0.23-0.73)ã€‚"},
    
    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775 (Study 309)", "pharma": "MSD/Eisai", "drug": "Lenvatinib + Pembrolizumab", 
     "pop_results": "Lenvatinibï¼‹Pembrolizumabåœ¨å¾©ç™¼/æ™šæœŸå­å®®å…§è†œç™Œç›¸è¼ƒåŒ–ç™‚åŒæ™‚æ”¹å–„PFSèˆ‡OSï¼ˆpMMRï¼šPFS HR 0.60ã€OS HR 0.68ï¼›å…¨é«”ï¼šPFS HR 0.56ã€OS HR 0.62ï¼‰ï¼Œç¢ºç«‹äºŒç·šä»¥å¾Œçš„é‡è¦çµ„åˆ",
     "rationale": "çµåˆ VEGF-TKI é‡å¡‘è¡€ç®¡ä¸¦æ¸›è¼•å…ç–«æŠ‘åˆ¶ï¼Œå…‹æœ MSS è…«ç˜¤ä¹‹å…ç–«å†·å¾®ç’°å¢ƒã€‚",
     "regimen": "Lenvatinib 20mg QD (æ¯æ—¥å£æœ) + Pembrolizumab 200mg Q3W (éœè„ˆæ»´æ³¨) ç›´è‡³ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ã€‚",
     "inclusion": ["advanced/recurrent endometrial cancerã€‚", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚é€²å±•ä¹‹æ™šæœŸ EC (æœ€å¤šå‰ç·š 2 æ¬¡)ã€‚", "ECOG 0-1ã€‚", "ä¸é™ MMR ç‹€æ…‹ï¼Œä½†pMMR ç‚ºä¸»è¦æ—ç¾¤ä¹‹ä¸€ã€‚"],
     "exclusion": ["æ—¢å¾€ PD-1/PD-L1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æœªæ§åˆ¶é«˜è¡€å£“/é‡å¤§å¿ƒè¡€ç®¡é¢¨éšªï¼ˆlenvatinib ç›¸é—œï¼‰ã€‚", "å‡ºè¡€/å»”ç®¡é«˜é¢¨éšªç­‰ã€‚"],
     "outcomes": "pMMR OS: 17.4m vs 12.0m (HR 0.68, 95% CI 0.56-0.84, P<0.001); ITT OS: 18.3m vs 11.4m (HR 0.62)ï¼ŒPFS HR ~0.56; åæ‡‰ç‡äº¦å„ªæ–¼åŒ–ç™‚ï¼Œä½†æ¯’æ€§è¼ƒé«˜ï¼Œè‡¨åºŠå¸¸è¦‹ï¼šHTNã€è…¹ç€‰ã€ç–²å€¦ã€é«”é‡ä¸‹é™ã€ç”²ç‹€è…ºåŠŸèƒ½ç•°å¸¸ ç­‰ã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š GARNET", "pharma": "GSK", "drug": "Dostarlimab å–®è—¥", 
     "pop_results": "å±¬å–®è‡‚Dostarlimabç ”ç©¶ï¼ˆä¸»è¦å ±ORR/æŒçºŒåæ‡‰ï¼‰ï¼Œç„¡éš¨æ©Ÿæ¯”è¼ƒHRå¯å¡«ï¼ˆHRï¼šN/Aï¼‰ï¼ŒdMMR ORR 45.5%; DOR æŒä¹…",
     "rationale": "é‡å° MSI-H/dMMR é«˜å…ç–«åŸæ€§æ‚£è€…ï¼Œå–®è—¥ PD-1 é˜»æ–·å³å¯é”æˆæŒä¹…æ‡‰ç­”ã€‚",
     "regimen": "Dostarlimab 500mg Q3W x4 åŠ‘ -> 1000mg Q6W ç¶­æŒç›´åˆ°é€²å±•ã€‚",
     "inclusion": ["recurrent/advanced endometrial cancerï¼Œå…ˆå‰æ²»ç™‚å¾Œã€‚", "åˆ† dMMR/MSI-H èˆ‡ pMMR cohortã€‚"],
     "exclusion": ["æ—¢å¾€ PD-1/PD-L1ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "CNS æ´»å‹•æ€§ç—…ç¶ç­‰"],
     "outcomes": "dMMR/MSI-H ORR 45.5%ã€ä¸” DoR é•·; DOR æœªé”åˆ°ã€‚pMMR ORR è¼ƒä½ï¼ˆç´„ 10â€“15% ç­‰ç´šï¼Œä¾åˆ†æé›†è€Œç•°ï¼‰"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["dMMR / MSI-H / MMRd", "pMMR / NSMP / MSS", "POLE mutation (è¶…çªè®Šå‹)", "p53 mutation (é«˜æ‹·è²å‹)"], 
        "name": "ğŸ“š RAINBO Program", "pharma": "ENGOT / GOG", "drug": "åˆ†å­åˆ†å‹å°èˆªè¼”åŠ©æ²»ç™‚", 
        "pop_results": "ç²¾æº–è¼”åŠ©æ²»ç™‚æ–°æ¨™æº–ï¼šæ ¹æ“šå››å¤§åˆ†å­åˆ†å‹é€²è¡Œæ²»ç™‚é™éšæˆ–å¢ç›Š (Escalation/De-escalation)ï¼Œæ—¨åœ¨å„ªåŒ–è¡“å¾Œé å¾Œä¸¦æ¸›å°‘éåº¦æ²»ç™‚ã€‚",
        "rationale": "RAINBO ç”±å››å€‹å¹³å°çµ„æˆï¼šRED (p53abn åŠ åŒ–æ”¾ç™‚)ã€GREEN (NSMP åŠ æ¿€ç´ ç¶­æŒ)ã€AMBER (MMRd åŠ å…ç–«ç¶­æŒ) åŠ BLUE (POLE è§€å¯Ÿ)ï¼Œå°‡åˆ†å­åˆ†å‹è½å¯¦æ–¼è‡¨åºŠæ±ºç­–ã€‚",
        "regimen": "RED: åŒ–æ”¾ç™‚ + Olaparib ç¶­æŒæ²»ç™‚; GREEN: éª¨ç›†æ”¾ç™‚ + Letrozole ç¶­æŒæ²»ç™‚; AMBER: éª¨ç›†æ”¾ç™‚ + Dostarlimab ç¶­æŒæ²»ç™‚; BLUE: è¡“å¾Œè§€å¯Ÿ (De-escalation)ã€‚",
        "inclusion": ["FIGO Stage I-III å­å®®å…§è†œç™Œ", "è¡“å¾Œå®Œæˆåˆ†å­åˆ†å‹é‘‘å®š (POLE, MMR, p53)", "å…·å‚™ä¸­é«˜é¢¨éšªç‰¹å¾µè€…"],
        "outcomes": "è©¦é©—é€²è¡Œä¸­ (Ongoing)ï¼Œéƒ¨åˆ†å¹³å°å¦‚ BLUE æ—¨åœ¨é©—è­‰ POLE çªè®Šæ¥µä½³ä¹‹é å¾Œå¯å¦å…é™¤è¼”åŠ©æ²»ç™‚ã€‚"},
    
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["pMMR / NSMP / MSS"], 
        "name": "ğŸ“š PORTEC-4a", "pharma": "Leiden University", "drug": "Molecular-integrated Risk Profile", 
        "pop_results": "åˆ†å­æ•´åˆé¢¨éšªå°èˆªï¼šæ¯”è¼ƒã€åˆ†å­é¢¨éšªæ¨¡å‹ã€èˆ‡ã€å‚³çµ±è‡¨åºŠç—…ç†é¢¨éšªã€å°èˆªçš„è¼”åŠ©æ”¾ç™‚ï¼Œé”æˆæ›´ç²¾æº–çš„æ‚£è€…åˆ†æµã€‚",
        "rationale": "é©—è­‰åŸºæ–¼åˆ†å­ç‰¹å¾µï¼ˆå¦‚ p53, POLE, MMR, CTNNB1, L1CAMï¼‰çš„é¢¨éšªè©•ä¼°æ˜¯å¦å„ªæ–¼å‚³çµ±è‡¨åºŠåˆ†æœŸï¼Œä»¥æ±ºå®šæ”¾ç™‚ç¯„åœã€‚",
        "regimen": "è©¦é©—çµ„: ä¾æ“šåˆ†å­é¢¨éšªæ¨¡å‹æ±ºå®š (è§€å¯Ÿ/é™°é“æ®˜ç«¯æ”¾ç™‚/éª¨ç›†æ”¾ç™‚); å°ç…§çµ„: ä¾å‚³çµ±è‡¨åºŠé¢¨éšªæ¨™æº–é€²è¡Œé™°é“æ®˜ç«¯æ”¾ç™‚ (VBT)ã€‚",
        "inclusion": ["FIGO Stage I å­å®®å…§è†œç™Œ", "å…·å‚™ä¸­åº¦é¢¨éšªç—…ç†ç‰¹å¾µ", "å®Œæˆå®Œæ•´åˆ†å­åˆ†å‹æ¨™è¨˜æª¢æ¸¬"],
        "outcomes": "ä¸»è¦çµ‚é»ç‚ºé™°é“å¾©ç™¼ç‡ (Vaginal Recurrence Rate)ï¼Œé æœŸåˆ†å­å°èˆªçµ„èƒ½æ¸›å°‘ 15% çš„éåº¦æ”¾ç™‚ã€‚"},
    
    # ==========================
    # === Cervical Published ===
    # ==========================
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š KEYNOTE-A18 (ENGOT-cx11)", "pharma": "MSD", "drug": "Pembrolizumab + CCRT", 
     "pop_results": "èˆ‡åŒæ­¥åŒ–æ”¾ç™‚ç›¸æ¯”ï¼ŒåŠ å…¥Pembrolizumabå¯å¸¶ä¾†æ•´é«”å­˜æ´»æ”¹å–„çš„è¶¨å‹¢/æ—©æœŸè¨Šè™Ÿï¼ˆæœŸä¸­OS HR 0.67ï¼‰ï¼Œæ ¸å¿ƒæ„ç¾©åœ¨æ–¼æŠŠå…ç–«æ²»ç™‚æ¨é€²åˆ°ã€Œæ ¹æ²»æ„åœ–ã€åŒæ­¥åŒ–æ”¾ç™‚å ´æ™¯ï¼ŒLACC æ¨™æº–ï¼š36m OS 82.6% (HR 0.67)",
     "rationale": "å°‡å…ç–«æ•´åˆå…¥é«˜é¢¨éšªå±€éƒ¨æ™šæœŸä¹‹æ ¹æ²»åŒæ­¥åŒ–æ”¾ç™‚ã€‚",
     "regimen": "Arm A: CCRT (Cisplatin 40mg/m2 é€±æœ + RT 45-50.4 Gy) åŒæ­¥ Pembro 200mg Q3W x5 é€±æœŸ -> ç¶­æŒ Pembro 400mg Q6W x15 é€±æœŸã€‚ Arm B: CCRT + Placeboã€‚",
     "inclusion": ["æ–°è¨ºæ–· Stage IB2-IIB LN(+) æˆ– Stage III-IVA å±€éƒ¨æ™šæœŸã€‚"],
     "exclusion": ["æ—¢å¾€ç³»çµ±æ€§æ²»ç™‚/å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“", "æ”¾ç™‚ç¦å¿Œç­‰"],
     "outcomes": "24m PFS: 68% vs 57% (HR 0.70); 36m OS: 82.6% vs 74.8% (HR 0.67)ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], "name": "ğŸ“š INTERLACE", "pharma": "UCL", "drug": "Induction Carbo/Pacli x6 -> CCRT", 
     "pop_results": "ä»¥ã€Œèª˜å°åŒ–ç™‚â†’å†åŒæ­¥åŒ–æ”¾ç™‚ã€ç­–ç•¥æ”¹å–„é å¾Œï¼Œå ±å‘Šé¡¯ç¤ºPFSèˆ‡OSçš†æå‡ï¼ˆPFS HR 0.65ï¼›OS HR 0.60ï¼‰ï¼Œä»£è¡¨ã€Œæ²»ç™‚åºåˆ—ã€æœ¬èº«ä¹Ÿèƒ½å¸¶ä¾†å­˜æ´»å¢ç›Šï¼Œ5å¹´ OS 80% (vs 72%, HR 0.60)",
     "rationale": "åˆ©ç”¨èª˜å°åŒ–ç™‚ (Induction Chemo) è§£æ±ºæ”¾ç™‚å‰çš„å¾®å°è½‰ç§»ã€‚",
     "regimen": "Arm Aï¼šèª˜å°æœŸ: induction chemotherapyï¼ˆçŸ­ç™‚ç¨‹ï¼‰Paclitaxel 80mg/m2 + Carboplatin AUC2 æ¯é€±ä¸€æ¬¡ x6 é€±æœŸ -> æ¥çºŒæ¨™æº– CCRT (Cisplatin + RT)ã€‚Arm Bï¼šæ¨™æº– CCRT alone",
     "inclusion": ["treatment-naÃ¯veã€locally advanced cervical cancerï¼Œé©åˆæ ¹æ²»æ€§ CCRTã€‚"],
     "exclusion": ["ç„¡æ³•æ¥å—åŒ–ç™‚æˆ–æ ¹æ²»æ€§æ”¾ç™‚ã€‚", "é‡å¤§å…±ç—…/æ„ŸæŸ“ã€‚", "æ‡·å­•ç­‰"],
     "outcomes": "5yr OS: 80% vs 72% (HR 0.60); 5yr PFS: 73% vs 64% (HR 0.65)ã€‚"},
    
    {"cancer": "Cervical", "pos": "P-MT", "sub_pos": ["Maintenance"], 
        "name": "ğŸ“š KEYNOTE-826", "pharma": "MSD", "drug": "Pembrolizumab + Chemo Â± Bev", 
        "pop_results": "ä¸€ç·š R/M å­å®®é ¸ç™Œé»ƒé‡‘æ¨™æº–ï¼šåœ¨åŒ–ç™‚åŸºç¤ä¸Šä½µç”¨å…ç–«æ²»ç™‚é¡¯è‘—æ”¹å–„ OS (HR 0.63)ã€‚å®Œæˆèª˜å°åŒ–ç™‚å¾Œï¼Œå…ç–«è—¥ç‰©æ¥çºŒç¶­æŒæ²»ç™‚ç›´è‡³ PD æˆ–æ»¿ 24 å€‹æœˆã€‚",
        "rationale": "åˆ©ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚ç”¢ç”Ÿå”åŒæ•ˆæ‡‰ï¼Œä¸¦é€éå¾ŒçºŒå–®è—¥å…ç–«ç¶­æŒæ²»ç™‚ï¼ŒæŒçºŒæ´»åŒ–å…ç–«ç³»çµ±ä»¥æ§åˆ¶è…«ç˜¤é€²å±•ã€‚",
        "regimen": "Arm 1: Pembrolizumab 200mg Q3W + Chemo (Pacli+Cis/Carbo) Â± Bevacizumab 15mg/kg Q3Wã€‚ Arm 2: Placebo + Chemo Â± Bevã€‚",
        "inclusion": ["persistent/recurrent/metastatic cervical cancer", "1L systemic therapy", "å¯æ¥å— Â± bev", "ä¸»è¦åˆ†æå¸¸ä»¥ PD-L1 CPS åˆ†å±¤"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“ç­‰"],
        "outcomes": "CPSâ‰¥1 æ—ç¾¤ mOS: 28.6m vs 16.5m (HR 0.60); ITT å…¨äººç¾¤ OS HR 0.63; Grade â‰¥3 AE æ¯”ä¾‹é«˜ï¼ˆåŒ–ç™‚èƒŒæ™¯ç‚ºä¸»ï¼›åŠ  pembro å¾Œå…ç–«ç›¸é—œ AE å¢åŠ ï¼‰"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], "name": "ğŸ“š innovaTV 301 (ENGOT-cx12)", "pharma": "Genmab", "drug": "Tisotumab Vedotin (ADC)", 
     "pop_results": "Tisotumab vedotinç›¸è¼ƒé†«å¸«é¸æ“‡åŒ–ç™‚æ”¹å–„OSï¼ˆOS HR 0.70ï¼‰ï¼Œä»£è¡¨ADCåœ¨å¾©ç™¼/è½‰ç§»é ¸ç™Œçš„é‡Œç¨‹ç¢‘ï¼Œå¾Œç·š ADC çªç ´ï¼šOS HR 0.70; ORR 17.8%",
     "rationale": "æ¨™é¶çµ„ç¹”å› å­ (Tissue Factor) ADCï¼Œè§£æ±ºå¾Œç·šåŒ–ç™‚è€è—¥ã€‚",
     "regimen": "Arm A: Tisotumab Vedotin 2.0 mg/kg IV Q3Wã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ (Chemo SoC)ã€‚",
     "inclusion": ["recurrent/metastatic cervical cancerã€‚", "2L/3L æ²»ç™‚æƒ…å¢ƒï¼ˆä¾è©¦é©—ï¼‰"],
     "exclusion": ["ä¸é©åˆ ADC/æ—¢å¾€ç›¸é—œè—¥ç‰©é™åˆ¶ã€‚", "åš´é‡è§’è†œ/çœ¼éƒ¨é¢¨éšªéœ€è©•ä¼°ï¼ˆTV å¸¸è¦‹çœ¼æ¯’æ€§ç®¡ç†ï¼‰ã€‚", "å…¶ä»–å…±ç—…ç­‰"],
     "outcomes": "mOS: 11.5m vs 9.5m (HR 0.70); ORR 17.8% vs 5.2%ã€‚AEåŒ…æ‹¬å‡ºè¡€ã€å‘¨é‚Šç¥ç¶“ç—…è®Šã€çœ¼éƒ¨ AEï¼ˆéœ€é é˜²æ€§çœ¼è—¥æ°´/çœ¼ç§‘ç›£æ¸¬ï¼‰"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], 
        "name": "ğŸ“š CALLA", "pharma": "AZ", "drug": "Durvalumab + CCRT", 
        "pop_results": "æ•´é«”è©¦é©—çµæœç‚ºé™°æ€§ã€‚åœ¨å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œä¸­ï¼ŒåŒæ­¥åŒ–æ”¾ç™‚åŠ å…¥ Durvalumab ä¸¦æœªé¡¯è‘—æ”¹å–„ PFS (HR 0.84; P=0.174)ã€‚",
        "rationale": "æ¢ç´¢ PD-L1 æŠ‘åˆ¶åŠ‘èˆ‡åŒæ­¥åŒ–æ”¾ç™‚ (CCRT) è¯ç”¨æ˜¯å¦èƒ½ç”¢ç”Ÿå”åŒå…ç–«æ•ˆæ‡‰ã€‚",
        "regimen": "Arm Aï¼šdurvalumab + CCRTï¼ˆä¸¦æ–¼ CCRT å¾ŒæŒçºŒ durvalumabï¼‰ã€‚ Arm Bï¼šplacebo + CCRTï¼ˆä¸¦æ–¼å¾ŒçºŒæŒçºŒ placeboï¼‰ã€‚",
        "inclusion": ["untreated locally advanced cervical cancerï¼Œæ¥å—æ ¹æ²»æ€§ CCRTã€‚"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "æ”¾ç™‚/åŒ–ç™‚ç¦å¿Œç­‰"],
        "outcomes": "PFSæœªé”é¡¯è‘—ï¼ŒHR 0.84 (95% CI 0.65-1.08)ï¼Œé¡¯ç¤ºã€Œall-comersã€ä¸‹åŠ  durvalumab æœªèƒ½æˆç‚ºæ–°æ¨™æº–ï¼ˆå¯èƒ½éœ€ biomarker ç²¾é¸ï¼‰ã€‚"},
    
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š GOG-240", "pharma": "NCI / GOG", "drug": "Chemo + Bevacizumab", 
        "pop_results": "è½‰ç§»æ€§å­å®®é ¸ç™Œé‡Œç¨‹ç¢‘ï¼šé¦–å€‹è­‰æ˜åŠ å…¥ Bevacizumab èƒ½é¡¯è‘—å»¶é•· OS (16.8m vs 13.3m, HR 0.71) çš„ç ”ç©¶ã€‚",
        "rationale": "åˆ©ç”¨æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©å”åŒé›™æ¨™é¶åŒ–ç™‚ï¼Œå¼·åŒ–å°æ™šæœŸå­å®®é ¸ç™Œçš„ç³»çµ±æ€§æ§åˆ¶ã€‚",
        "regimen": "Cisplatin + Paclitaxel (æˆ– Topotecan + Paclitaxel) è¯ç”¨ Bevacizumab 15mg/kg Q3Wã€‚",
        "inclusion": ["å¾©ç™¼ã€æŒä¹…æ€§æˆ–è½‰ç§»æ€§å­å®®é ¸ç™Œ", "å…ˆå‰æœªæ¥å—éé‡å° R/M ä¹‹åŒ–ç™‚", "ECOG 0-1"],
        "exclusion": ["è‡¨åºŠé¡¯è‘—ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…", "æ›¾å—éå…¨èº«æ€§è¡€ç®¡æŠ‘åˆ¶åŠ‘æ²»ç™‚"],
        "outcomes": "mOS: 16.8m (vs 13.3m, HR 0.71, P=0.004)ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Locally Advanced (CCRT)"], 
        "name": "ğŸ“š GOG-240", "pharma": "NCI / GOG", "drug": "Chemo + Bevacizumab", 
        "pop_results": "è½‰ç§»æ€§å­å®®é ¸ç™Œé‡Œç¨‹ç¢‘ï¼šé¦–å€‹è­‰æ˜åŠ å…¥ Bevacizumab èƒ½é¡¯è‘—å»¶é•· OS (16.8m vs 13.3m, HR 0.71) çš„ç ”ç©¶ã€‚",
        "rationale": "åˆ©ç”¨æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©å”åŒé›™æ¨™é¶åŒ–ç™‚ï¼Œå¼·åŒ–å°æ™šæœŸå­å®®é ¸ç™Œçš„ç³»çµ±æ€§æ§åˆ¶ã€‚",
        "regimen": "Cisplatin + Paclitaxel (æˆ– Topotecan + Paclitaxel) è¯ç”¨ Bevacizumab 15mg/kg Q3Wã€‚",
        "inclusion": ["å¾©ç™¼ã€æŒä¹…æ€§æˆ–è½‰ç§»æ€§å­å®®é ¸ç™Œ", "å…ˆå‰æœªæ¥å—éé‡å° R/M ä¹‹åŒ–ç™‚", "ECOG 0-1"],
        "exclusion": ["è‡¨åºŠé¡¯è‘—ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…", "æ›¾å—éå…¨èº«æ€§è¡€ç®¡æŠ‘åˆ¶åŠ‘æ²»ç™‚"],
        "outcomes": "mOS: 16.8m (vs 13.3m, HR 0.71, P=0.004)ã€‚"},
    
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š EMPOWER-Cervical 1", "pharma": "Regeneron", "drug": "Cemiplimab å–®è—¥", 
        "pop_results": "äºŒç·šå¾Œå–®è—¥å…ç–«æ²»ç™‚é‡è¦æŒ‡æ¨™ï¼šç›¸è¼ƒåŒ–ç™‚é¡¯è‘—å»¶é•· OS (mOS 12.0m vs 8.5m; HR 0.69)ï¼Œä¸è«–çµ„ç¹”å‹æ…‹å‡æœ‰ç²ç›Šã€‚",
        "rationale": "é‡å°ä¸€ç·šé‰‘é¡åŒ–ç™‚å¤±æ•—å¾Œä¹‹æ‚£è€…ï¼Œåˆ©ç”¨ PD-1 é˜»æ–·æä¾›æŒä¹…ç·©è§£èˆ‡ç”Ÿå­˜å„ªå‹¢ã€‚",
        "regimen": "Arm Aï¼šcemiplimabã€‚ Arm Bï¼šphysicianâ€™s choice single-agent chemoã€‚",
        "inclusion": ["recurrent/metastatic cervical cancerã€‚", "progressed after 1L platinum"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸å¯æ§æ„ŸæŸ“ç­‰"],
        "outcomes": "OS é¡¯è‘—æ”¹å–„ï¼ŒITT å…¨äººç¾¤ OS HR 0.69 (95% CI 0.56-0.84)ã€‚"},
    
    { "cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š BEATcc", "pharma": "Roche", "drug": "Atezolizumab + Chemo + Bev", 
        "pop_results": "ä¸€ç·š R/M å­å®®é ¸ç™Œï¼šåœ¨åŒ–ç™‚+æ¨™é¶åŸºç¤ä¸ŠåŠ å…¥ Atezolizumabï¼Œé¡¯è‘—å»¶é•· PFS (13.7m vs 10.4m) èˆ‡ OS (32.1m vs 22.8m)ï¼ŒPFS HR 0.62ï¼›OS HR 0.68ï¼‰ã€‚",
        "rationale": "PD-L1 é˜»æ–·ä½µç”¨ VEGF æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚ï¼Œä¸‰è»Œè¯ç”¨å¼·åŒ–è…«ç˜¤å¾®ç’°å¢ƒä¹‹æ®ºå‚·åŠ›ã€‚",
        "regimen": "Arm Aï¼šatezolizumab + bevacizumab + platinum chemoï¼ˆå« paclitaxelï¼‰ â†’ atezolizumab + bev maintenanceã€‚ Arm Bï¼šbevacizumab + platinum chemo â†’ bev maintenanceã€‚",
        "inclusion": ["untreated metastatic/persistent/recurrent cervical cancerã€‚", "å¯æ¥å—å« bev çš„æ¨™æº–ä¸€ç·š"],
        "exclusion": ["æ—¢å¾€å…ç–«æ²»ç™‚ã€‚", "æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚ã€‚", "ä¸é©åˆ bevï¼ˆå‡ºè¡€/å»”ç®¡/è¡€æ “é«˜é¢¨éšªç­‰ï¼‰"],
        "outcomes": "mPFS HR 0.62; mOS HR 0.68 (95% CI 0.52-0.88)ã€‚PFS èˆ‡ OS çš†é¡¯è‘—æ”¹å–„ï¼Œå»ºç«‹ã€ŒPD-L1 inhibitor + GOG240 backboneã€çš„æ–°ä¸€ç·šé¸é …"},
    
    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Early Stage (Surgery)"], 
        "name": "ğŸ“š LACC Trial", "pharma": "NEJM / Academic", "drug": "Open vs MIS Radical Hysterectomy", 
        "pop_results": "æ‰‹è¡“é»ƒé‡‘æº–å‰‡ï¼šè­‰å¯¦å¾®å‰µæ‰‹è¡“ (MIS) ç›¸è¼ƒæ–¼å‚³çµ±é–‹è…¹æ‰‹è¡“ï¼Œå…¶å¾©ç™¼é¢¨éšªé¡¯è‘—è¼ƒé«˜ä¸”ä¸‰å¹´å­˜æ´»ç‡è¼ƒä½ã€‚",
        "rationale": "è©•ä¼°åœ¨å­å®®é ¸ç™Œæ ¹æ²»è¡“ä¸­ï¼Œé”æ–‡è¥¿æˆ–è…¹è…”é¡å¾®å‰µæ‰‹è¡“æ˜¯å¦èƒ½é”æˆèˆ‡é–‹è…¹æ‰‹è¡“åŒç­‰çš„è…«ç˜¤å­¸é å¾Œã€‚",
        "regimen": "å°ç…§çµ„: å‚³çµ±é–‹è…¹æ ¹æ²»æ€§å­å®®åˆ‡é™¤è¡“ (Open Radical Hysterectomy); è©¦é©—çµ„: å¾®å‰µæ ¹æ²»æ€§å­å®®åˆ‡é™¤è¡“ (MIS Radical Hysterectomy)ã€‚",
        "inclusion": [
            "FIGO 2009 Stage IA1 (æœ‰ LVSI), IA2, æˆ– IB1 å­å®®é ¸ç™Œ",
            "çµ„ç¹”å­¸åˆ†å‹ç‚ºé±—ç™Œã€è…ºç™Œæˆ–è…ºé±—ç™Œ",
            "ECOG 0-1"],
        "exclusion": [
            "è…«ç˜¤ç›´å¾‘ > 4cm",
            "å·²çŸ¥æœ‰æ·‹å·´çµè½‰ç§»æˆ–é ç«¯è½‰ç§»"],
        "outcomes": "3yr DFS Rate: 91.2% (MIS) vs 97.1% (Open); HR for recurrence 3.74 (P=0.002)ã€‚"},
    
    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Early Stage (Surgery)"], 
        "name": "ğŸ“š SHAPE Trial (CCTG CX.5)", "pharma": "CCTG / Academic", "drug": "Simple vs Radical Hysterectomy", 
        "pop_results": "ä½é¢¨éšªæ‰‹è¡“é™éšï¼šé‡å°ä½é¢¨éšªæ—©æœŸæ‚£è€…ï¼Œå–®ç´”å­å®®åˆ‡é™¤ (Simple) çš„ä¸‰å¹´ç›†è…”å¾©ç™¼ç‡ä¸åŠ£æ–¼å»£æ³›æ€§å­å®®åˆ‡é™¤ (Radical)ã€‚",
        "rationale": "æ¢è¨å°æ–¼é å¾Œæ¥µä½³çš„ä½é¢¨éšªæ—©æœŸæ‚£è€…ï¼Œæ˜¯å¦èƒ½é€éæ¸›å°‘åˆ‡é™¤ç¯„åœä¾†é™ä½è¡“å¾Œä½µç™¼ç—‡ä¸¦ç¶­æŒç”Ÿå­˜ç‡ã€‚",
        "regimen": "å°ç…§çµ„: å»£æ³›æ€§å­å®®åˆ‡é™¤ (Radical Hysterectomy) + ç›†è…”æ·‹å·´çµæ¸…æƒ; è©¦é©—çµ„: å–®ç´”å­å®®åˆ‡é™¤ (Simple Hysterectomy) + ç›†è…”æ·‹å·´çµæ¸…æƒã€‚",
        "inclusion": [
            "FIGO 2018 Stage IA2 æˆ– IB1 (â‰¤ 2cm)",
            "é–“è³ªæµ¸æ½¤æ·±åº¦ < 10mm",
            "Grade 1-3 é±—ç™Œã€è…ºç™Œæˆ–è…ºé±—ç™Œ"],
        "exclusion": [
            "å½±åƒå­¸æ‡·ç–‘æ·‹å·´çµè½‰ç§»",
            "å°ç´°èƒç¥ç¶“å…§åˆ†æ³Œç™Œ"],
        "outcomes": "3yr Pelvic Recurrence: 2.52% (Simple) vs 2.17% (Radical); ç¬¦åˆéåŠ£æ•ˆæ€§æ¨™æº– (P<0.05)ã€‚"},

    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Locally Advanced (NIC)"], 
        "name": "ğŸ“š NACI Study", "pharma": "Henlius", "drug": "Camrelizumab + NACT", 
        "pop_results": "æ–°è¼”åŠ©å…ç–«å¼·æ•ˆæ‡‰ï¼šé‡å°å±€éƒ¨æ™šæœŸ (LACC)ï¼ŒpCRï¼ˆç—…ç†å®Œå…¨ç·©è§£ï¼‰ç‡é«˜é” 38.6%ï¼Œé¡¯è‘—å„ªæ–¼å‚³çµ±æ–°è¼”åŠ©åŒ–ç™‚ã€‚",
        "rationale": "åˆ©ç”¨ PD-1 æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚è¯ç”¨ä½œç‚ºæ‰‹è¡“å‰çš„å‰å°æ²»ç™‚ï¼Œæ—¨åœ¨ç¸®å°è…«ç˜¤é«”ç©ä¸¦æ¸…é™¤å¾®å°è½‰ç§»ç—…ç¶ï¼Œæé«˜æ‰‹è¡“åˆ‡é™¤ç‡èˆ‡é•·æœŸå­˜æ´»ã€‚",
        "regimen": "Camrelizumab 200mg + Cisplatin/Paclitaxel æ¯ 3 é€±ä¸€é€±æœŸï¼Œå…± 2-3 é€±æœŸï¼Œéš¨å¾Œé€²è¡Œæ ¹æ²»æ€§æ‰‹è¡“ã€‚",
        "inclusion": ["Stage IB3, IIA2, IIB (FIGO 2018) å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œ", "ECOG 0-1", "æœªæ›¾æ¥å—éåŒ–æ”¾ç™‚"],
        "outcomes": "pCR Rate: 38.6%; ORR: 97.7%; ä¸»è¦çµ‚é»ç‚ºç—…ç†ç·©è§£ç‡èˆ‡æ‰‹è¡“è½‰åŒ–ç‡ã€‚"},
    
    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Locally Advanced (CCRT)"], 
        "name": "ğŸ“š OUTBACK (ANZGOG 0902)", "pharma": "GOG / ANZGOG", "drug": "CCRT + Adjuvant Chemo", 
        "pop_results": "è¼”åŠ©åŒ–ç™‚è² å‘çµè«–ï¼šåœ¨æ¨™æº– CCRT å¾Œé¡å¤–å¢åŠ  4 é€±æœŸè¼”åŠ©åŒ–ç™‚ï¼Œä¸¦ã€æœªã€æ”¹å–„ 5 å¹´ OS æˆ– PFS (HR 0.91)ã€‚",
        "rationale": "é©—è­‰åœ¨åŒæ­¥åŒ–æ”¾ç™‚å®Œæˆå¾ŒåŠ å…¥å…¨èº«æ€§åŒ–ç™‚ï¼Œæ˜¯å¦èƒ½é€²ä¸€æ­¥æ¸…é™¤é ç«¯è½‰ç§»ï¼Œçµæœè­‰æ˜å…¶æ¯’æ€§è¼ƒé«˜ä¸”ç„¡é¡å¤–ç›Šè™•ã€‚",
        "regimen": "æ¨™æº–åŒæ­¥åŒ–æ”¾ç™‚ (CCRT) çµæŸå¾Œï¼Œæ¥çºŒ Carboplatin/Paclitaxel æ¯ 3 é€±ä¸€é€±æœŸï¼Œå…± 4 é€±æœŸã€‚",
        "inclusion": ["Stage IB2-IVA å±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œ", "é©åˆæ¥å— CCRT èˆ‡éš¨å¾Œä¹‹åŒ–ç™‚"],
        "outcomes": "5yr OS: 72% (CCRT+Chemo) vs 71% (CCRT); PFS HR: 0.91 (P=0.61)ã€‚"},
    
    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Locally Advanced (NIC)"], 
        "name": "ğŸ“š NATIC Trial", "pharma": "BeiGene / SYSU", "drug": "Tislelizumab + NACT", 
        "pop_results": "æ–°è¼”åŠ©å…ç–«æ–°é¸æ“‡ï¼šTislelizumab è¯ç”¨åŒ–ç™‚é”æˆ 41% çš„ pCR ç‡ï¼Œå±•ç¾å¼·å¤§çš„è¡“å‰è…«ç˜¤é™éšèƒ½åŠ›ã€‚",
        "rationale": "æ¢ç´¢ PD-1 æŠ‘åˆ¶åŠ‘ Tislelizumab åœ¨å±€éƒ¨æ™šæœŸæ‚£è€…æ‰‹è¡“å‰çš„æ‡‰ç”¨ï¼Œä»¥è©•ä¼°å…¶å°å¾ŒçºŒæ‰‹è¡“ç—…ç†çµæœçš„æ”¹å–„ç¨‹åº¦ã€‚",
        "regimen": "Tislelizumab 200mg + Paclitaxel/Cisplatin Q3Wï¼Œå…± 3 é€±æœŸï¼Œéš¨å¾Œé€²è¡Œå»£æ³›æ€§å­å®®åˆ‡é™¤è¡“ã€‚",
        "inclusion": ["FIGO 2018 Stage IB3-IIB å±€éƒ¨æ™šæœŸé±—ç™Œ/è…ºç™Œ/è…ºé±—ç™Œ", "ECOG 0-1"],
        "outcomes": "pCR Rate: 41%; ORR: 94.7%; 3 ç´šä»¥ä¸Šæ²»ç™‚ç›¸é—œä¸è‰¯åæ‡‰ç‡ç´„ 25.6%ã€‚"},
    
    {"cancer": "Cervical", 
        "pos": ["P-TX"], 
        "sub_pos": ["Locally Advanced (NIC)"], 
        "name": "ğŸ“ Cadonilimab + NACT â†’ Surgery", "pharma": "Akeso", "drug": "Cadonilimab + NACT", 
        "pop_results": "é›™ç‰¹ç•°æ€§æŠ—é«”é ˜èˆªï¼šPD-1/CTLA-4 é›™ç‰¹ç•°æ€§æŠ—é«”è¯ç”¨åŒ–ç™‚ä½œç‚ºæ–°è¼”åŠ©æ²»ç™‚ï¼Œå±•ç¾å‡ºæ¯”å–®å…ç–«æ›´é«˜çš„è‡¨åºŠç²ç›Šæ½›åŠ›ã€‚",
        "rationale": "åˆ©ç”¨é›™é¶é»é˜»æ–·æ©Ÿåˆ¶å¼·åŒ–è…«ç˜¤å¾®ç’°å¢ƒçš„å…ç–«æ´»åŒ–ï¼Œç‚ºé«˜å¾©ç™¼é¢¨éšªçš„ LACC æ‚£è€…æä¾›æ‰‹è¡“å‰çš„å¼·åŠ›ä»‹å…¥æ–¹æ¡ˆã€‚",
        "regimen": "Cadonilimab (10mg/kg) + Carboplatin/Paclitaxel Q3W x 3 é€±æœŸï¼Œè©•ä¼°å¾Œé€²è¡Œæ‰‹è¡“æˆ–æ”¾ç™‚ã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage IB3-IIA2 (éœ€å«å·¨å¤§è…«ç˜¤) æˆ– IIB-IVA æœŸæ‚£è€…"],
        "outcomes": "åˆæ­¥ç ”ç©¶é¡¯ç¤º ORR è¡¨ç¾å„ªç•°ï¼Œç—…ç†ç·©è§£æ•¸æ“šæ­£åœ¨è¿½è¹¤ä¸­ (Ongoing)ã€‚"},
    
    # ==========================
    # === Ovarian Published ===
    # ==========================
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], "name": "ğŸ“š MIRASOL (GOG-3045)", "pharma": "ImmunoGen", "drug": "Mirvetuximab Soravtansine", 
     "pop_results": "åœ¨FRÎ±é«˜è¡¨ç¾ã€é‰‘æŠ—è—¥åµå·¢ç™Œä¸­ï¼ŒMirvetuximabè¼ƒåŒ–ç™‚æ”¹å–„PFSèˆ‡OSï¼ˆPFS HR 0.65ï¼›OS HR 0.67ï¼‰ï¼Œç¢ºç«‹FRÎ± ADCçš„é—œéµåœ°ä½ï¼ŒPROC OS çªç ´ï¼šOS HR 0.67; ORR 42.3%",
     "rationale": "é‡å° FRÎ± é«˜è¡¨ç¾ PROC æ‚£è€…ï¼Œé¦–å€‹ ADC ç”Ÿå­˜ç²ç›Šç ”ç©¶ã€‚",
     "regimen": "æ—ç¾¤ï¼šFRÎ±-highã€platinum-resistantï¼ˆä¾ IHC é–€æª»ï¼‰ã€‚Arm A: Mirvetuximab 6.0 mg/kg (AIBW) IV Q3W ç›´è‡³é€²å±•ã€‚ Arm B: é†«å¸«é¸æ“‡åŒ–ç™‚ å¦‚ weekly paclitaxel / PLD / topotecanï¼‰ã€‚",
     "inclusion": ["platinum-resistant é«˜ç´šåˆ¥æ¼¿æ¶²æ€§ç‚ºä¸»ã€‚", "FRÎ± é«˜è¡¨ç¾ã€‚", "æ—¢å¾€æ²»ç™‚ç·šæ•¸ä¾è©¦é©—ã€‚"],
     "exclusion": ["ä¸ç¬¦åˆ FRÎ± é–€æª»ã€‚", "ä¸å¯æ§çœ¼éƒ¨/ç¥ç¶“æ¯’æ€§é¢¨éšªã€‚"],
     "outcomes": "mOS: 16.4m vs 12.7m (HR 0.67); mPFS 5.6m vs 4.0m (HR 0.65)ã€‚ORR äº¦é¡¯è‘—è¼ƒä½³ï¼›Grade â‰¥3 AE è¼ƒå°‘"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], 
        "name": "ğŸ“š GOG-0218", "pharma": "Roche / GOG", "drug": "Chemo + Bevacizumab", 
        "pop_results": "ä¸€ç·šæ¨™é¶åŸºçŸ³ï¼šé¦–å€‹è­‰æ˜åœ¨åŒ–ç™‚åŸºç¤ä¸ŠåŠ å…¥ Bevacizumab ä¸¦æ¥çºŒç¶­æŒæ²»ç™‚ï¼Œèƒ½é¡¯è‘—å»¶é•· PFS (HR 0.72)ï¼Œå¥ å®šæ¨™é¶ç¶­æŒæ¨™æº–ã€‚",
        "rationale": "é€éæŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©é˜»æ–· VEGF é€šè·¯ï¼Œåœ¨ä¸€ç·šåŒ–ç™‚æœŸé–“èˆ‡ä¹‹å¾ŒæŠ‘åˆ¶è…«ç˜¤æ–°ç”Ÿè¡€ç®¡ï¼Œé”åˆ°é•·æœŸæ§åˆ¶ã€‚",
        "regimen": "Bevacizumab (15mg/kg Q3W) è¯ç”¨ Carbo/Pacli x6 é€±æœŸï¼Œéš¨å¾Œå–®è—¥ Bevacizumab ç¶­æŒæ²»ç™‚è‡³ç¬¬ 22 é€±æœŸã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage III (ä¸å…¨åˆ‡é™¤) æˆ– Stage IV ä¸Šçš®æ€§åµå·¢ç™Œ", "ECOG 0-2", "æ¥å—éæ¸›ç©æ‰‹è¡“"],
        "exclusion": ["éä¸Šçš®æ€§åµå·¢ç™Œ", "æœ‰è…¸ç©¿å­”ç—…å²æˆ–é«˜é¢¨éšªè€…", "å‚·å£æœªç™’åˆ"],
        "outcomes": "mPFS: 14.1m (vs 10.3m, HR 0.717, P<0.001)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], 
        "name": "ğŸ“š ICON7", "pharma": "Roche / ENGOT", "drug": "Chemo + Bevacizumab (Low Dose)", 
        "pop_results": "ä¸€ç·šæ¨™é¶è­‰å¯¦ï¼šç¢ºèª Bev è¯ç”¨åŒ–ç™‚å…·å‚™ PFS ç²ç›Š (HR 0.81)ï¼Œä¸”åœ¨ã€é«˜é¢¨éšªæ—ç¾¤ã€è§€å¯Ÿåˆ° OS å»¶é•·ç²ç›Šã€‚",
        "rationale": "é©—è­‰è¼ƒä½åŠ‘é‡çš„ Bevacizumab (7.5mg/kg) è¯ç”¨åŒ–ç™‚èˆ‡ç¶­æŒæ²»ç™‚å°å…¨çƒåµå·¢ç™Œæ‚£è€…çš„æœ‰æ•ˆæ€§èˆ‡å®‰å…¨æ€§ã€‚",
        "regimen": "Bevacizumab (7.5mg/kg Q3W) è¯ç”¨ Carbo/Pacli x6 é€±æœŸï¼Œéš¨å¾Œå–®è—¥ç¶­æŒæ²»ç™‚å…± 12 é€±æœŸã€‚",
        "inclusion": ["FIGO Stage I-II (é«˜é¢¨éšª) æˆ– Stage III-IV ä¸Šçš®æ€§åµå·¢ç™Œ", "ä¸é™æ‰‹è¡“åˆ‡é™¤ç¨‹åº¦"],
        "exclusion": ["è‡¨åºŠé¡¯è‘—ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…", "è¿‘æœŸæœ‰é‡å¤§æ‰‹è¡“å²"],
        "outcomes": "PFS HR: 0.81; é«˜é¢¨éšªæ—ç¾¤ mOS: 39.7m (vs 30.2m, HR 0.64)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], 
        "name": "ğŸ“š BOOST / ENGOT-ov15", "pharma": "Roche / ENGOT", "drug": "Bev 15m vs 30m", 
        "pop_results": "ç¶­æŒæ™‚ç¨‹å®šæ¡ˆï¼šæ¯”è¼ƒ Bev ç¶­æŒ 15 å€‹æœˆèˆ‡ 30 å€‹æœˆï¼Œçµæœé¡¯ç¤ºå»¶é•·è‡³ 30 å€‹æœˆä¸¦ã€ç„¡é¡å¤–ç”Ÿå­˜ç²ç›Šã€(HR 0.99)ã€‚",
        "rationale": "æ—¨åœ¨ç¢ºå®š Bevacizumab åœ¨ä¸€ç·šç¶­æŒæ²»ç™‚çš„æœ€ä½³æŒçºŒæ™‚é–“ï¼Œæ¢è¨å»¶é•·çµ¦è—¥æ˜¯å¦èƒ½æ›´æœ‰æ•ˆå»¶ç·©å¾©ç™¼ã€‚",
        "regimen": "æ§åˆ¶çµ„: Bev (15mg/kg Q3W) ç¶­æŒ 15 å€‹æœˆ; è©¦é©—çµ„: Bev (15mg/kg Q3W) ç¶­æŒè‡³ 30 å€‹æœˆã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage IIB-IV ä¸Šçš®æ€§åµå·¢ç™Œ", "å®ŒæˆåŒ–ç™‚ä½µç”¨ Bev èª˜å°æ²»ç™‚è€…"],
        "exclusion": ["èª˜å°æœŸé–“ç–¾ç—…å·²é€²å±•è€…", "å° Bevacizumab ä¸è€å—è€…"],
        "outcomes": "mPFS: 24.2m (15m) vs 26.0m (30m) (HR 0.99, P=0.90)ã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“ NRG-GY019", "pharma": "NRG Oncology", "drug": "Letrozole vs Chemoâ†’Letrozole", 
        "pop_results": "ä¸€ç·šå»åŒ–ç™‚æŒ‘æˆ°ï¼šè©•ä¼°å°æ–¼æ–°è¨ºæ–· LGSOC æ‚£è€…ï¼Œå–®ç”¨ Letrozole æ˜¯å¦ä¸åŠ£æ–¼å‚³çµ±åŒ–ç™‚å¾Œæ¥çºŒç¶­æŒæ²»ç™‚ã€‚",
        "rationale": "ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§ç™Œ (LGSOC) å°å‚³çµ±åŒ–ç™‚åæ‡‰ç‡è¼ƒä½ï¼Œæ­¤ç ”ç©¶æ—¨åœ¨é©—è­‰åˆæœŸå³ä½¿ç”¨å…§åˆ†æ³Œæ²»ç™‚çš„è‡¨åºŠæ•ˆç›Šã€‚",
        "regimen": "Arm 1: Letrozole (2.5mg QD) å–®è—¥æ²»ç™‚ç›´åˆ°é€²å±•ï¼›Arm 2: å‚³çµ± 6 é€±æœŸåŒ–ç™‚ (CP) å¾Œæ¥çºŒ Letrozole ç¶­æŒæ²»ç™‚ã€‚",
        "inclusion": ["æ–°è¨ºæ–· Stage II-IV ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "ECOG 0-2", "éœ€æä¾›çµ„ç¹”å­¸åˆ¤å®šå ±å‘Š"],
        "exclusion": ["æ›¾å—éé‡å°æ­¤ç–¾ç—…ä¹‹å…¨èº«æ€§åŒ–ç™‚æˆ–æ¨™é¶æ²»ç™‚", "è¨ˆç•«æ¥å—ç¶­æŒæ€§ PARPi æ²»ç™‚è€…"],
        "outcomes": "æ‹›å‹Ÿä¸­ (Ongoing Recruitment)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], "name": "ğŸ“š DESKTOP III", "pharma": "AGO", "drug": "Secondary Cytoreduction Surgery", 
     "pop_results": "å¾©ç™¼åµå·¢ç™Œåœ¨åš´æ ¼é¸äººï¼ˆå¦‚AGO scoreï¼‰ä¸‹ï¼Œæ¬¡æ¸›ç©æ‰‹è¡“å¸¶ä¾†OSæ”¹å–„ï¼ˆæ­»äº¡HR 0.75ï¼‰ï¼Œå¥ å®šã€Œé¸å°äººåšæ‰‹è¡“ã€çš„åƒ¹å€¼ï¼ŒäºŒæ¬¡æ‰‹è¡“åƒ¹å€¼ï¼šR0 åˆ‡é™¤ mOS 53.7m",
     "rationale": "è­‰æ˜åš´é¸æ‚£è€… (AGO Score+) äºŒæ¬¡æ‰‹è¡“å…·ç”Ÿå­˜ç²ç›Šã€‚",
     "regimen": "platinum-sensitive recurrent ovarian cancerï¼ˆä»¥ AGO score ç­‰æ¢ä»¶ç¯©é¸å¯å®Œå…¨åˆ‡é™¤è€…ï¼‰ã€‚æ‰‹è¡“çµ„: è…«ç˜¤å®Œå…¨åˆ‡é™¤æ‰‹è¡“å¾Œæ¥çºŒå«é‰‘åŒ–ç™‚ã€‚ åŒ–ç™‚çµ„: å–®ç´”å«é‰‘è¤‡æ–¹åŒ–ç™‚ã€‚",
     "inclusion": ["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m)ã€‚", "å¯æœ›é”åˆ° complete resectionï¼ŒAGO Score é™½æ€§ (ECOG 0/å¤§é‡è…¹æ°´é™¤å¤–/R0 å®Œå…¨åˆ‡é™¤æ½›åŠ›)ã€‚"],
     "exclusion": ["ç„¡æ³•é”åˆ° R0 æˆ–æ‰‹è¡“é¢¨éšªéé«˜ã€‚", "å…¶ä»–é‡å¤§å…±ç—…ã€‚"],
     "outcomes": "ITT mOS: 53.7m vs 46.0m (HR 0.75, 95% CI 0.59-0.96); R0 åˆ‡é™¤è€… mOS é” 61.9mï¼ˆæ‰‹è¡“çµ„è¼ƒä½³ï¼Œå‰ææ˜¯é«˜æ¯”ä¾‹ R0ï¼‰ã€‚"},

    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["Neoadjuvant Setting"], "name": "ğŸ“š van Driel HIPEC", "pharma": "NEJM", "drug": "Surgery + HIPEC (Cisplatin)", 
     "pop_results": "é–“éš”æ¸›ç©æ‰‹è¡“åŠ å…¥HIPECå¯æ”¹å–„OSï¼ˆæ­»äº¡é¢¨éšªä¸‹é™ï¼šOS HR 0.67ï¼‰ï¼Œç‚ºã€Œç‰¹å®šä¸€ç·šæ‰‹è¡“æƒ…å¢ƒã€å¼•å…¥HIPECçš„é‡è¦è­‰æ“šï¼ŒIDS åŠ æº«ï¼šmOS å»¶é•· 12 å€‹æœˆ (HR 0.67)",
     "rationale": "è¡“ä¸­åŠ æº«è…¹è…”åŒ–ç™‚å¼·åŒ–ç‰©ç†æ®ºå‚·èˆ‡æ»²é€åŠ›ã€‚",
     "regimen": "stage IIIã€NACT å¾Œ é–“æ­‡æ¸›ç©æ‰‹è¡“ (IDS) æ™‚åŒæ­¥é€²è¡ŒåŠ æº« (42Â°C) è…¹è…”çŒæ³¨ Cisplatin (100 mg/m2) 90 åˆ†é˜ã€‚Arm Aï¼šsurgery + HIPEC cisplatinï¼ˆå¸¸è¦‹ 100 mg/mÂ²ã€90 åˆ†é˜ï¼‰+ å¾ŒçºŒåŒ–ç™‚ã€‚Arm Bï¼šsurgeryï¼ˆno HIPECï¼‰+ å¾ŒçºŒåŒ–ç™‚ã€‚",
     "inclusion": ["stage III epithelial ovarian cancerã€‚", "NACT å¾Œé©åˆ interval debulkingã€‚"],
     "exclusion": ["ä¸é©åˆå¤§æ‰‹è¡“æˆ– HIPECï¼ˆè…åŠŸèƒ½ã€å…¨èº«ç‹€æ³ç­‰ï¼‰ã€‚", "å…¶ä»–é‡å¤§å…±ç—…ã€‚"],
     "outcomes": "mOS: 45.7m vs 33.9m (HR 0.67, 95% CI 0.48-0.94)ã€‚recurrence-free survival äº¦æ”¹å–„ï¼›Grade 3â€“4 AE ç‡ç›¸è¿‘ã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“š EORTC 55971 (NEJM 2010)", "pharma": "EORTC", "drug": "PDS vs NACT", 
        "pop_results": "NACT éåŠ£æ•ˆæ€§é‡Œç¨‹ç¢‘ï¼šé¦–å€‹è­‰æ˜ NACT éš¨å¾Œé€²è¡Œ IDS èˆ‡ PDS ç›¸æ¯”ï¼Œç¸½ç”Ÿå­˜æœŸ (OS) ç›¸ç•¶ï¼Œä¸”æ‰‹è¡“ä½µç™¼ç—‡èˆ‡æ­»äº¡ç‡é¡¯è‘—é™ä½ã€‚",
        "rationale": "é‡å° Stage IIIC/IV æ‚£è€…ï¼Œæ¢è¨å…ˆçµ¦äºˆåŒ–ç™‚ç¸®å°è…«ç˜¤é«”ç©å¾Œå†æ‰‹è¡“ï¼Œæ˜¯å¦èƒ½é”æˆèˆ‡ç›´æ¥å¤§ç¯„åœæ‰‹è¡“åŒç­‰çš„é å¾Œä¸¦é™ä½é¢¨éšªã€‚",
        "regimen": "PDS çµ„: ç›´æ¥æ¸›ç©æ‰‹è¡“ -> å«é‰‘åŒ–ç™‚; NACT çµ„: 3 é€±æœŸåŒ–ç™‚ -> IDS æ‰‹è¡“ -> 3 é€±æœŸåŒ–ç™‚ã€‚",
        "inclusion": ["FIGO Stage IIIC æˆ– IV ä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "ECOG 0-2", "å…·å‚™çµ„ç¹”å­¸è­‰æ“š"],
        "outcomes": "mOS: 30m (NACT) vs 29m (PDS)ï¼›NACT çµ„é‡å¤§ä½µç™¼ç—‡é¡¯è‘—è¼ƒå°‘ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“š CHORUS (Lancet 2015)", "pharma": "MRC", "drug": "PDS vs NACT (UK Standard)", 
        "pop_results": "NACT æ¨™æº–å†æ¬¡ç¢ºç«‹ï¼šç¢ºèª NACT éåŠ£æ–¼ PDSï¼Œä¸”é¡¯è‘—æ¸›å°‘è¡“å¾Œ 28 å¤©å…§çš„æ­»äº¡ç‡èˆ‡åš´é‡ä½µç™¼ç—‡ã€‚",
        "rationale": "åœ¨è‹±åœ‹é†«ç™‚é«”ç³»ä¸‹é©—è­‰ EORTC 55971 çš„çµæœï¼Œæ—¨åœ¨è©•ä¼° NACT æ˜¯å¦æ‡‰æˆç‚ºæ™šæœŸé«˜é¢¨éšªæ‚£è€…çš„å¸¸è¦é¸æ“‡ã€‚",
        "regimen": "NACT çµ„: 3 é€±æœŸ CP æ–¹æ¡ˆ -> IDS -> 3 é€±æœŸ CPï¼›PDS çµ„: ç›´æ¥æ‰‹è¡“ -> 6 é€±æœŸ CPã€‚",
        "inclusion": ["æ™šæœŸä¸Šçš®æ€§åµå·¢ç™Œ", "CT é¡¯ç¤ºè…«ç˜¤è² è·å¤§æˆ–é«”èƒ½ç‹€æ³è¼ƒå·®è€…"],
        "outcomes": "mOS: 24.1m (NACT) vs 22.6m (PDS)ï¼›NACT é¡¯è‘—æ”¹å–„ç”Ÿæ´»å“è³ªèˆ‡æ‰‹è¡“å®‰å…¨æ€§ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“š EORTC+CHORUS Pooled / Long-term", "pharma": "Lancet Oncol 2018", "drug": "NACT vs PDS Meta-analysis", 
        "pop_results": "ç²¾æº–åˆ†æµæŒ‡å¼•ï¼šé•·æœŸéš¨è¨ªé¡¯ç¤º Stage IV æˆ–è…«ç˜¤è² è·æ¥µå¤§ (>5cm) è€…ï¼ŒNACT å…·å‚™é¡¯è‘—ç”Ÿå­˜ç²ç›Šå„ªå‹¢ã€‚",
        "rationale": "åˆä½µå…©å¤§è©¦é©—æ•¸æ“šé€²è¡Œäºçµ„åˆ†æï¼Œå›ç­”ã€Œå“ªäº›äººæ›´é©åˆå…ˆåš NACTã€é€™å€‹æ ¸å¿ƒè‡¨åºŠå•é¡Œã€‚",
        "regimen": "å° EORTC 55971 èˆ‡ CHORUS å…± 1,220 åæ‚£è€…é€²è¡Œé•·æœŸå­˜æ´»èˆ‡ç—…ç¶ç‰¹å¾µåˆ†æã€‚",
        "inclusion": ["Stage IIIC/IV æ‚£è€…", "è…«ç˜¤ç›´å¾‘ >5cm æˆ– Stage IV è½‰ç§»è€…"],
        "outcomes": "Stage IV æ—ç¾¤: NACT é¡¯è‘—æå‡ OS (HR 0.76)ï¼›Stage IIIC ä¸”è½‰ç§»ç¶è¼ƒå°è€… PDS å¯èƒ½ç•¥å„ªã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“š SCORPION (Phase III, 2020)", "pharma": "Fagotti et al.", "drug": "NACT vs PDS (High Tumor Burden)", 
        "pop_results": "é«˜è…«ç˜¤è² è·å°ç­–ï¼šé‡å° Fagotti è©•åˆ† â‰¥8 è€…ï¼ŒNACT é¡¯è‘—é™ä½åœè¡“æœŸç™¼ç—…ç‡ä¸”ä¸å½±éŸ¿ PFS/OSã€‚",
        "rationale": "åˆ©ç”¨è…¹è…”é¡ Fagotti è©•åˆ†ç²¾æº–ç¯©é¸ã€Œç„¡æ³•é”æˆ R0ã€çš„é«˜é¢¨éšªæ‚£è€…ï¼Œæ¢è¨ NACT çš„ä»‹å…¥åƒ¹å€¼ã€‚",
        "regimen": "NACT çµ„: å…ˆè¡ŒåŒ–ç™‚å¾Œé€²è¡Œ IDSï¼›PDS çµ„: å¼·åŠ›å˜—è©¦ç›´æ¥æ¸›ç©æ‰‹è¡“ã€‚",
        "inclusion": ["æ™šæœŸåµå·¢ç™Œ", "è…¹è…”é¡é ä¼° Fagotti è©•åˆ† â‰¥8ï¼ˆè…«ç˜¤åˆ†å¸ƒæ¥µå»£ï¼‰"],
        "outcomes": "é‡å¤§ä½µç™¼ç—‡ç‡: NACT çµ„é¡¯è‘—è¼ƒä½ï¼›PFS èˆ‡ OS å…©çµ„ç„¡é¡¯è‘—çµ±è¨ˆå­¸å·®ç•°ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“š JCOG0602 (Phase III)", "pharma": "Japan Oncology", "drug": "NACT vs PDS (Japanese Data)", 
        "pop_results": "æ—¥æœ¬å¯¦è­‰æ”¯æŒï¼šè­‰å¯¦ NACT å¯é¡¯è‘—ç¸®çŸ­æ‰‹è¡“æ™‚é–“ã€æ¸›å°‘å¤±è¡€é‡ï¼Œä¸¦é”æˆèˆ‡ PDS ç›¸ç•¶çš„ç”Ÿå­˜é å¾Œã€‚",
        "rationale": "åœ¨äºæ´²äººç¾¤ä¸­é©—è­‰ NACT çš„éåŠ£æ•ˆæ€§ï¼Œç‰¹åˆ¥è§€å¯Ÿæ‰‹è¡“ä¾µè¥²æ€§çš„é™ä½ç¨‹åº¦ã€‚",
        "regimen": "NACT çµ„: 4 é€±æœŸ CP -> IDS -> 4 é€±æœŸ CPï¼›PDS çµ„: ç›´æ¥æ‰‹è¡“ -> 8 é€±æœŸ CPã€‚",
        "inclusion": ["FIGO Stage III/IV åµå·¢ç™Œ/è…¹è†œç™Œ", "é ä¼°æ‰‹è¡“é›£åº¦é«˜è€…"],
        "outcomes": "mOS: 44.3m (NACT) vs 49.0m (PDS)ï¼›é”åˆ°éåŠ£æ•ˆæ€§çµ‚é»ä¸” NACT æ‰‹è¡“è² æ“”æ¥µè¼•ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Neoadjuvant Setting"], 
        "name": "ğŸ“ TRUST (Ongoing)", "pharma": "ENGOT-ov33", "drug": "Quality-controlled PDS vs NACT", 
        "pop_results": "é«˜å“è³ªæ‰‹è¡“æŒ‘æˆ°ï¼šåœ¨å…¨çƒé«˜å“è³ªæ‰‹è¡“ä¸­å¿ƒé‡æ–°è©•ä¼° PDS æ˜¯å¦å„ªæ–¼ NACTï¼Œå‚™å—å­¸ç•ŒæœŸå¾…ã€‚",
        "rationale": "æ‰¹è©•è€…èªç‚ºæ—©æœŸè©¦é©—çš„ PDS æ‰‹è¡“å“è³ªä¸ä¸€ï¼ŒTRUST è¦æ±‚æ¥µé«˜çš„ R0 ç‡ï¼Œæ—¨åœ¨ç‚º PDS é‡æ–°æ­£åã€‚",
        "regimen": "ç”±ç¶“éèªè­‰çš„ã€Œé«˜å“è³ªæ‰‹è¡“ä¸­å¿ƒã€é€²è¡Œéš¨æ©Ÿåˆ†é…ï¼Œåš´æ ¼åŸ·è¡Œæ ¹æ²»æ€§ PDS æ‰‹è¡“ã€‚",
        "inclusion": ["æ–°è¨ºæ–· Stage IIIB-IVB åµå·¢ç™Œ", "é«”èƒ½ç‹€æ³è‰¯å¥½ (ECOG 0-1)"],
        "outcomes": "è©¦é©—é€²è¡Œä¸­ (Ongoing)ï¼›ä¸»è¦çµ‚é»ç‚ºç¸½ç”Ÿå­˜æœŸ (OS)ï¼Œé è¨ˆå°‡æä¾› PDS æœ€çµ‚åœ°ä½çš„é—œéµè­‰æ“šã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["DDCT Setting"], 
        "name": "ğŸ“š JGOG 3016", "pharma": "JGOG", "drug": "Dose-dense Paclitaxel", 
        "pop_results": "åŠ‘é‡å¯†é›†åŒ–ç™‚é‡å¤§çªç ´ï¼šåœ¨äºæ´²äººç¾¤ä¸­ï¼Œæ¯é€± Paclitaxel é¡¯è‘—å»¶é•· PFS (28m vs 17m) èˆ‡ OS (HR 0.75)ã€‚",
        "rationale": "åˆ©ç”¨æ›´é »ç¹çš„çµ¦è—¥é »ç‡ï¼ˆæ¯é€±ä¸€æ¬¡ï¼‰ä¾†æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿä¸¦æ¸›å°‘è…«ç˜¤ç´°èƒåœ¨åŒ–ç™‚é–“æœŸçš„ä¿®å¾©æ©Ÿæœƒã€‚",
        "regimen": "Dose-dense: Paclitaxel 80mg/m2 (D1, 8, 15) + Carboplatin (AUC 6, D1) æ¯ 21 å¤©ä¸€é€±æœŸï¼Œå…± 6 é€±æœŸã€‚",
        "inclusion": ["Stage II-IV ä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "å®Œæˆåˆæ­¥æ¸›ç©æ‰‹è¡“è€…", "ECOG 0-2"],
        "outcomes": "mPFS: 28.2m (vs 17.5m, HR 0.71, P=0.0015)ï¼›mOS: 100.5m (vs 62.2m, HR 0.75, P=0.039)ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["DDCT Setting"], 
        "name": "ğŸ“š GOG-262", "pharma": "GOG", "drug": "Weekly Paclitaxel Â± Bev", 
        "pop_results": "æ¨™é¶ä½µç”¨ä¹‹æ¬Šè¡¡ï¼šåœ¨ã€ä¸ä½¿ç”¨ã€Bevacizumab çš„æ‚£è€…ä¸­ï¼Œæ¯é€±çµ¦è—¥é¡¯è‘—å»¶é•· PFSï¼›ä½†è‹¥ä½µç”¨æ¨™é¶ï¼Œå‰‡ç„¡é¡å¤–ç²ç›Šã€‚",
        "rationale": "åœ¨åŒ—ç¾äººç¾¤ä¸­é©—è­‰ JGOG 3016 çš„çµæœï¼Œä¸¦æ¢è¨ä½µç”¨ Bevacizumab æ˜¯å¦æœƒå½±éŸ¿æ¯é€±åŒ–ç™‚æ–¹æ¡ˆçš„å„ªå‹¢ã€‚",
        "regimen": "Weekly: Paclitaxel 80mg/m2 æ¯é€±é€£çºŒçµ¦è—¥ + Carboplatin (AUC 6) æ¯ 3 é€±ä¸€æ¬¡ï¼ŒÂ± Bevacizumabã€‚",
        "inclusion": ["Stage II-IV ä¸Šçš®æ€§åµå·¢ç™Œ", "ä¸é™æ‰‹è¡“åˆ‡é™¤ç¨‹åº¦ (PDS æˆ– NACT/IDS å‡å¯)"],
        "outcomes": "ä¸å« Bev æ—ç¾¤ PFS: 14.2m (Weekly) vs 10.3m (Q3W)ï¼›å« Bev æ—ç¾¤å‰‡å…©çµ„ç„¡å·®ç•°ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["DDCT Setting"], 
        "name": "ğŸ“š ICON8", "pharma": "GCIG / MRC", "drug": "Standard vs Weekly Pacli vs Weekly Carbo/Pacli", 
        "pop_results": "æ­æ´²å¤§å‹å¯¦è­‰ï¼šåœ¨æ­æ´²äººç¾¤ä¸­ï¼Œæ¯é€±åŒ–ç™‚æ–¹æ¡ˆ (Arm 2/3) ç›¸è¼ƒæ–¼æ¨™æº– Q3W æ–¹æ¡ˆã€ä¸¦æœªã€å»¶é•· PFSã€‚",
        "rationale": "æ—¨åœ¨åˆ©ç”¨ä¸‰è‡‚éš¨æ©Ÿè©¦é©—ç¢ºå®šæ¯é€±å–®è—¥æˆ–é›™è—¥åŒ–ç™‚æ˜¯å¦æ‡‰æˆç‚ºä¸Šçš®æ€§åµå·¢ç™Œçš„æ–°æ¨™æº–è¼”åŠ©æ²»ç™‚ã€‚",
        "regimen": "Arm 1: Q3W (Standard); Arm 2: Weekly Pacli (80mg/m2) + Q3W Carbo; Arm 3: Weekly Pacli (70mg/m2) + Weekly Carbo (AUC 2)ã€‚",
        "inclusion": ["Stage IC-IV ä¸Šçš®æ€§åµå·¢ç™Œ", "è¨ˆç•«æ¥å—è¼”åŠ©åŒ–ç™‚æˆ– NACT è€…"],
        "outcomes": "mPFS: Arm 1 (17.7m), Arm 2 (20.8m), Arm 3 (21.0m)ï¼›ä¸‰çµ„é–“ç„¡çµ±è¨ˆå­¸é¡¯è‘—å·®ç•°ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["DDCT Setting"], 
        "name": "ğŸ“š MITO-7", "pharma": "MITO / ENGOT", "drug": "Low-dose Weekly Carbo/Pacli", 
        "pop_results": "å»æ¯’å¼·åŒ–æ¨™æº–ï¼šæ¯é€±ä½åŠ‘é‡çµ„åˆé›–æœªå»¶é•· PFSï¼Œä½†é¡¯è‘—æå‡ç”Ÿæ´»å“è³ªä¸¦é™ä½è¡€æ¶²èˆ‡ç¥ç¶“æ¯’æ€§ã€‚",
        "rationale": "é‡å°é«”èƒ½ç‹€æ³æˆ–æ“”å¿ƒæ¯’æ€§çš„æ‚£è€…ï¼Œæ¢è¨ä½¿ç”¨æ›´æº«å’Œçš„æ¯é€±ä½åŠ‘é‡çµ„åˆæ˜¯å¦èƒ½ç¶­æŒç™‚æ•ˆä¸¦æ”¹å–„è€å—æ€§ã€‚",
        "regimen": "Weekly: Paclitaxel 60mg/m2 + Carboplatin (AUC 2) åŒæ™‚æ¯é€±çµ¦è—¥ä¸€æ¬¡ï¼Œå…± 18 é€±ã€‚",
        "inclusion": ["Stage I-IV ä¸Šçš®æ€§åµå·¢ç™Œ", "ECOG 0-2", "é©åˆæ¥å—ä¸€ç·šé‰‘é¡åŒ–ç™‚è€…"],
        "outcomes": "mPFS: 17.3m (Weekly) vs 18.3m (Q3W, P=0.66)ï¼›ç”Ÿæ´»å“è³ªé‡è¡¨æ•¸æ“šé¡¯è‘—å„ªæ–¼ Q3W çµ„ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š LION", "pharma": "NEJM", "drug": "No Lymphadenectomy", 
     "pop_results": "ç³»çµ±æ€§æ·‹å·´æ¸…æƒä¸æ”¹å–„å­˜æ´»ï¼ˆOS HR 1.06ï¼›PFS HR 1.11ï¼‰ä¸”ä½µç™¼ç—‡å¢åŠ ï¼Œæ”¹è®Šäº†ã€Œå¤–è§€æ­£å¸¸æ·‹å·´çµã€æ‚£è€…çš„æ‰‹è¡“ç¯„å¼ï¼Œè‡¨åºŠ LN é™°æ€§å…æ¸…æƒï¼šOS ç„¡å·®ç•° (HR 1.06)",
     "regimen": "åœ¨ã€Œè‡¨åºŠ/å½±åƒé™°æ€§æ·‹å·´çµã€ä¸”å®Œæˆè…«ç˜¤åˆ‡é™¤çš„ advanced ovarian cancerã€‚Arm Aï¼šsystematic pelvic + para-aortic lymphadenectomyã€‚Arm Bï¼šno lymphadenectomyã€‚",
     "inclusion": ["advanced ovarian cancerã€‚", "complete resectionã€‚", "æ·‹å·´çµè‡¨åºŠé™°æ€§ã€‚"],
     "exclusion": ["æ˜é¡¯æ·‹å·´çµç—…ç¶ã€‚", "ç„¡æ³•è€å—æ‰‹è¡“å»¶é•·ã€‚"],
     "outcomes": "OS HR 1.06ï¼ˆç„¡ç²ç›Šï¼‰ï¼›PFS äº¦ç„¡å·®ï¼›ä½†æ‰‹è¡“ä½µç™¼ç—‡å¢åŠ ã€‚mOS: 65.5m vs 69.2m (HR 1.06)ã€‚è‡¨åºŠ LN(-) è€…å…æ¸…æƒã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["IP Setting"], 
        "name": "ğŸ“š SWOG-8501 / GOG-104 (NEJM 1996)", "pharma": "GOG / SWOG", "drug": "IP Cisplatin vs IV Cisplatin", 
        "pop_results": "IP åŒ–ç™‚é¦–å€‹é‡Œç¨‹ç¢‘ï¼šé‡å° Stage III æ¸›ç©æ‰‹è¡“å¾Œæ®˜é¤˜ç—…ç¶ <2cm æ‚£è€…ï¼ŒIP Cisplatin é¡¯è‘—æ”¹å–„ OS (HR 0.76)ã€‚",
        "rationale": "åˆ©ç”¨è…¹è…”å…§ç›´æ¥çµ¦è—¥ï¼Œå¢åŠ è…¹è†œç—…ç¶è™•çš„å±€éƒ¨è—¥ç‰©æ¿ƒåº¦ï¼Œä¸¦æ¸›å°‘å…¨èº«æ€§æ¯’æ€§ã€‚",
        "regimen": "IP çµ„: Cisplatin 100mg/m2 (IP) + Cyclophosphamide 600mg/m2 (IV) Q3W x6 é€±æœŸã€‚",
        "inclusion": ["Stage III ä¸Šçš®æ€§åµå·¢ç™Œ", "æ¸›ç©æ‰‹è¡“å¾Œæ®˜é¤˜è…«ç˜¤ç›´å¾‘ <2cm", "ECOG 0-2"],
        "outcomes": "mOS: 49m (IP) vs 41m (IV)ï¼›æ­»äº¡é¢¨éšªé™ä½ 24%ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["IP Setting"], 
        "name": "ğŸ“š GOG-114", "pharma": "GOG", "drug": "IP Cisplatin/Pacli vs IV Standard", 
        "pop_results": "IP å¼·åŒ–æ–¹æ¡ˆæ¢ç´¢ï¼šè­‰å¯¦ IP Cisplatin è¯ç”¨ Paclitaxel ç¶­æŒäº†ç”Ÿå­˜ç²ç›Šï¼Œä½†æ¯’æ€§é¡¯è‘—å¢åŠ  (è¡€æ¶²æ¯’æ€§èˆ‡ç¥ç¶“æ¯’æ€§)ã€‚",
        "rationale": "æ¢è¨åœ¨ IP Cisplatin çš„åŸºç¤ä¸ŠåŠ å…¥ç¾ä»£åŒ–ç™‚è—¥ç‰© Paclitaxel æ˜¯å¦èƒ½é€²ä¸€æ­¥æå‡ PFS èˆ‡ OSã€‚",
        "regimen": "IP çµ„: Carboplatin (IV) èª˜å° -> IP Cisplatin 100mg/m2 + IV Paclitaxel -> ç¶­æŒæœŸ IP Paclitaxelã€‚",
        "inclusion": ["Stage III ä¸Šçš®æ€§åµå·¢ç™Œ", "æ®˜é¤˜ç—…ç¶ â‰¤1cm", "å…·å‚™è‰¯å¥½çš„è…åŠŸèƒ½èˆ‡é«”èƒ½"],
        "outcomes": "mPFS: 27.9m (IP) vs 22.2m (IV, P=0.01)ï¼›mOS äº¦æœ‰é¡¯è‘—ç²ç›Šè¶¨å‹¢ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["IP Setting"], 
        "name": "ğŸ“š GOG-172 (NEJM 2006)", "pharma": "GOG", "drug": "The IP Gold Standard", 
        "pop_results": "IP åŒ–ç™‚é»ƒé‡‘æ¨™æº–ï¼šå¥ å®š Stage III æ®˜é¤˜ç—…ç¶ â‰¤1cm æ‚£è€…ä½¿ç”¨ IP åŒ–ç™‚çš„åœ°ä½ï¼ŒOS é©šäººå»¶é•·é” 16 å€‹æœˆã€‚",
        "rationale": "ç¢ºèªåœ¨ R0/R1 æ‰‹è¡“å¾Œï¼Œåˆä½µä½¿ç”¨ IV èˆ‡ IP Paclitaxel/Cisplatin æ˜¯ç›®å‰æœ€æœ‰æ•ˆçš„è¼”åŠ©åŒ–ç™‚ç­–ç•¥ã€‚",
        "regimen": "D1: Paclitaxel 135mg/m2 (IV 24h); D2: Cisplatin 100mg/m2 (IP); D8: Paclitaxel 60mg/m2 (IP) Q3W x6ã€‚",
        "inclusion": ["Stage III ä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "æœ€å„ªæ¸›ç©æ‰‹è¡“å¾Œ (æ®˜é¤˜ç—…ç¶ â‰¤1cm)", "ECOG 0-1"],
        "outcomes": "mOS: 65.6m (IP) vs 49.7m (IV, P=0.03)ï¼›mPFS: 23.8m (IP) vs 18.3m (IV)ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["IP Setting"], 
        "name": "ğŸ“š GOG-252", "pharma": "GOG", "drug": "IP vs IV with Bevacizumab", 
        "pop_results": "IP åœ°ä½é‡æª¢è¦–ï¼šåœ¨æ‰€æœ‰çµ„åˆ¥å‡ä½µç”¨ Bevacizumab çš„æƒ…æ³ä¸‹ï¼ŒIP èˆ‡ IV çµ„çš„ PFS ä¸¦ç„¡é¡¯è‘—å·®ç•°ä¸” IP çµ„æ¯’æ€§è¼ƒé«˜ã€‚",
        "rationale": "æ¢è¨åœ¨æ¨™é¶æ™‚ä»£ (Bevacizumab)ï¼ŒIP æŠ•è—¥æ¨¡å¼æ˜¯å¦ä»èƒ½ç¶­æŒå…¶å„ªæ–¼å‚³çµ± IV æŠ•è—¥çš„ç”Ÿå­˜å„ªå‹¢ã€‚",
        "regimen": "ä¸‰çµ„å‡åŠ  Bev: 1. IV Carbo/Pacli; 2. IP Carbo/IV Pacli; 3. IP Cis/Pacli (æŒ‰ GOG-172 ä¿®æ”¹)ã€‚",
        "inclusion": ["Stage II-III ä¸Šçš®æ€§åµå·¢ç™Œ", "æ®˜é¤˜ç—…ç¶ â‰¤1cm", "é©åˆä½¿ç”¨æ¨™é¶è—¥ç‰© Bevacizumab"],
        "outcomes": "mPFS: ä¸‰çµ„å‡è½åœ¨ 27-28 å€‹æœˆå·¦å³ (ç„¡çµ±è¨ˆå·®ç•°)ï¼›IP çµ„å°ç®¡ç›¸é—œä½µç™¼ç—‡è¼ƒå¤šã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["IP Setting", "Neoadjuvant Setting"], 
        "name": "ğŸ“š OV21/PETROC (GCIG)", "pharma": "NCIC / GCIG", "drug": "IP Carboplatin vs IV Carboplatin", 
        "pop_results": "IP è—¥ç‰©æ”¹è‰¯ç ”ç©¶ï¼šè­‰æ˜ IP Carboplatin å…·æœ‰è‰¯å¥½è€å—æ€§ï¼Œä¸”åœ¨ PFS ä¸Šå±•ç¾å‡ºèˆ‡ IP Cisplatin ç«¶çˆ­çš„æ½›åŠ› (Phase II)ã€‚",
        "rationale": "æ—¨åœ¨åˆ©ç”¨æ¯’æ€§è¼ƒä½çš„ Carboplatin å–ä»£ Cisplatin é€²è¡Œè…¹è…”çµ¦è—¥ï¼Œä»¥è§£æ±º GOG-172 æ–¹æ¡ˆçš„é«˜æ¯’æ€§èˆ‡ä½å®Œæˆç‡å•é¡Œã€‚",
        "regimen": "IP çµ„: Carboplatin (AUC 6) IP Q3W x6 é€±æœŸï¼›å°ç…§çµ„ç‚º IV Carboplatinã€‚",
        "inclusion": ["Stage II-III åµå·¢ç™Œ/è…¹è†œç™Œ", "æ–°è¼”åŠ©åŒ–ç™‚ (NACT) éš¨å¾Œæ¥å— IDS è€…äº¦å¯å…¥æ¡ˆ"],
        "outcomes": "PFS HR: 0.82 (P=0.20)ï¼›å°æ–¼ NACT æ‚£è€…ï¼ŒIP çµ„é¡¯ç¤ºå‡ºè¼ƒä½³çš„è…¹è†œæ§åˆ¶è¶¨å‹¢ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“š GOG-281 / LOGS", "pharma": "Targeted", "drug": "Trametinib", 
        "pop_results": "LGSOC æ¨™é¶é‡å¤§çªç ´ï¼šèˆ‡é†«å¸«é¸æ“‡åŒ–ç™‚ç›¸æ¯”ï¼ŒTrametinib é¡¯è‘—é™ä½ 52% ç–¾ç—…é€²å±•é¢¨éšª (HR 0.48)ï¼ŒORR é” 26%ã€‚",
        "rationale": "é‡å°ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ (LGSOC) ä¸­å¸¸è¦‹çš„ MAPK è·¯å¾‘ç•°å¸¸æ´»åŒ–ï¼Œåˆ©ç”¨ MEK æŠ‘åˆ¶åŠ‘é€²è¡Œç²¾æº–æ¨™é¶é˜»æ–·ã€‚",
        "regimen": "Trametinib 2.0 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ä¹‹æ¯’æ€§ã€‚",
        "inclusion": ["å¾©ç™¼æ€§ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ/è…¹è†œç™Œ", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚", "ECOG 0-1"],
        "exclusion": ["æ›¾å—éå…¶ä»– MEK æŠ‘åˆ¶åŠ‘æ²»ç™‚", "è‡¨åºŠé¡¯è‘—çš„å¿ƒè‡ŸåŠŸèƒ½ç•°å¸¸"],
        "outcomes": "mPFS: 13.0m (vs 7.2m, HR 0.48, 95% CI 0.36-0.64)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“ RAMP-201", "pharma": "Verastem Oncology", "drug": "Avutometinib + Defactinib", 
        "pop_results": "LGSOC é›™é‡é˜»æ–·æ–°é«˜åº¦ï¼šKRAS çªè®Šæ—ç¾¤ ORR é«˜é” 55%ï¼›å…¨é«”æ—ç¾¤ ORR é” 45%ã€‚",
        "rationale": "çµåˆ RAF/MEK é›™é‡æŠ‘åˆ¶åŠ‘ (Avutometinib) èˆ‡ FAK æŠ‘åˆ¶åŠ‘ (Defactinib)ï¼Œæ—¨åœ¨å…‹æœå–®ä¸€é€šè·¯é˜»æ–·å¾Œç”¢ç”Ÿçš„è£œå„Ÿæ€§è€è—¥æ©Ÿåˆ¶ã€‚",
        "regimen": "Avutometinib 3.2 mg (å…©æ¬¡/é€±) + Defactinib 200 mg (å…©æ¬¡/æ—¥)ï¼Œæ¡ 3 é€±çµ¦è—¥ 1 é€±ä¼‘æ¯ä¹‹é€±æœŸè¨­è¨ˆã€‚",
        "inclusion": ["å¾©ç™¼æ€§ LGSOC (ä¸é™ KRAS ç‹€æ…‹)", "å…ˆå‰æ¥å—éå«é‰‘åŒ–ç™‚åŠæ¨™é¶æ²»ç™‚", "æä¾›è…«ç˜¤çµ„ç¹”æ¨£å“"],
        "exclusion": ["æ´»å‹•æ€§è…¦è½‰ç§»", "æ›¾å—éåŒé¡ FAK æŠ‘åˆ¶åŠ‘æ²»ç™‚"],
        "outcomes": "KRAS mut ORR: 55%; å…¨é«” ORR: 45% (åˆæ­¥æ•¸æ“šäº®çœ¼)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“š GOG-3026", "pharma": "Novartis", "drug": "Ribociclib + Letrozole", 
        "pop_results": "LGSOC å»åŒ–ç™‚çµ„åˆï¼šCDK4/6 æŠ‘åˆ¶åŠ‘ä½µç”¨èŠ³é¦™ç’°è½‰åŒ–é…¶æŠ‘åˆ¶åŠ‘ï¼Œé”æˆ ORR 23% èˆ‡ 79% çš„è‡¨åºŠç²ç›Šç‡ (CBR)ã€‚",
        "rationale": "åˆ©ç”¨å…§åˆ†æ³Œæ²»ç™‚é˜»æ–·æ¿€ç´ å—é«”ï¼Œä¸¦å”åŒ CDK4/6 æŠ‘åˆ¶åŠ‘é”æˆæ›´å¼·çš„ç´°èƒé€±æœŸåœæ»¯æ•ˆæ‡‰ã€‚",
        "regimen": "Ribociclib 400 mg QD (é€£æœ 3 é€±ä¼‘æ¯ 1 é€±) + Letrozole 2.5 mg QD (æŒçºŒæ¯æ—¥å£æœ)ã€‚",
        "inclusion": ["å¾©ç™¼æ€§ LGSOC", "ER/PR é™½æ€§è¡¨é”è€…å„ªå…ˆ", "ä¸é™å…ˆå‰æ²»ç™‚ç·šæ•¸"],
        "exclusion": ["ç„¡æ³•ååš¥å£æœè—¥ç‰©è€…", "ä½µç”¨å¼·æ•ˆ CYP3A4 èª˜å°åŠ‘"],
        "outcomes": "mPFS: 19.1m; ORR: 23%; CBR: 79%ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["Low grade serous carcinoma"], 
        "name": "ğŸ“š MILO / ENGOT-ov11", "pharma": "Array BioPharma", "drug": "Binimetinib", 
        "pop_results": "LGSOC æ¨™é¶æ¢ç´¢ï¼šæ¯”è¼ƒ MEK æŠ‘åˆ¶åŠ‘ Binimetinib èˆ‡åŒ–ç™‚ï¼Œé›–è©¦é©—å› ç„¡æ•ˆæ€§æ—©æœŸåœæ­¢ï¼Œä½†ä»ç‚º LGSOC é‡è¦ç ”ç©¶æ•¸æ“šã€‚",
        "rationale": "é‡å°ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§ç™Œ (LGSOC) å¸¸è¦‹ä¹‹ MAPK é€šè·¯æ¿€æ´»ï¼Œå˜—è©¦åˆ©ç”¨å–®è—¥ MEK æŠ‘åˆ¶åŠ‘é”æˆæ§åˆ¶ã€‚",
        "regimen": "Binimetinib 45 mg æ¯æ—¥å£æœå…©æ¬¡ï¼Œå°æ¯”é†«å¸«é¸æ“‡ä¹‹åŒ–ç™‚ (PLD/Pacli/Topo)ã€‚",
        "inclusion": ["å¾©ç™¼æ€§ä½æƒ¡æ€§åº¦æ¼¿æ¶²æ€§åµå·¢ç™Œ", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€ç·šå«é‰‘åŒ–ç™‚", "ä¸é™ KRAS/BRAF ç‹€æ…‹"],
        "outcomes": "mPFS: 9.1m (Binimetinib) vs 10.6m (Chemo)ï¼ŒHR 1.21 (æœªé”é æœŸç²ç›Š)ã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["P-TX"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“š JGOG3017 / GCIG", "pharma": "JGOG", "drug": "Irinotecan + Cisplatin vs TC", 
        "pop_results": "OCCC ä¸€ç·šæ¨™æº–æŒ‘æˆ°ï¼šæ¯”è¼ƒ Irinotecan/Cisplatin (CP) èˆ‡å‚³çµ± TC æ–¹æ¡ˆï¼Œçµæœé¡¯ç¤ºåœ¨ PFS æˆ– OS ä¸Šç„¡é¡¯è‘—å·®ç•°ã€‚",
        "rationale": "è€ƒé‡æ˜ç´°èƒç™Œ (OCCC) å° Paclitaxel è¼ƒä¸æ•æ„Ÿï¼Œå˜—è©¦åˆ©ç”¨å° OCCC å…·æ½›åœ¨æ´»æ€§çš„ Irinotecan æ–¹æ¡ˆé€²è¡Œä¸€ç·šæŒ‘æˆ°ã€‚",
        "regimen": "Arm A: Irinotecan (60mg/m2 D1, 8, 15) + Cisplatin (60mg/m2 D1) Q4W; Arm B: Carboplatin (AUC 6) + Paclitaxel (175mg/m2) Q3Wã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage I-IV æ˜ç´°èƒç™Œ (OCCC)", "ECOG 0-2", "æ‰‹è¡“å¾Œç—…ç†è­‰å¯¦"],
        "outcomes": "2yr PFS: 63.0% (CP) vs 67.3% (TC); mOS HR: 1.06 (P=0.72)ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["P-MT"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“š Temsirolimus + TC (Phase II)", "pharma": "GOG / NCI", "drug": "TC + Temsirolimus â†’ Maint", 
        "pop_results": "OCCC ç¶­æŒæ²»ç™‚æ¢ç´¢ï¼šåœ¨ä¸€ç·š TC åŒ–ç™‚åŸºç¤ä¸ŠåŠ å…¥ mTOR æŠ‘åˆ¶åŠ‘ä¸¦æ¥çºŒç¶­æŒï¼Œçµæœé¡¯ç¤ºè€å—æ€§è‰¯å¥½ä½†æœªé”é æœŸä¹‹é¡¯è‘— PFS å»¶é•·ã€‚",
        "rationale": "æ˜ç´°èƒç™Œå¸¸ä¼´éš¨ PI3K/Akt/mTOR é€šè·¯æ´»åŒ–ï¼Œåˆ©ç”¨ Temsirolimus é€²è¡Œæ¨™é¶å¹²é ä¸¦é€éæ•´åˆèˆ‡éå›ºç­–ç•¥å¼·åŒ–ç™‚æ•ˆã€‚",
        "regimen": "èª˜å°æœŸ: TC + Temsirolimus (25mg IV æ¯é€±) x6 é€±æœŸ; ç¶­æŒæœŸ: Temsirolimus å–®è—¥æŒçºŒæ²»ç™‚ç›´è‡³é€²å±•ã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage III-IV æ˜ç´°èƒç™Œ", "ECOG 0-1", "å®Œæˆåˆæ­¥æ¸›ç©æ‰‹è¡“"],
        "outcomes": "12m PFS Rate: 48%; mPFS: 11.2m; è­‰å¯¦ OCCC ä»å…·å‚™æ¥µå¼·çš„æŠ—è—¥æ€§ç“¶é ¸ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“š GOG-254", "pharma": "GOG / NCI", "drug": "Sunitinib", 
        "pop_results": "OCCC æ¨™é¶æ•‘æ´ï¼šå¤šé¶é» TKI Sunitinib åœ¨ç¶“æ²»çš„æ˜ç´°èƒç™Œä¸­å±•ç¾ä¸­ç­‰æ´»æ€§ï¼ŒPFS é” 2.7 å€‹æœˆã€‚",
        "rationale": "é‡å° OCCC é«˜åº¦è¡¨é” VEGF çš„ç‰¹æ€§ï¼Œåˆ©ç”¨å£æœå¤šé¶é» TKI é˜»æ–·è¡€ç®¡æ–°ç”Ÿä»¥å°‹æ±‚äºŒç·šå¾Œçš„ç·©è§£æ©Ÿæœƒã€‚",
        "regimen": "Sunitinib 50 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼Œæ¡ 4 é€±çµ¦è—¥ 2 é€±ä¼‘æ¯ä¹‹é€±æœŸ (Schedule 4/2)ã€‚",
        "inclusion": ["å¾©ç™¼æˆ–æŒä¹…æ€§æ˜ç´°èƒåµå·¢ç™Œ", "å…ˆå‰æ¥å—é 1-2 ç·šå«é‰‘æ²»ç™‚å¤±æ•—è€…", "ECOG 0-2"],
        "outcomes": "ORR: 6.7%; PFS-6 Rate: 23.3%; mPFS: 2.7mã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“š MoST-CIRCUIT (Non-randomized)", "pharma": "Garvan Institute", "drug": "Nivolumab + Ipilimumab", 
        "pop_results": "OCCC å…ç–«é›™é˜»æ–·ï¼šé‡å°é›£æ²»å‹ OCCCï¼ŒNivo+Ipi çµ„åˆå±•ç¾äº®çœ¼çš„ ORR (24%) èˆ‡æŒä¹…çš„ç–¾ç—…æ§åˆ¶ã€‚",
        "rationale": "è€ƒé‡ OCCC å…·å‚™ç‰¹å®šçš„å…ç–«æŠ‘åˆ¶ç’°å¢ƒï¼Œé€é PD-1 èˆ‡ CTLA-4 é›™é‡é˜»æ–·æ¿€ç™¼æ›´å¼·çš„ T ç´°èƒæŠ—è…«ç˜¤åæ‡‰ã€‚",
        "regimen": "Nivolumab 3mg/kg + Ipilimumab 1mg/kg æ¯ 3 é€±ä¸€æ¬¡ x4 é€±æœŸï¼Œéš¨å¾Œ Nivolumab ç¶­æŒæ²»ç™‚ã€‚",
        "inclusion": ["å¾©ç™¼æ€§æ˜ç´°èƒåµå·¢ç™Œ", "å…ˆå‰æ¥å—éè‡³å°‘ä¸€ç·šåŒ–ç™‚", "å…·å‚™å¯æ¸¬é‡ç—…ç¶"],
        "outcomes": "ORR: 24%; è‡¨åºŠç²ç›Šç‡ (CBR): 52%; å±•ç¾å…ç–«æ²»ç™‚åœ¨ OCCC äºå‹ä¸­çš„ç‰¹æ®Šæ½›åŠ›ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“š BrUOG 354 (Randomized Phase II)", "pharma": "Brown University", "drug": "Nivolumab vs Nivo+Ipi", 
        "pop_results": "OCCC å…ç–«æ–¹æ¡ˆå°æ¯”ï¼šéš¨æ©Ÿå°ç…§é¡¯ç¤ºï¼Œé›™å…ç–« (Nivo+Ipi) åœ¨ ORR èˆ‡ PFS ä¸Šå‡å„ªæ–¼å–®è—¥ Nivolumabã€‚",
        "rationale": "æ—¨åœ¨ç¢ºå®šé‡å°æ˜ç´°èƒç™Œäºå‹ï¼Œæ˜¯å¦å¿…é ˆè¯ç”¨ CTLA-4 æŠ‘åˆ¶åŠ‘æ‰èƒ½å…‹æœå…¶å…ç–«å†·è…«ç˜¤çš„ç‰¹å¾µã€‚",
        "regimen": "Arm A: Nivolumab å–®è—¥; Arm B: Nivolumab + Ipilimumab (1mg/kg) Q3Wã€‚",
        "inclusion": ["å¾©ç™¼æˆ–è½‰ç§»æ€§æ˜ç´°èƒåµå·¢ç™Œ", "ECOG 0-1", "å…è¨±å…ˆå‰æ¥å—éæŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚"],
        "outcomes": "Nivo+Ipi çµ„ ORR é¡¯è‘—æå‡ï¼›ä¸­ä½ PFS èˆ‡æŒçºŒç·©è§£æ™‚é–“äº¦ä½”å„ªå‹¢ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["Clear Cell Carcinoma"], 
        "name": "ğŸ“ ATARI (ceralasertib Â± olaparib)", "pharma": "ENGOT-ov58 / AstraZeneca", "drug": "Ceralasertib Â± Olaparib", 
        "pop_results": "ARID1A é¶é»ç²¾æº–é†«ç™‚ï¼šé‡å° ARID1A çªè®Šçš„ OCCCï¼ŒATR æŠ‘åˆ¶åŠ‘å±•ç¾å‡º 14% çš„ ORR èˆ‡è‰¯å¥½çš„ç–¾ç—…æ§åˆ¶æ½›åŠ›ã€‚",
        "rationale": "ARID1A çªè®Šå°è‡´ DNA æå‚·ä¿®å¾©å£“åŠ›å¢åŠ ï¼Œåˆ©ç”¨ ATR æŠ‘åˆ¶åŠ‘ (Ceralasertib) èª˜å°åˆæˆè‡´æ­»ï¼Œä¸¦æ¢ç´¢èˆ‡ PARPi çš„å”åŒæ•ˆæ‡‰ã€‚",
        "regimen": "Cohort 1 (ARID1A def): Ceralasertib å–®è—¥; Cohort 2: Ceralasertib + Olaparibã€‚",
        "inclusion": ["å¾©ç™¼æ€§æ˜ç´°èƒç™Œæˆ–å­å®®å…§è†œæ¨£ç™Œ", "ç¶“ NGS è­‰å¯¦å…·å‚™ ARID1A ç¼ºå¤±/çªè®Š", "é‰‘é¡è€è—¥æˆ–ä¸é©åˆå«é‰‘æ²»ç™‚è€…"],
        "outcomes": "ARID1A ç¼ºå¤±çµ„ ORR: 14%; è‡¨åºŠç²ç›Šç‡ (CBR) at 16w: 47%ã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["P-TX", "R-TX"], 
        "sub_pos": ["Mucinous (MOC) é‘‘å®š"], 
        "name": "ğŸ“š mEOC / GOG-0241", "pharma": "NRG Oncology / GOG", "drug": "Pac-Carbo vs Oxal-Cape Â± Bev", 
        "pop_results": "ç½•è¦‹ç™Œåˆ¥æ¨™èªŒæ€§ç ”ç©¶ï¼šé›–ç„¶å› æ”¶æ¡ˆå›°é›£æå‰çµ‚æ­¢ (N=50)ï¼Œä½†åœ¨ç¢ºèªç‚ºåŸç™¼æ€§ mEOC çš„äºçµ„ä¸­ï¼ŒGI æ–¹æ¡ˆ (Oxal-Cape) å±•ç¾è¼ƒä½³çš„ç”Ÿå­˜ç²ç›Šè¶¨å‹¢ã€‚",
        "rationale": "ç¬¬ä¸€å€‹é‡å° mEOC é€²è¡Œçš„å¤šåœ‹éš¨æ©Ÿè©¦é©—ï¼Œå°æ¯”å‚³çµ±å©¦ç™ŒåŒ–ç™‚ (Gyn-type) èˆ‡è…¸èƒƒé“ç™ŒåŒ–ç™‚ (GI-type) æ–¹æ¡ˆï¼Œä¸¦æ¢ç´¢ Bevacizumab çš„è§’è‰²ã€‚",
        "regimen": "1. Paclitaxel + Carboplatin Â± Bevacizumab (15mg/kg) Q3W; 2. Oxaliplatin (130mg/m2) + Capecitabine (850mg/m2 bid D1-14) Â± Bevacizumabã€‚",
        "inclusion": ["æ–°è¨ºæ–· FIGO Stage II-IV æˆ– Stage I å¾©ç™¼ä¹‹åŸç™¼é»æ¶²æ€§ä¸Šçš®æ€§åµå·¢ç™Œ", "å…ˆå‰æœªæ¥å—éé‡å° R/M ä¹‹åŒ–ç™‚"],
        "outcomes": "åŸç™¼æ€§ mEOC äºçµ„ OS HR: 0.36 (p=0.14); PFS HR: 0.62 (p=0.40)ã€‚"},
    
    {"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["Mucinous (MOC) é‘‘å®š"], 
        "name": "ğŸ“ mFOLFIRINOX + Bev (NCT05665023)", "pharma": "Yonsei University", "drug": "modified FOLFIRINOX + Bevacizumab", 
        "pop_results": "GI-style æ–¹æ¡ˆå‰ç»æ¢ç´¢ï¼šé‡å°é›£æ²»å‹ mEOCï¼Œåˆ©ç”¨é«˜å¼·åº¦çš„ä¸‰è—¥åŒ–ç™‚è¯ç”¨æ¨™é¶ï¼Œæ—¨åœ¨å…‹æœå‚³çµ±åŒ–ç™‚çš„è€è—¥æ€§ã€‚",
        "rationale": "è€ƒé‡ mEOC çš„ GI éºå‚³ç‰¹æ€§ï¼Œæ­¤è©¦é©—å°‡è½‰ç§»æ€§èƒ°è‡Ÿç™Œ/å¤§è…¸ç™Œçš„æ¨™æº–æ–¹æ¡ˆ (FOLFIRINOX) æ‡‰ç”¨æ–¼åµå·¢ç™Œï¼Œä¸¦é€é Bevacizumab å¼·åŒ–ç™‚æ•ˆã€‚",
        "regimen": "Bevacizumab (5mg/kg) + Oxaliplatin (85mg/m2) + Leucovorin (400mg/m2) + Irinotecan (150mg/m2) + 5-FU (2400mg/m2 46h) Q2Wã€‚",
        "inclusion": ["å¾©ç™¼æˆ–è½‰ç§»æ€§åµå·¢é»æ¶²æ€§è…ºç™Œ", "å…ˆå‰æ¥å—é 2 ç·šä»¥ä¸‹ä¹‹å…¨èº«æ€§æ²»ç™‚", "æ’é™¤ç¶“å…§è¦–é¡è¨ºæ–·ç‚º GI ä¾†æºä¹‹è…«ç˜¤"],
        "outcomes": "è©¦é©—é€²è¡Œä¸­ (Ongoing)ï¼Œé è¨ˆ 2025 å¹´ 2 æœˆå®Œæˆä¸»è¦æŒ‡æ¨™æ”¶æ¡ˆã€‚"},

    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], 
        "name": "ğŸ“š Calypso Trial", "pharma": "ENGOT / GOG", "drug": "Carboplatin + PLD", 
        "pop_results": "é‰‘æ•å¾©ç™¼å»æ¯’æ¨™æº–ï¼šè­‰å¯¦ Carbo/PLD åœ¨ PFS ä¸Šå„ªæ–¼å‚³çµ± Carbo/Pacliï¼Œä¸”å…·å‚™æ›´ä½³çš„è€å—æ€§ (è¼ƒå°‘æ‰é«®èˆ‡ç¥ç¶“æ¯’æ€§)ã€‚",
        "rationale": "æ—¨åœ¨ç‚ºé‰‘é¡æ•æ„Ÿå¾©ç™¼æ‚£è€…å°‹æ‰¾ä¸€å€‹èˆ‡å‚³çµ±æ–¹æ¡ˆç™‚æ•ˆç›¸ç•¶ã€ä½†æ¯’æ€§è¼ƒä½çš„åŒ–ç™‚çµ„åˆã€‚",
        "regimen": "Carboplatin (AUC 5) + Pegylated Liposomal Doxorubicin (30mg/m2) æ¯ 4 é€±çµ¦è—¥ä¸€æ¬¡ï¼Œå…± 6 é€±æœŸã€‚",
        "inclusion": ["é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m) ä¸Šçš®æ€§åµå·¢ç™Œ", "å…ˆå‰åƒ…æ¥å—éä¸€ç·šå«é‰‘è¼”åŠ©åŒ–ç™‚"],
        "outcomes": "mPFS: 11.3m (vs 9.4m, HR 0.82, P=0.005)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], 
        "name": "ğŸ“š OCEANS", "pharma": "Roche / GOG", "drug": "Chemo + Bevacizumab (PSOC)", 
        "pop_results": "é‰‘æ•å¾©ç™¼æ¨™é¶æ¨™æº–ï¼šåœ¨åŒ–ç™‚åŸºç¤ä¸ŠåŠ å…¥ Bevacizumab ç¶­æŒæ²»ç™‚ï¼Œé¡¯è‘—å»¶é•· PFS é” 4 å€‹æœˆ (HR 0.48)ã€‚",
        "rationale": "é‡å°é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼æ‚£è€…ï¼Œåˆ©ç”¨æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©å¼·åŒ–å«é‰‘è¤‡æ–¹åŒ–ç™‚ (Gem/Carbo) çš„ç™‚æ•ˆä¸¦å»¶ç·©äºŒæ¬¡å¾©ç™¼ã€‚",
        "regimen": "Bevacizumab (15mg/kg Q3W) è¯ç”¨ Gemcitabine/Carboplatin 6-10 é€±æœŸï¼Œéš¨å¾Œå–®è—¥ç¶­æŒç›´è‡³é€²å±•ã€‚",
        "inclusion": ["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PFI > 6m) ä¸Šçš®æ€§åµå·¢ç™Œ", "å…ˆå‰æœªæ¥å—éæŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚", "å…·å‚™å¯æ¸¬é‡ç—…ç¶"],
        "exclusion": ["æ›¾å—é VEGF æŠ‘åˆ¶åŠ‘æ²»ç™‚", "æœ‰è…¸æ¢—é˜»ç—‡ç‹€æˆ–ç—…å²"],
        "outcomes": "mPFS: 12.4m (vs 8.4m, HR 0.484, P<0.0001)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], 
        "name": "ğŸ“š GOG-0213", "pharma": "Roche / GOG", "drug": "Chemo + Bevacizumab (OS Benefit)", 
        "pop_results": "é‰‘æ•å¾©ç™¼ OS çªç ´ï¼šè­‰å¯¦åŠ å…¥ Bevacizumab ç¶­æŒæ²»ç™‚èƒ½ç‚º PSOC æ‚£è€…å¸¶ä¾†é¡¯è‘—çš„ç”Ÿå­˜è·ç›Š (mOS å»¶é•·ç´„ 5 å€‹æœˆ)ã€‚",
        "rationale": "è©•ä¼° Bevacizumab è¯ç”¨ Paclitaxel/Carboplatin å°æ–¼é‰‘æ•å¾©ç™¼æ‚£è€…çš„ Overall Survival (OS) å½±éŸ¿ã€‚",
        "regimen": "Bevacizumab (15mg/kg Q3W) è¯ç”¨ Pacli/Carboï¼Œéš¨å¾Œå–®è—¥ç¶­æŒç›´è‡³é€²å±•ã€‚",
        "inclusion": ["é‰‘é¡æ•æ„Ÿå¾©ç™¼ä¸Šçš®æ€§åµå·¢ç™Œ", "ECOG 0-1", "é©åˆå†æ¬¡æ¥å—é‰‘é¡åŒ–ç™‚"],
        "outcomes": "mOS: 42.6m (vs 37.3m, HR 0.829, P=0.0447)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive Recur)"], 
        "name": "ğŸ“š MITO16B / MaNGO OV2B / ENGOT-ov17", "pharma": "Roche / ENGOT", "drug": "Bevacizumab Beyond Bevacizumab", 
        "pop_results": "æ¨™é¶è·¨ç·šæ²»ç™‚é¦–é¸ï¼šè­‰æ˜ä¸€ç·šç”¨é Bev å¾Œï¼Œå¾©ç™¼æ™‚ã€æŒçºŒä½¿ç”¨ Bevã€ä»å…·å‚™é¡¯è‘— PFS ç²ç›Š (HR 0.51)ã€‚",
        "rationale": "æŒ‘æˆ°æŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚çš„è€è—¥æ¦‚å¿µï¼Œé©—è­‰è·¨ç·šç¶­æŒ (Beyond PD) æ˜¯å¦èƒ½æŒçºŒæŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€‚",
        "regimen": "å«é‰‘è¤‡æ–¹åŒ–ç™‚è¯ç”¨ Bevacizumab (15mg/kg Q3W)ï¼Œéš¨å¾Œå–®è—¥ç¶­æŒç›´è‡³é€²å±•ã€‚",
        "inclusion": ["ä¸€ç·šæ¥å—éæ¨™é¶ (Bev) æ²»ç™‚ä¹‹é‰‘æ•å¾©ç™¼æ‚£è€…", "ECOG 0-1"],
        "outcomes": "mPFS: 11.8m (vs 8.8m, HR 0.51, 95% CI 0.41-0.65)ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)"], 
        "name": "ğŸ“š AURELIA", "pharma": "Roche", "drug": "Bev + non-Platinum Chemo (PROC)", 
        "pop_results": "é‰‘æŠ—å¾©ç™¼åŸºçŸ³ï¼šé¦–å€‹è­‰æ˜ Bev è¯ç”¨å–®è—¥åŒ–ç™‚èƒ½ä½¿ PFS ç¿»å€ (6.7m vs 3.4m) ä¸”æ”¹å–„ç”Ÿæ´»å“è³ªã€‚",
        "rationale": "é‡å°é å¾Œæ¥µå·®çš„é‰‘é¡æŠ—è—¥å‹æ‚£è€…ï¼Œåˆ©ç”¨ Bev å”åŒå‚³çµ±å–®è—¥åŒ–ç™‚å…‹æœåŒ–ç™‚è€è—¥æ€§ã€‚",
        "regimen": "Bevacizumab (10mg/kg Q2W æˆ– 15mg/kg Q3W) è¯ç”¨å–®è—¥åŒ–ç™‚ (Pacli/PLD/Topotecan)ã€‚",
        "inclusion": ["é‰‘é¡æŠ—è—¥å‹ (PFI < 6m) ä¸Šçš®æ€§åµå·¢ç™Œ", "å…ˆå‰æ²»ç™‚ç·šæ•¸ â‰¤ 2 ç·š", "ç„¡è…¸é“å—ç´¯é¢¨éšª"],
        "exclusion": ["å…ˆå‰ä¸€ç·šå³é€²å±•è€…", "æ´»å‹•æ€§è…¸é“ç–¾ç—…"],
        "outcomes": "mPFS: 6.7m (vs 3.4m, HR 0.48, P<0.001)ã€‚"},
    
    {"cancer": "Ovarian", 
    "pos": "P-MT", 
    "sub_pos": ["HRD positive (wt)", "HRD negative (pHRD)"], 
    "name": "ğŸ“š DUO-O (ENGOT-OV46)", 
    "pharma": "AstraZeneca", 
    "drug": "Durvalumab + Olaparib + Bev",
    "pop_results": "ä¸€ç·šåˆä½µå…ç–«/æŠ—è¡€ç®¡/ï¼ˆéƒ¨åˆ†æ—ç¾¤åŠ PARPiï¼‰å¸¶ä¾†PFSæ”¹å–„ï¼›ç™¼è¡¨è³‡æ–™é¡¯ç¤ºã€ŒDurvalumabï¼‹Bevã€çµ„åˆå°æ¯”å°ç…§PFS HR 0.49ï¼ŒåŠ å…¥Olaparibå¾ŒPFS HR 0.61ï¼Œå‡¸é¡¯å¤šæ©Ÿè½‰ä¸€ç·šç­–ç•¥çš„æ–¹å‘ï¼ŒHRD+ ä¸‰è—¥çµ„ PFS HR 0.49; ITT HR 0.63",
    "rationale": "åˆ©ç”¨ IO + PARPi + anti-VEGF ä¸‰è—¥è¯ç”¨ï¼Œæ–¼ä¸€ç·šåæ‡‰å¾Œæ¸…é™¤å¾®å°æ®˜ç•™ç—…ç¶ä¸¦å»¶ç·©å¾©ç™¼ã€‚",
    "regimen": "backboneï¼šcarboplatin/paclitaxel + bevacizumab; éš¨æ©ŸåŠ å…¥ durvalumabï¼ˆèˆ‡åŒ–ç™‚ä½µç”¨ï¼‰ä¸¦åœ¨ç¶­æŒæœŸåˆä½µ durvalumab + bev Â± olaparib; Arm 3: Bevacizumab + Durvalumab + Olaparib (300mg bid) ç¶­æŒç›´è‡³ç–¾ç—…é€²å±•ã€‚",
    "inclusion": ["æ–°è¨ºæ–· FIGO III-IV æœŸä¸Šçš®æ€§åµå·¢ç™Œã€‚", "æ¥å— PDS æˆ– IDS ä¸”å°é‰‘é¡æœ‰åæ‡‰ã€‚", "ç‰¹åˆ¥é‡å° nonâ€“tumor BRCA-mutï¼ˆnon-tBRCAmï¼‰ã€ä¸¦ä»¥ HRD/ITT åšä¸»è¦åˆ†æã€‚"],
    "exclusion": ["ä¸é©åˆ bevã€‚", "æ—¢å¾€å…ç–«æ²»ç™‚ / PARPã€‚"],
    "outcomes": "åœ¨ HRD+ èˆ‡ ITTï¼ˆnon-tBRCAmï¼‰ æ—ç¾¤ï¼Œå« durvalumab+olaparib çš„ç­–ç•¥é”æˆ PFS ä¸»è¦çµ‚é»ï¼›OS ä»éœ€æ›´é•·è¿½è¹¤ï¼ŒHRD+ (non-BRCAm) PFS HR 0.49 (95% CI 0.34-0.69); ITT ITT HR 0.63ã€‚"},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation"], 
        "name": "ğŸ“š SOLO-1", "pharma": "AZ", "drug": "Olaparib", 
        "pop_results": "BRCAm ä¸€ç·šç¶­æŒé‡‘æ¨™æº–ï¼š7 å¹´å­˜æ´»ç‡é” 67% (HR 0.33)ã€‚",
        "rationale": "é‡å°ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰è‰¯å¥½ä¹‹ BRCA çªè®Šæ‚£è€…ï¼Œåˆ©ç”¨ PARPi é”æˆã€åˆæˆè‡´æ­»ã€æ•ˆæœä»¥å»¶ç·©å¾©ç™¼ã€‚",
        "regimen": "Arm Aï¼šolaparib 300 mg BID maintenanceï¼ˆé€šå¸¸è‡³ 2 å¹´æˆ–é€²å±•ï¼‰ã€‚Arm Bï¼šplacebo maintenanceã€‚",
        "inclusion": ["newly diagnosed advanced ovarian cancerã€‚", "germline æˆ– somatic BRCA1/2 mutationã€‚", "ä¸€ç·š platinum åŒ–ç™‚å¾Œ CR/PRã€‚"],
        "exclusion": ["å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "mPFS: 56.0m vs 13.8m (HR 0.30)ã€‚AEï¼šè²§è¡€ã€å™å¿ƒã€ç–²å€¦å¸¸è¦‹ï¼›éœ€ç›£æ¸¬è¡€çƒã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt", "HRD negative (pHRD)"], 
        "name": "ğŸ“š PRIMA", "pharma": "GSK", "drug": "Niraparib", 
        "pop_results": "ä¸é™ BRCA ç‹€æ…‹çš„å…¨äººç¾¤ä¸€ç·šç¶­æŒï¼šHRD+ PFS HR 0.43ï¼›å…¨é«” ITT HR 0.62ï¼Œç¢ºç«‹ã€Œä¸éœ€é™ç¸®åˆ°BRCAã€çš„ä¸€ç·šç¶­æŒç­–ç•¥ã€‚",
        "rationale": "ä¸è«– HRD ç‹€æ…‹ï¼Œé€é PARPi å¼·åŒ–ä¸€ç·šåŒ–ç™‚å¾Œçš„ç¶­æŒç²ç›Šï¼Œç‰¹åˆ¥æ˜¯é‡å°é«˜é¢¨éšªæ—ç¾¤ã€‚",
        "regimen": "Arm Aï¼šniraparib maintenanceï¼ˆèµ·å§‹åŠ‘é‡å¯ä¾é«”é‡/è¡€å°æ¿èª¿æ•´ï¼›è‡³ 36 å€‹æœˆæˆ–é€²å±•ï¼‰ã€‚Arm Bï¼šplacebo maintenanceã€‚",
        "inclusion": ["newly diagnosed stage III/IVã€é«˜å¾©ç™¼é¢¨éšªã€‚", "ä¸€ç·š platinum åŒ–ç™‚å¾Œ CR/PRã€‚"],
        "exclusion": ["MDS/AML é¢¨éšªè©•ä¼°ç­‰ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "HRD+ PFS HR 0.43 (95% CI 0.31-0.59)ã€‚overall PFS HR 0.62ã€‚AEï¼šGrade â‰¥3 å¸¸è¦‹ è¡€å°æ¿ä¸‹é™ã€è²§è¡€ã€ä¸­æ€§çƒä½ä¸‹ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive / BRCA wt"], 
        "name": "ğŸ“š PAOLA-1", "pharma": "AZ", "drug": "Olaparib + Bevacizumab", 
        "pop_results": "Olaparibï¼‹Bevacizumabç¶­æŒåœ¨å…¨é«”æ”¹å–„PFSï¼ˆHR 0.59ï¼‰ï¼Œåœ¨HRDé™½æ€§æ—ç¾¤æ•ˆç›Šæ›´å¤§ï¼ˆHR 0.33ï¼‰ï¼Œå¥ å®šã€ŒHRDå°å‘ã€åˆä½µç¶­æŒçš„æ¨™æº–ï¼ŒHRD+ é»ƒé‡‘çµ„åˆç¶­æŒï¼š5 å¹´ OS ç‡é” 75.2%ã€‚",
        "rationale": "çµåˆ anti-VEGFï¼ˆBevï¼‰é‡å¡‘è¡€ç®¡ç’°å¢ƒèˆ‡ PARPiï¼ˆOlaï¼‰æŠ‘åˆ¶ DNA ä¿®å¾©ä¹‹é›™é‡æ©Ÿè½‰ã€‚",
        "regimen": "æ‰€æœ‰æ‚£è€…å…ˆæ¥å—å« bevacizumab çš„ä¸€ç·šåŒ–ç™‚; Arm Aï¼šolaparib + bevacizumab maintenanceã€‚Arm Bï¼šbevacizumab maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["newly diagnosed stage III/IVã€é«˜å¾©ç™¼é¢¨éšªã€‚", "åŒ–ç™‚ + bev å¾Œ CR/PRã€‚", "ä¸¦åˆ†å±¤ HRD/BRCAã€‚"],
        "exclusion": ["ä¸é©åˆ bevï¼ˆå‡ºè¡€/å»”ç®¡/è¡€æ “é¢¨éšªï¼‰ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "PFS é¡¯è‘—æ”¹å–„ï¼ˆå°¤å…¶ HRD+ï¼‰ã€‚HRD+ 5yr OS: 75.2% vs 58.3% (HR 0.62)å…·è‡¨åºŠæ„ç¾©çš„ OS æ”¹å–„ã€‚AEï¼šPARPï¼ˆè²§è¡€ï¼‰+ bevï¼ˆé«˜è¡€å£“/è›‹ç™½å°¿ï¼‰æ¯’æ€§éœ€ä¸¦è¡Œç®¡ç†ã€‚"},
    
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive / BRCA wt"], 
        "name": "ğŸ“š ATHENAâ€“MONO", "pharma": "Clovis", "drug": "Rucaparib", 
        "pop_results": "Rucaparibä¸€ç·šç¶­æŒæ”¹å–„PFSï¼ˆITTï¼šHR 0.52ï¼›HRDï¼šHR 0.47ï¼›HRD-negativeäº¦æœ‰è¨Šè™Ÿï¼šHR 0.65ï¼‰ï¼Œæ“´å……äº†ä¸€ç·šPARPiç¶­æŒçš„è­‰æ“šç‰ˆåœ–ã€‚",
        "rationale": "è­‰å¯¦ Rucaparib åœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„å–®è—¥ç¶­æŒåƒ¹å€¼ï¼Œä¸è«–å…¶ HRD ç‹€æ…‹ã€‚",
        "regimen": "Arm Aï¼šrucaparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["newly diagnosed advancedï¼ˆå¤šç‚º III/IVï¼‰ã€‚", "ä¸€ç·š platinum å¾Œ CR/PRã€‚", "æ¶µè“‹ HRD/HRPã€‚"],
        "exclusion": ["è‚åŠŸèƒ½ç•°å¸¸ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "ä¸»è¦çµ‚é»ç‚º PFSï¼Œåœ¨ HRD èˆ‡ ITT å‡å‘ˆç¾é¡¯è‘—ç²ç›Š: ITT PFS: 28.7m vs 11.3m (HR 0.52)ã€‚AEï¼šè²§è¡€ã€è‚é…µç´ ä¸Šå‡ç­‰ PARP å…¸å‹æ¯’æ€§ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š NOVA", "pharma": "GSK", "drug": "Niraparib", 
        "pop_results": "å¾©ç™¼ã€é‰‘æ•æ„Ÿæƒ…å¢ƒä¸‹Niraparibç¶­æŒé¡¯è‘—å»¶é•·PFSï¼ˆgBRCAï¼šHR 0.27ï¼›non-gBRCAï¼šHR 0.45ï¼‰ï¼Œæ˜¯ã€Œå¾©ç™¼ç¶­æŒPARPiã€çš„ç¶“å…¸è©¦é©—",
        "rationale": "é¦–å€‹è­‰æ˜ PARPi åœ¨é‰‘é¡æ•æ„Ÿå¾©ç™¼ï¼ˆPSOCï¼‰æ‚£è€…ä¸­ï¼Œä¸è«– BRCA æ˜¯å¦çªè®Šçš†æœ‰ç²ç›Šçš„ç ”ç©¶ã€‚",
        "regimen": "Arm Aï¼šniraparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å°æœ€è¿‘ä¸€æ¬¡ platinum æœ‰åæ‡‰ã€‚", "åˆ† gBRCA èˆ‡ non-gBRCA cohortã€‚"],
        "exclusion": ["MDS/AML é¢¨éšªã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "gBRCAm mPFS: 21.0m vs 5.5m (HR 0.27)ã€‚non-gBRCA HR 0.45ã€‚AEï¼šè¡€å°æ¿ä¸‹é™/è²§è¡€/ä¸­æ€§çƒä½ä¸‹å¸¸è¦‹ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š ARIEL3", "pharma": "Clovis", "drug": "Rucaparib", 
        "pop_results": "Rucaparibç¶­æŒæ”¹å–„PFSï¼ˆæ„å‘æ²»ç™‚å…¨é«”ï¼šHR 0.36ï¼›BRCAçªè®Šï¼šHR 0.23ï¼‰ï¼Œæ”¯æŒä»¥åˆ†å±¤æ—ç¾¤æ–¹å¼ä½¿ç”¨PARPiï¼Œç²¾ç¢ºåˆ†æµç¶­æŒç²ç›Šï¼šBRCAm PFS HR 0.23ï¼›HRD+ HR 0.32ã€‚",
        "rationale": "åˆ©ç”¨ LOHï¼ˆé›œåˆæ€§ä¸Ÿå¤±ï¼‰æª¢æ¸¬è¼”åŠ©åˆ¤å®š HRD ç‹€æ…‹ï¼Œå°èˆª PARPi åœ¨å¾©ç™¼éšæ®µçš„ä½¿ç”¨ã€‚",
        "regimen": "Arm Aï¼šrucaparib maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å° platinum æœ‰åæ‡‰ã€‚", "åˆ†å±¤ BRCA-mut / HRD / ITTã€‚"],
        "exclusion": ["é‡å¤§å…±ç—…ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "BRCAm mPFS 16.6m vs 5.4m (HR 0.23)ï¼›HRD HR ~0.32ï¼›ITT HR ~0.36ã€‚AEï¼šè²§è¡€ã€è‚é…µç´ ä¸Šå‡ç­‰ã€‚"},
    
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["PARPi Maint"], 
        "name": "ğŸ“š SOLO2", "pharma": "AZ", "drug": "Olaparib", 
        "pop_results": "Olaparibç¶­æŒå¯å»¶é•·PFSï¼ˆHR 0.30ï¼‰ï¼Œä½†æœ€çµ‚OSå„ªå‹¢ä¸æ˜é¡¯ï¼ˆOS HR 0.74ã€æœªé”é¡¯è‘—ï¼‰ï¼Œæ˜¯è§£è®€ã€Œäº¤å‰æ²»ç™‚/å¾Œç·šPARPiä½¿ç”¨ã€å½±éŸ¿OSçš„ä»£è¡¨æ¡ˆä¾‹ï¼Œå¾©ç™¼ç¶­æŒç”Ÿå­˜çªç ´ï¼šBRCAm æ—ç¾¤ mOS é¡¯è‘—å»¶é•·è‡³ 51.7m (HR 0.74)ã€‚",
        "rationale": "ç¢ºèª Olaparib åœ¨å¾©ç™¼ç¶­æŒéšæ®µèƒ½å°‡ PFS ç²ç›Šè½‰åŒ–ç‚ºæœ€çµ‚ OS ç²ç›Šã€‚",
        "regimen": "Arm Aï¼šolaparib tablets maintenanceã€‚Arm Bï¼šplacebo maintenanceï¼ˆå°ç…§ï¼‰ã€‚",
        "inclusion": ["platinum-sensitive recurrent ovarian cancerã€‚", "å° platinum æœ‰åæ‡‰ã€‚", "BRCA1/2 mutationã€‚"],
        "exclusion": ["é‡å¤§å…±ç—…ã€‚", "å…ˆå‰æ¥å—é PARP æŠ‘åˆ¶åŠ‘ã€‚", "æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©ã€‚"],
        "outcomes": "mOS: 51.7m vs 38.8m (HR 0.74)ã€‚PFS é¡¯è‘—æ”¹å–„ï¼ŒHR ç´„ 0.30ï¼Œæœ€çµ‚ OS åˆ†æé¡¯ç¤º median OS +12.9 monthsã€‚AEï¼šè²§è¡€ã€å™å¿ƒã€ç–²å€¦ã€‚ "},

    # ==========================
    # === Uterine Sarcoma Published ===
    # ==========================

    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“š GOG-0277", "pharma": "GOG / NCI", "drug": "Gem/Doce vs Observation", 
        "pop_results": "é«˜æƒ¡æ€§åº¦ LMS è¼”åŠ©æ²»ç™‚ï¼šGemcitabine + Docetaxel è¼”åŠ©åŒ–ç™‚ç›¸è¼ƒæ–¼è§€å¯Ÿçµ„ï¼Œé›–æœ‰ PFS ç²ç›Šè¶¨å‹¢ä½†æœªé”é¡¯è‘—å·®ç•°ã€‚",
        "rationale": "é‡å°å®Œå…¨åˆ‡é™¤çš„é«˜æƒ¡æ€§åº¦å­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (uLMS)ï¼Œæ¢è¨è¼”åŠ©åŒ–ç™‚æ˜¯å¦èƒ½é™ä½æ¥µé«˜çš„å¾©ç™¼ç‡ã€‚",
        "regimen": "Gemcitabine (900mg/m2 D1, D8) + Docetaxel (75mg/m2 D8) æ¯ 21 å¤©ä¸€é€±æœŸï¼Œå…± 4 é€±æœŸã€‚",
        "inclusion": ["å®Œå…¨åˆ‡é™¤ä¹‹ Stage I å­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (uLMS)", "ECOG 0-1"],
        "outcomes": "ç”±æ–¼æ”¶æ¡ˆå›°é›£æå‰çµ‚æ­¢ï¼Œæœªé”é¡¯è‘—çµ±è¨ˆå­¸å·®ç•°ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“š EORTC 55874", "pharma": "EORTC", "drug": "Adjuvant Radiotherapy", 
        "pop_results": "è¡“å¾Œæ”¾ç™‚åƒ¹å€¼ï¼šå°æ–¼æ—©æœŸå­å®®è‚‰ç˜¤ï¼Œè¼”åŠ©æ€§éª¨ç›†æ”¾ç™‚èƒ½é™ä½å±€éƒ¨å¾©ç™¼ç‡ï¼Œä½†ç„¡æ³•æ”¹å–„ PFS èˆ‡ OSã€‚",
        "rationale": "æ¢è¨ Stage I/II å­å®®è‚‰ç˜¤æ‚£è€…è¡“å¾Œæ¥å—éª¨ç›†é«”å¤–æ”¾å°„æ²»ç™‚ (EBRT) çš„è‡¨åºŠç²ç›Šã€‚",
        "regimen": "éª¨ç›†è…”é«”å¤–æ”¾å°„æ²»ç™‚ (EBRT)ï¼Œç¸½åŠ‘é‡ 50.4 Gy åˆ† 28 æ¬¡ç…§å°„ã€‚",
        "inclusion": ["Stage I/II å­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (LMS) æˆ–å­å®®è‚‰ç˜¤ (uS)", "æ‰‹è¡“å®Œå…¨åˆ‡é™¤å¾Œ"],
        "outcomes": "å±€éƒ¨å¾©ç™¼ç‡é™ä½ï¼›OS HR 0.94 (P=0.69) ç„¡é¡¯è‘—å·®ç•°ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“š EORTC 62012", "pharma": "EORTC", "drug": "Doxorubicin + Ifosfamide", 
        "pop_results": "æ™šæœŸä¸€ç·šçµ„åˆï¼šè¯ç”¨æ–¹æ¡ˆé¡¯è‘—æå‡ ORR (26%) èˆ‡ PFSï¼Œä½†åœ¨ç¸½ç”Ÿå­˜æœŸ (OS) ä¸Šèˆ‡å–®è—¥ Dox ç›¸æ¯”ç„¡é¡¯è‘—å·®ç•°ã€‚",
        "rationale": "é‡å°ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§è‚‰ç˜¤ï¼Œæ¯”è¼ƒã€åŠ å¼·å‹è¯ç”¨åŒ–ç™‚ã€èˆ‡ã€å–®è—¥åŒ–ç™‚ã€çš„ç™‚æ•ˆæ¬Šè¡¡ã€‚",
        "regimen": "Doxorubicin (75mg/m2) è¯ç”¨ Ifosfamide (5g/m2 + Mesna) Q3Wã€‚",
        "inclusion": ["æ™šæœŸ/è½‰ç§»æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤ (å«å­å®®è‚‰ç˜¤)", "å…ˆå‰æœªæ¥å—éç³»çµ±åŒ–ç™‚"],
        "outcomes": "mPFS: 7.4m vs 4.6m (HR 0.74); ORR: 26% vs 14%ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“š GeDDiS (Phase III)", "pharma": "CRUK", "drug": "Gem/Doce vs Doxorubicin", 
        "pop_results": "ä¸€ç·šæ¨™æº–å°ç…§ï¼šGem/Doce èˆ‡ Doxorubicin ä½œç‚ºä¸€ç·šæ²»ç™‚ï¼Œåœ¨ PFS ä¸Šç„¡é¡¯è‘—å·®ç•°ï¼ŒDox å…·å‚™æ›´ä½³çš„ç”¨è—¥ä¾¿åˆ©æ€§ã€‚",
        "rationale": "æ—¨åœ¨ç¢ºå®š Gem/Doce æ˜¯å¦èƒ½å–ä»£ Doxorubicin æˆç‚ºæ™šæœŸè‚‰ç˜¤çš„ä¸€ç·šé¦–é¸æ¨™æº–ã€‚",
        "regimen": "Gemcitabine (675mg/m2 D1, D8) + Docetaxel (75mg/m2 D8) vs Doxorubicin (75mg/m2 D1) Q3Wã€‚",
        "inclusion": ["ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤", "ECOG 0-1"],
        "outcomes": "mPFS: 23.3 é€± (Gem/Doce) vs 23.3 é€± (Dox)ï¼ŒHR 1.14 (P=0.06)ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“š LMS-04 (Phase III)", "pharma": "French Sarcoma Group", "drug": "Doxorubicin + Trabectedin", 
        "pop_results": "LMS ä¸€ç·šæ–°é«˜åº¦ï¼šè¯ç”¨ Trabectedin é¡¯è‘—å»¶é•·å­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ä¸­ä½ PFS é”å…©å€ (12.2m vs 6.2m)ã€‚",
        "rationale": "å°ˆå°å¹³æ»‘è‚Œè‚‰ç˜¤ (LMS)ï¼Œåˆ©ç”¨ Doxorubicin è¯ç”¨ Trabectedin æŒ‘æˆ°å‚³çµ±å–®è—¥æ²»ç™‚ç“¶é ¸ã€‚",
        "regimen": "Doxorubicin (60mg/m2) + Trabectedin (1.1mg/m2) Q3Wï¼Œæ¥çºŒ Trabectedin å–®è—¥ç¶­æŒã€‚",
        "inclusion": ["æ™šæœŸ/è½‰ç§»æ€§å­å®®æˆ–éå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (LMS)", "ä¸€ç·šæ²»ç™‚"],
        "outcomes": "mPFS: 12.2m vs 6.2m (HR 0.37); mOS: 31.6m vs 24.1mã€‚"},

    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX", "R-TX"], 
        "sub_pos": ["Carcinosarcoma"], 
        "name": "ğŸ“š NRG/GOG-0261 (Phase III)", "pharma": "NRG Oncology", "drug": "Pacli/Carbo vs Pacli/Ifo", 
        "pop_results": "å­å®®ç™Œè‚‰ç˜¤ (UCS) çš„æ–°æ¨™æº–ï¼šPaclitaxel + Carboplatin åœ¨ PFS ä¸Šä¸åŠ£æ–¼ä¸”ç•¥å„ªæ–¼ Pacli/Ifoï¼Œä¸”æ¯’æ€§é¡¯è‘—é™ä½ã€‚",
        "rationale": "æ—¨åœ¨ç¢ºå®š Pacli/Carbo (PC) æ˜¯å¦èƒ½å–ä»£æ¯’æ€§è¼ƒå¤§çš„ Ifosfamide åŸºç¤æ–¹æ¡ˆï¼Œæˆç‚ºç™Œè‚‰ç˜¤ä¸€ç·šæ²»ç™‚çš„æ–°æ¨™ç«¿ã€‚",
        "regimen": "Arm A: Paclitaxel 175mg/m2 + Carboplatin (AUC 6) Q3W; Arm B: Paclitaxel 135mg/m2 + Ifosfamide 1.6g/m2 (D1-3) Q3Wã€‚",
        "inclusion": ["æ–°è¨ºæ–· Stage III-IV æˆ–å¾©ç™¼æ€§å­å®®/åµå·¢ç™Œè‚‰ç˜¤ (Carcinosarcoma)", "ECOG 0-2"],
        "outcomes": "PFS: 14.6m (PC) vs 10.3m (PI); OS: 37m vs 29m (éåŠ£æ•ˆæ€§é”æˆä¸”å…·çµ±è¨ˆè¶¨å‹¢å„ªå‹¢)ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Carcinosarcoma"], 
        "name": "ğŸ“š GOG-161 (Phase III)", "pharma": "GOG / NCI", "drug": "Ifosfamide + Paclitaxel", 
        "pop_results": "é›™è—¥è¯ç”¨ç²ç›Šï¼šåœ¨ç™Œè‚‰ç˜¤æ²»ç™‚ä¸­ï¼ŒIfosfamide è¯ç”¨ Paclitaxel æ¯”å–®ç”¨ Ifosfamide é¡¯è‘—å»¶é•· PFS (5.8m vs 3.6m) èˆ‡ OSã€‚",
        "rationale": "æ—©æœŸè©¦é©—ï¼Œé©—è­‰åœ¨ Ifosfamide åŸºç¤ä¸ŠåŠ å…¥ç´«æ‰é†‡é¡è—¥ç‰©æ˜¯å¦èƒ½å…‹æœ UCS çš„åŒ–ç™‚æŠ—è—¥æ€§ã€‚",
        "regimen": "è©¦é©—çµ„: Ifosfamide 1.6 g/m2 (D1-3) + Paclitaxel 135 mg/m2 (D1) Q3W; å°ç…§çµ„: Ifosfamide å–®è—¥ 2.0 g/m2 (D1-3)ã€‚",
        "inclusion": ["ä¸å¯åˆ‡é™¤ã€æŒä¹…æ€§æˆ–å¾©ç™¼æ€§å­å®®ç™Œè‚‰ç˜¤", "å…ˆå‰æœªæ¥å—éé‡å°æ™šæœŸç–¾ç—…ä¹‹åŒ–ç™‚"],
        "outcomes": "mPFS: 5.8m vs 3.6m (HR 0.71); mOS: 13.5m vs 8.4mã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Carcinosarcoma"], 
        "name": "ğŸ“š GOG-108 (Phase III)", "pharma": "GOG", "drug": "Ifosfamide vs Cisplatin", 
        "pop_results": "æ—©æœŸå–®è—¥å°æ¯”ï¼šé‡å°æ™šæœŸå­å®®è‚‰ç˜¤ï¼ŒIfosfamide å±•ç¾å‡ºè¼ƒé«˜çš„ç·©è§£ç‡èˆ‡è¼ƒä½³çš„ç”Ÿå­˜ç²ç›Šè¶¨å‹¢ã€‚",
        "rationale": "åœ¨ 1990 å¹´ä»£åˆæœŸï¼Œæ—¨åœ¨ç¢ºå®šå“ªç¨®å«é‰‘æˆ–çƒ·åŒ–åŠ‘é¡è—¥ç‰©æœ€é©åˆè™•ç†æƒ¡æ€§ç¨‹åº¦æ¥µé«˜çš„å­å®®ç™Œè‚‰ç˜¤ã€‚",
        "regimen": "Ifosfamide 1.5 g/m2 (D1-5) æ¯ 21 å¤©ä¸€é€±æœŸ; æˆ– Cisplatin 50 mg/m2 æ¯ 21 å¤©ä¸€é€±æœŸã€‚",
        "inclusion": ["æ™šæœŸæˆ–å¾©ç™¼æ€§å­å®®è‚‰ç˜¤ (ä»¥ç™Œè‚‰ç˜¤ç‚ºä¸»)", "ECOG 0-2"],
        "outcomes": "Ifosfamide çµ„ç·©è§£ç‡ (ORR) é¡¯è‘—å„ªæ–¼ Cisplatin çµ„ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Carcinosarcoma"], 
        "name": "ğŸ“š GOG-150 (Phase III)", "pharma": "GOG / NCI", "drug": "Adjuvant AP Chemo vs WAI", 
        "pop_results": "è¡“å¾Œè¼”åŠ©ç­–ç•¥ï¼šæ¯”è¼ƒå…¨è…¹éƒ¨æ”¾å°„æ²»ç™‚ (WAI) èˆ‡åŒ–ç™‚ (AP)ï¼Œé›–ç„¶ OS ç„¡é¡¯è‘—å·®ç•°ï¼Œä½†åŒ–ç™‚å°æ–¼ Stage I-II ç™Œè‚‰ç˜¤çš„ç³»çµ±æ§åˆ¶åŠ›æ›´ä½³ã€‚",
        "rationale": "æ¢è¨ Stage I-II ç™Œè‚‰ç˜¤å®Œå…¨åˆ‡é™¤å¾Œï¼Œå±€éƒ¨æ”¾ç™‚èˆ‡å…¨èº«åŒ–ç™‚å“ªç¨®èƒ½æ›´æœ‰æ•ˆé™ä½é«˜å¾©ç™¼ç‡ã€‚",
        "regimen": "åŒ–ç™‚çµ„: Doxorubicin 60mg/m2 + Cisplatin 50mg/m2 (AP) Q3W x8; æ”¾ç™‚çµ„: WAI 30 Gy åˆ† 20 æ¬¡ç…§å°„ã€‚",
        "inclusion": ["å®Œå…¨åˆ‡é™¤ä¹‹ Stage I æˆ– II å­å®®ç™Œè‚‰ç˜¤", "æ‰‹è¡“æ¢æŸ¥è­‰å¯¦ç„¡è…¹è†œå…§è½‰ç§»"],
        "outcomes": "å…©çµ„é–“ OS ç„¡é¡¯è‘—çµ±è¨ˆå­¸å·®ç•°ï¼Œä½† AP åŒ–ç™‚çµ„ä¹‹å¾©ç™¼é¢¨éšªæ¯”ç‡ (HR) å‘ˆä¸‹é™è¶¨å‹¢ã€‚"},

    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š ET743-SAR-3007", "pharma": "Janssen", "drug": "Trabectedin vs Dacarbazine", 
        "pop_results": "LMS æ•‘æ´äºŒç·šæ¨™æº–ï¼šTrabectedin ç›¸æ¯” Dacarbazine å¯é¡¯è‘—é™ä½ 45% çš„ç–¾ç—…é€²å±•é¢¨éšª (HR 0.55)ã€‚",
        "rationale": "é‡å°å…ˆå‰æ¥å—éå« Anthracycline åŒ–ç™‚å¤±æ•—çš„æ™šæœŸå¹³æ»‘è‚Œè‚‰ç˜¤ (LMS)ï¼Œé©—è­‰ Trabectedin çš„ç™‚æ•ˆã€‚",
        "regimen": "Trabectedin 1.5 mg/m2 (24å°æ™‚æŒçºŒéœè„ˆæ»´æ³¨) Q3Wï¼›å°ç…§çµ„ Dacarbazine 1000 mg/m2 Q3Wã€‚",
        "inclusion": ["ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§å¹³æ»‘è‚Œè‚‰ç˜¤ (LMS) æˆ–è„‚è‚ªè‚‰ç˜¤", "å…ˆå‰æ¥å—éå« Anthracycline æ–¹æ¡ˆæ²»ç™‚"],
        "outcomes": "LMS æ—ç¾¤ mPFS: 4.2m vs 1.5m (HR 0.55, P<0.001)ï¼›ITT OS ç„¡é¡¯è‘—å·®ç•°ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š PALETTE", "pharma": "Novartis / GSK", "drug": "Pazopanib (TKI)", 
        "pop_results": "éè„‚è‚ªè‚‰ç˜¤äºŒç·šæ¨™æº–ï¼šPazopanib é¡¯è‘—å»¶é•·ä¸­ä½ PFS é”ä¸‰å€ (4.6m vs 1.6m, HR 0.31)ã€‚",
        "rationale": "åˆ©ç”¨å¤šé¶é» TKI æŠ‘åˆ¶ VEGFã€PDGFR èˆ‡ c-Kit é€šè·¯ï¼Œé˜»æ–·è‚‰ç˜¤çš„è¡€ç®¡æ–°ç”Ÿèˆ‡ç”Ÿé•·è¨Šè™Ÿã€‚",
        "regimen": "Pazopanib 800 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•æˆ–ä¸å¯è€å—ã€‚",
        "inclusion": ["å…ˆå‰åŒ–ç™‚å¤±æ•—ä¹‹æ™šæœŸéè„‚è‚ªè‚‰ç˜¤æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤ (å«å­å®® LMS)", "ECOG 0-1"],
        "outcomes": "mPFS: 4.6m vs 1.6m (HR 0.31, P<0.0001)ï¼›OS å‘ˆç¾ç²ç›Šè¶¨å‹¢ä½†æœªé”çµ±è¨ˆé¡¯è‘—ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š REGOSARC", "pharma": "Bayer", "drug": "Regorafenib (TKI)", 
        "pop_results": "äºŒç·š TKI æ–°æ•¸æ“šï¼šåœ¨ LMS æ—ç¾¤ä¸­ï¼ŒRegorafenib é¡¯è‘—å»¶é•· PFS (HR 0.46)ï¼Œå…·å‚™è‡¨åºŠæ•‘æ´åƒ¹å€¼ã€‚",
        "rationale": "éš¨æ©Ÿã€é›™ç›²ã€å®‰æ…°åŠ‘å°ç…§ä¹‹ç¬¬ II æœŸè©¦é©—ï¼Œé©—è­‰ Regorafenib åœ¨å„é¡è‚‰ç˜¤åˆ†å‹ä¸­çš„æ´»æ€§ã€‚",
        "regimen": "Regorafenib 160 mg QD (æœç”¨ 3 é€±ä¼‘æ¯ 1 é€±)ï¼Œæ¯ 28 å¤©ç‚ºä¸€é€±æœŸã€‚",
        "inclusion": ["å…ˆå‰æ¥å—éå« Anthracycline æˆ–å¤šç·šæ²»ç™‚å¤±æ•—ä¹‹æ™šæœŸè‚‰ç˜¤", "åŒ…å«å­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (uLMS) éšŠåˆ—"],
        "outcomes": "LMS éšŠåˆ— PFS: 4.4m vs 1.4m (HR 0.46, P=0.0045)ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Recurr / Metastatic"], 
        "name": "ğŸ“š Eribulin vs Dacarbazine", "pharma": "Eisai", "drug": "Eribulin", 
        "pop_results": "LMS/LPS å­˜æ´»ç²ç›Šï¼šé‡å°å¹³æ»‘è‚Œè‚‰ç˜¤èˆ‡è„‚è‚ªè‚‰ç˜¤ï¼ŒEribulin é¡¯è‘—å»¶é•·ä¸­ä½ OS (13.5m vs 11.5m)ã€‚",
        "rationale": "éå¾®ç®¡è›‹ç™½è§£èšé¡è—¥ç‰©ï¼Œæ—¨åœ¨æ¢ç´¢å…¶åœ¨é›£æ²»å‹è‚‰ç˜¤ä¸­å°æ–¼ç¸½é«”ç”Ÿå­˜ç‡ (OS) çš„è²¢ç»ã€‚",
        "regimen": "Eribulin 1.4 mg/m2 (D1, D8) æ¯ 21 å¤©ç‚ºä¸€é€±æœŸã€‚",
        "inclusion": ["å…ˆå‰æ¥å—éè‡³å°‘ 2 ç·šæ²»ç™‚ (é ˆå« Anthracycline) å¤±æ•—ä¹‹æ™šæœŸ LMS æˆ– LPS", "ECOG 0-1"],
        "outcomes": "mOS: 13.5m vs 11.5m (HR 0.77, P=0.016)ï¼›LMS æ—ç¾¤æ•¸æ“šç©©å®šã€‚"},

    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Low grade ESS"], 
        "name": "ğŸ“š PARAGON (ANZGOG 0903)", "pharma": "ANZGOG", "drug": "Anastrozole", 
        "pop_results": "LG-ESS æ¿€ç´ æ²»ç™‚é‡Œç¨‹ç¢‘ï¼šé‡å° ER/PR é™½æ€§æ‚£è€…ï¼Œ3 å€‹æœˆçš„è‡¨åºŠç²ç›Šç‡ (CBR) é«˜é” 73.3%ï¼Œä¸”ä¸­ä½ PFS å°šæœªé”åˆ°ã€‚",
        "rationale": "åˆ©ç”¨èŠ³é¦™ç’°è½‰åŒ–é…¶æŠ‘åˆ¶åŠ‘ (AI) é˜»æ–·é›Œæ¿€ç´ ç”Ÿæˆï¼Œé‡å°å…·é«˜åº¦æ¿€ç´ ä¾è³´æ€§çš„ LG-ESS æä¾›å»åŒ–ç™‚çš„é•·æœŸæ§åˆ¶é¸æ“‡ã€‚",
        "regimen": "Anastrozole 1 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•ã€‚",
        "inclusion": ["å¾©ç™¼æ€§æˆ–è½‰ç§»æ€§ ER/PR(+) å­å®®å…§è†œé–“è³ªè‚‰ç˜¤ (LGESS)", "ECOG 0-2", "éœ€å…·å‚™å¯æ¸¬é‡ç—…ç¶"],
        "outcomes": "CBR at 3m: 73.3%; ORR: 26.7%; 25% æ—ç¾¤ PFS è¶…é 44 å€‹æœˆã€‚"},

        {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Low grade ESS"], 
        "name": "ğŸ“š PARAGON (ANZGOG 0903)", "pharma": "ANZGOG", "drug": "Anastrozole", 
        "pop_results": "LG-ESS æ¿€ç´ æ²»ç™‚é‡Œç¨‹ç¢‘ï¼šé‡å° ER/PR é™½æ€§æ‚£è€…ï¼Œ3 å€‹æœˆçš„è‡¨åºŠç²ç›Šç‡ (CBR) é«˜é” 73.3%ï¼Œä¸”ä¸­ä½ PFS å°šæœªé”åˆ°ã€‚",
        "rationale": "åˆ©ç”¨èŠ³é¦™ç’°è½‰åŒ–é…¶æŠ‘åˆ¶åŠ‘ (AI) é˜»æ–·é›Œæ¿€ç´ ç”Ÿæˆï¼Œé‡å°å…·é«˜åº¦æ¿€ç´ ä¾è³´æ€§çš„ LG-ESS æä¾›å»åŒ–ç™‚çš„é•·æœŸæ§åˆ¶é¸æ“‡ã€‚",
        "regimen": "Anastrozole 1 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒæ²»ç™‚ç›´åˆ°ç–¾ç—…é€²å±•ã€‚",
        "inclusion": ["å¾©ç™¼æ€§æˆ–è½‰ç§»æ€§ ER/PR(+) å­å®®å…§è†œé–“è³ªè‚‰ç˜¤ (LGESS)", "ECOG 0-2", "éœ€å…·å‚™å¯æ¸¬é‡ç—…ç¶"],
        "outcomes": "CBR at 3m: 73.3%; ORR: 26.7%; 25% æ—ç¾¤ PFS è¶…é 44 å€‹æœˆã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Primary Sarcoma", "Recurr / Metastatic"], 
        "name": "ğŸ“š NTRK Basket Trials", "pharma": "Bayer / Roche", "drug": "Larotrectinib / Entrectinib", 
        "pop_results": "è·¨ç™Œåˆ¥ç²¾æº–é†«ç™‚ï¼šé‡å°å¸¶æœ‰ NTRK åŸºå› èåˆçš„è‚‰ç˜¤ï¼ŒLarotrectinib çš„å®¢è§€ç·©è§£ç‡ (ORR) é«˜é” 75%ã€‚",
        "rationale": "NTRK èåˆé›–åœ¨å­å®®è‚‰ç˜¤ä¸­ç½•è¦‹ï¼Œä½†å±¬æ–¼é«˜åº¦è‡´ç™Œé©…å‹•å› å­ï¼Œä½¿ç”¨ TRK æŠ‘åˆ¶åŠ‘å¯é”æˆæ¥µé«˜ä¸”æŒä¹…çš„è‡¨åºŠåæ‡‰ã€‚",
        "regimen": "Larotrectinib 100 mg æ¯æ—¥å…©æ¬¡å£æœï¼›æˆ– Entrectinib 600 mg æ¯æ—¥ä¸€æ¬¡å£æœã€‚",
        "inclusion": ["ç¶“ NGS è­‰å¯¦å…·å‚™ NTRK1/2/3 åŸºå› èåˆä¹‹æ™šæœŸå›ºé«”è…«ç˜¤", "ç„¡ç¾æœ‰æ¨™æº–æ²»ç™‚æˆ–æ²»ç™‚å¤±æ•—"],
        "outcomes": "ITT ORR: ~75%; ä¸­ä½ PFS é¡¯è‘—å„ªæ–¼å‚³çµ±åŒ–ç™‚ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["R-TX"], 
        "sub_pos": ["Primary Sarcoma", "Recurr / Metastatic"], 
        "name": "ğŸ“š Olaparib + Temozolomide (NCT03880019)", "pharma": "NCI / Columbia", "drug": "Olaparib + TMZ", 
        "pop_results": "uLMS äºŒç·šæ–°çµ„åˆï¼šé‡å°ç¶“æ²»çš„æ™šæœŸå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ï¼ŒORR é” 27%ï¼Œä¸­ä½ PFS ç‚º 6.9 å€‹æœˆã€‚",
        "rationale": "åˆ©ç”¨ TMZ èª˜å° DNA æå‚·ï¼Œä½µç”¨ PARP æŠ‘åˆ¶åŠ‘ (Olaparib) é˜»æ–·ä¿®å¾©è·¯å¾‘ï¼Œé‡å° uLMS ç”¢ç”Ÿåˆæˆè‡´æ­»æ•ˆæ‡‰ã€‚",
        "regimen": "Temozolomide 75mg/m2 QD (D1-7) + Olaparib 300mg bid (D1-21)ï¼Œæ¯ 21 å¤©ç‚ºä¸€é€±æœŸã€‚",
        "inclusion": ["çµ„ç¹”å­¸è­‰å¯¦ä¹‹æ™šæœŸå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (uLMS)", "å…ˆå‰è‡³å°‘æ¥å—éä¸€ç·šç³»çµ±æ²»ç™‚å¾Œé€²å±•"],
        "outcomes": "ORR: 27%; mPFS: 6.9m; è‡¨åºŠç²ç›Šç‡ (CBR): 68%ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX", "R-TX"], 
        "sub_pos": ["Low grade ESS"], 
        "name": "ğŸ“ Letrozole (NCT05649956)", "pharma": "Investigator-Initiated", "drug": "Letrozole", 
        "pop_results": "LG-ESS é•·æœŸç¶­æŒæ–°å¯¦è­‰ï¼šè©•ä¼° Letrozole åœ¨æ—©æœŸè¡“å¾Œè¼”åŠ©æˆ–æ™šæœŸç¶­æŒä¸­çš„é•·æœŸç™‚æ•ˆèˆ‡å®‰å…¨æ€§ã€‚",
        "rationale": "é‡å°é«˜åº¦è¡¨é” ER/PR çš„é–“è³ªè‚‰ç˜¤ï¼ŒLetrozole ä½œç‚ºä¸€ç·šæˆ–äºŒç·šå…§åˆ†æ³Œæ²»ç™‚å·²é¡¯ç¤ºå‡ºæ¥µä½³çš„ç·©è§£ç‡èˆ‡ä½æ¯’æ€§ã€‚",
        "regimen": "Letrozole 2.5 mg æ¯æ—¥å£æœä¸€æ¬¡ï¼Œé•·æœŸæœç”¨ç›´è‡³ç–¾ç—…é€²å±•ã€‚",
        "inclusion": ["æ–°è¨ºæ–·æˆ–å¾©ç™¼æ€§ä½æƒ¡æ€§åº¦å­å®®å…§è†œé–“è³ªè‚‰ç˜¤ (LGESS)", "ER/PR é™½æ€§"],
        "outcomes": "éƒ¨åˆ†å€‹æ¡ˆé¡¯ç¤ºå¯é” 7 å¹´ä»¥ä¸Šä¹‹ç©©å®šç·©è§£ (Stable Disease)ã€‚"},
    
    {"cancer": "Uterine Sarcoma", 
        "pos": ["P-TX"], 
        "sub_pos": ["Primary Sarcoma"], 
        "name": "ğŸ“ NCT07076186 (Adjuvant Doxo + Trab)", "pharma": "Decentralized Pragmatic Trial", "drug": "Doxorubicin + Trabectedin", 
        "pop_results": "æ—©æœŸè¼”åŠ©å¼·åŒ–ç ”ç©¶ï¼šæ¢ç´¢ Stage Ib/2 uLMS è¡“å¾Œä½¿ç”¨ Doxo+Trab æ˜¯å¦èƒ½é¡¯è‘—å»¶é•·ç„¡ç—…ç”Ÿå­˜æœŸã€‚",
        "rationale": "åŸºæ–¼ LMS-04 è©¦é©—åœ¨æ™šæœŸä¸€ç·šçš„æˆåŠŸï¼Œå°‡ Doxo è¯ç”¨ Trabectedin æå‰è‡³è¼”åŠ©æ²»ç™‚éšæ®µä»¥é™ä½é«˜å¾©ç™¼é¢¨éšªã€‚",
        "regimen": "Doxorubicin (60mg/m2) + Trabectedin (1.1mg/m2) æ¯ 21 å¤©ä¸€æ¬¡ï¼Œéš¨å¾Œé€²è¡Œ Trabectedin ç¶­æŒæ²»ç™‚ã€‚",
        "inclusion": ["Stage Ib æˆ– II æœŸå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤ (uLMS)", "æ‰‹è¡“å®Œå…¨åˆ‡é™¤ (R0) å¾Œ 3 å€‹æœˆå…§"],
        "outcomes": "è©¦é©—é€²è¡Œä¸­ (Ongoing)ï¼Œé è¨ˆ 2025 å¹´åº•é–‹å§‹æ­£å¼æ”¶æ¡ˆã€‚"},

    # ==========================
    # === Ongoing Trials (8æ ¸å¿ƒæ¥µé‡åŒ–) ===
    # ==========================
    {"cancer": "Endometrial", "name": "ğŸ“ MK2870-033/TroFuse-033/GOG-3119/ENGOT-en29", "pharma": "MSD", "drug": "Sac-TMT + Pembrolizumab", "pos": "P-MT", "sub_pos": ["Maintenance Therapy"], "type": "Ongoing",
     "pop_results": "ç”¨ TROP2-ADCå¢åŠ è…«ç˜¤ç´°èƒæ®ºå‚·ä¸¦èˆ‡ PD-1 æŠ‘åˆ¶ä½µç”¨ï¼Œç›®æ¨™æ˜¯è£œè¶³ã€ŒpMMR å­å®®å…§è†œç™Œå°å…ç–«å–®è—¥åæ‡‰è¼ƒå·®ã€éœ€è¦æ›´å¼·çš„ä¸€ç·š/ç¶­æŒç­–ç•¥ã€çš„ç¼ºå£ã€‚",
     "rationale": "æ¨™é¶ Trop-2 ADC (Sac-TMT) å”åŒ PD-1ã€‚é€é ADC èª˜å°ä¹‹ ICD æ”¹å–„å¾®ç’°å¢ƒï¼Œæ—¨åœ¨æå‡ pMMR æˆ– NSMP æ‚£è€…ä¸€ç·šç¶­æŒéšæ®µæ‡‰ç­”æ·±åº¦èˆ‡æŒçºŒæ™‚é–“ã€‚",
     "regimen": "Arm A (åˆ†çµ„ 1): Sac-TMT 5mg/kg Q6W + Pembrolizumab 400mg Q6W ç¶­æŒæ²»ç™‚ç›´åˆ° PDã€‚ Arm B (åˆ†çµ„ 2): é†«å¸«é¸æ“‡ç¶­æŒæ–¹æ¡ˆ (å°ç…§çµ„)ã€‚",
     "inclusion": ["æ–°è¨ºæ–· pMMR/MSS å­å®®å…§è†œç™Œ (ä¸­å¿ƒ IHC æª¢æ¸¬ç¢ºèª)ã€‚", "FIGO III-IV æœŸã€ä¸€ç·šå«é‰‘åŒ–ç™‚ + Pembrolizumab å¾Œé” CR/PRã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—éé‡å°å¾©ç™¼ç—…ç¶ä¹‹ç³»çµ± IO æ²»ç™‚ã€‚", "çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤ (Sarcoma)ã€‚"],
     "outcomes": "é€²è¡Œä¸­ (Ongoing)ï¼›æ—©æœŸæ•¸æ“šé¡¯ç¤º sac-TMT æ–¼ç¶“æ²» EC æ‚£è€…ä¹‹ ORR é” 34.1%ã€mPFS ç‚º 5.7 å€‹æœˆã€‚"},

    {"cancer": "Endometrial", 
        "pos": ["R-TX"], 
        "sub_pos": ["Recurrent EC"], "type": "Ongoing",
        "name": "ğŸ“ BLUESTAR (NCT05123482)", "pharma": "AstraZeneca", "drug": "Puxitatug samrotecan (AZD8205)", 
        "pop_results": "B7-H4 ADC çªç ´è¨Šè™Ÿï¼šåœ¨æ™šæœŸ/è½‰ç§»æ€§å­å®®å…§è†œç™Œæ“´å±•éšŠåˆ—ä¸­ï¼ŒORR é” 34.6-38.5%ï¼Œä¸­ä½ PFS é” 7.0 å€‹æœˆã€‚",
        "rationale": "åˆ©ç”¨ B7-H4 (æ–¼å©¦ç™Œé«˜åº¦è¡¨ç¾ä¹‹å…ç–«èª¿æ§åˆ†å­) ä½œç‚ºå°å¼•ï¼Œæ­è¼‰ DAR 8 çš„ TOP1i è¼‰è·ï¼Œé€éæ—è§€è€…æ•ˆæ‡‰å…‹æœè…«ç˜¤ç•°è³ªæ€§ã€‚",
        "regimen": "AZD8205 1.6 - 2.4 mg/kg IV Q3Wï¼›å–®è—¥æˆ–è¯ç”¨ Rilvegostomig (PD-1/TIGIT) æˆ– Saruparib (PARPi)ã€‚",
        "inclusion": ["æ™šæœŸ/è½‰ç§»æ€§å­å®®å…§è†œç™Œ (æˆ– HR+/HER2- ä¹³ç™Œ)ï¼Œå…ˆå‰æ¨™æº–æ²»ç™‚é€²å±•è€…",
            "B7-H4 IHC é™½æ€§ (å®šç¾©ç‚º >25% è…«ç˜¤ç´°èƒè¡¨ç¾)",
            "ECOG 0-1"],
        "exclusion": ["å…ˆå‰æ¥å—é TOP1 æŠ‘åˆ¶åŠ‘ (å¦‚å…¶ä»– TOP1i-ADC) æ²»ç™‚è€…",
            "å…·æœ‰ ILD/è‚ºç‚ç—…å²éœ€é¡å›ºé†‡æ²»ç™‚è€…"],
        "outcomes": "EC æ“´å±•éšŠåˆ— ORR: 34.6% (2.0mg/kg) / 38.5% (2.4mg/kg); mPFS: 7.0mï¼›å¸¸è¦‹ â‰¥G3 AE ç‚ºè²§è¡€èˆ‡å—œä¸­æ€§çƒä½ä¸‹ã€‚"},

    {"cancer": "Ovarian", "name": "ğŸ“ FRAmework-01 (LY4170156)", "pharma": "Eli Lilly", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PROC (Resistant Recur)", "PSOC (Sensitive Recur)"], "type": "Ongoing",
     "pop_results": "ä»¥ FRÎ± æ¨™çš„ ADCï¼ˆæŠŠç´°èƒæ¯’è¼‰è·ç²¾æº–é€å…¥è…«ç˜¤ï¼‰æ”»å…‹é‰‘æŠ—è—¥åµå·¢ç™Œï¼Œä¸¦å˜—è©¦æ“´å¤§åˆ°æ›´å¤š FRÎ± è¡¨ç¾ç¯„åœ/æˆ–æ­é… bevï¼Œç›®çš„åœ¨å½Œè£œã€Œé‰‘æŠ—è—¥æœŸæœ‰æ•ˆä¸”å¯è€å—çš„ç³»çµ±æ²»ç™‚ä»ä¸è¶³ã€FRÎ±-ADC å—æƒ æ—ç¾¤ä»æœ‰é™ã€çš„ç¼ºå£ã€‚",
     "rationale": "æ¨™é¶ FRÎ± ADC è¯ç”¨ anti-VEGFã€‚åˆ©ç”¨ Bevacizumab è¡€ç®¡èª¿ç¯€ä½œç”¨é™ä½è…«ç˜¤é–“è³ªå£“ï¼Œæå‡ ADC æ–¼å¯¦é«”è…«ç˜¤å…§çš„æ»²é€æ·±åº¦æŒ‘æˆ°è€è—¥ç“¶é ¸ã€‚",
     "regimen": "PROC éšŠåˆ—åˆ†çµ„ï¼š Arm A: LY 3.0mg/kg + Bev 15mg/kg Q3W; Arm B: LY 4.0mg/kg + Bev 15mg/kg Q3Wã€‚ PSOC éšŠåˆ— (PFI 6-12m): Arm C: LY 3.0mg/kg + Bev 15mg/kg Q3Wã€‚ å°ç…§çµ„ (Arm D): é†«å¸«é¸æ“‡åŒ–ç™‚ SoCã€‚",
     "inclusion": ["ç¶“æª¢æ¸¬ç¢ºèª FRÎ± è¡¨é”é™½æ€§ (IHC)ã€‚", "æœ€å¾Œé‰‘é¡å¾Œé€²å±•ä¹‹ PROC æˆ– PSOC (PFI 90d-365d)ã€‚"],
     "exclusion": ["æ›¾ç”¨éé‡å° FRÎ± ä¹‹ ADC (å¦‚ Enhertu æ›¾è©¦éè€…éœ€è©•ä¼°)ã€‚", "æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—… (ILD)ã€‚"]},

    {"cancer": "Endometrial", "name": "ğŸ“ ASCENT-GYN-01/GS-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "type": "Ongoing",
     "pop_results": "é‡å°ã€Œé‰‘é¡åŒ–ç™‚+PD-(L)1 å¾Œä»é€²å±•ã€é å¾Œå·®ä¸”å¾Œç·šç¼ºä¹æœ‰æ•ˆæ–¹æ¡ˆã€çš„æ—ç¾¤ï¼Œè©•ä¼° **TROP2-ADCï¼ˆsacituzumab govitecanï¼Œè¼‰è· SN-38ï¼‰**èƒ½å¦åœ¨ PFS/OS è¶…è¶Šå‚³çµ±å–®è—¥åŒ–ç™‚ï¼Œå¡«è£œå¾Œç·šæ²»ç™‚ç©ºçª—ã€‚",
     "rationale": "é‡å° Trop-2 æ¨™é¶ã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼å¼·åŠ› DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ (ICI) å¤±æ•—å¾Œä¹‹å¾©ç™¼æ•‘æ´ã€‚",
     "regimen": "Sacituzumab govitecan 10mg/kg (Day 1, Day 8) æ¯ 21 å¤©ç‚ºä¸€é€±æœŸ (Q21D) ç›´è‡³ç–¾ç—…é€²å±•ã€‚",
     "inclusion": ["å¾©ç™¼æ€§ EC (ä¸å«è‚‰ç˜¤)ã€‚", "å…ˆå‰æ›¾æ¥å—éè‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚åŠ PD-1/L1 å¤±æ•—é€²å±•è€…ã€‚", "ECOG 0-1ã€‚"],
     "exclusion": ["å…ˆå‰æ¥å—é TROP2 ADC æ²»ç™‚è€…",
            "æ´»å‹•æ€§è…¦è½‰ç§»æˆ–åš´é‡é–“è³ªæ€§è‚ºç—… (ILD) å²"],
     "outcomes": "é€²è¡Œä¸­ (Ongoing)ï¼›åƒè€ƒ TROPiCS-03 ç ”ç©¶ï¼ŒSG åœ¨ EC éšŠåˆ—å±•ç¾å‡ºå¯è§€çš„æŠ—è…«ç˜¤æ´»æ€§èˆ‡å¯ç®¡ç†çš„å®‰å…¨æ€§ã€‚"},
    
    {"cancer": "Cervical", 
        "pos": ["P-MT"], 
        "sub_pos": ["Maintenance"], "type": "Ongoing",
        "name": "ğŸ“ eVOLVE-Cervical (NCT06079671)", "pharma": "AstraZeneca", "drug": "Volrustomig (PD-1/CTLA-4)", 
        "pop_results": "LACC è¼”åŠ©å¼·åŒ–æ¢ç´¢ï¼šé‡å°å±€éƒ¨æ™šæœŸé«˜é¢¨éšªæ‚£è€…ï¼Œæ–¼ CCRT å®Œçµä¸”æœªé€²å±•å¾Œï¼Œè©•ä¼°é›™ç‰¹ç•°æ€§æŠ—é«”ç¶­æŒæ²»ç™‚ä¹‹åƒ¹å€¼ã€‚",
        "rationale": "åˆ©ç”¨ PD-1/CTLA-4 é›™é‡é˜»æ–· (Volrustomig) ä½œç‚ºåºåˆ—å…ç–«æ²»ç™‚ï¼Œæ—¨åœ¨æ–¼åŒ–æ”¾ç™‚å¾Œä¹‹å…ç–«åŸæ€§ç©ºçª—æœŸé€²ä¸€æ­¥é™ä½å¾©ç™¼é¢¨éšªã€‚",
        "regimen": "Arm A: Volrustomig (IV) ç¶­æŒæ²»ç™‚; Arm B: Placebo (IV) ç¶­æŒæ²»ç™‚ã€‚(å°è±¡ç‚º CCRT å¾Œé” CR/PR/SD ä¹‹æ‚£è€…)ã€‚",
        "inclusion": ["FIGO 2018 IIIAâ€“IVA é«˜é¢¨éšªå±€éƒ¨æ™šæœŸå­å®®é ¸ç™Œ (é±—/è…º/è…ºé±—ç™Œ)",
            "å®Œæˆ Platinum-based CCRT å¾Œæœªé€²å±•è€…",
            "éœ€æä¾›æ¨£æœ¬è©•ä¼° PD-L1 ç‹€æ…‹"],
        "exclusion": ["CCRT æ²»ç™‚æœŸé–“å·²ç™¼ç”Ÿç–¾ç—…é€²å±•",
            "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…æˆ–ä¸å¯æ§åˆ¶ä¹‹æ„ŸæŸ“"],
        "outcomes": "é€²è¡Œä¸­ (Ongoing)ï¼›ä¸»è¦çµ‚é»ç‚º PFS èˆ‡ OSï¼Œéœ€åš´æ ¼ç›£æ¸¬ PD-1/CTLA-4 é›™é˜»æ–·ä¹‹ irAEs ç™¼ç”Ÿç‡ã€‚"},

    {"cancer": "Ovarian", "name": "ğŸ“ DOVE", "pharma": "GSK", "drug": "Dostarlimab + Bevacizumab", "pos": "R-TX", "sub_pos": ["Clear Cell Carcinoma"], "type": "Ongoing",
     "pop_results": "ç”¨ **PD-1 æŠ‘åˆ¶ï¼ˆdostarlimabï¼‰**å–®ç”¨æˆ–åˆä½µ æŠ—è¡€ç®¡æ–°ç”Ÿï¼ˆbevacizumabï¼‰ï¼Œæƒ³æŠŠã€Œå°åŒ–ç™‚ç‰¹åˆ¥ä¸æ•æ„Ÿã€å¾©ç™¼å¾Œé¸æ“‡å¾ˆå°‘ã€çš„é€æ˜ç´°èƒç™Œï¼Œå¾å‚³çµ±åŒ–ç™‚å°å‘è½‰æˆå…ç–«/å…ç–«åˆä½µæŠ—è¡€ç®¡æ–°ç”Ÿçš„æ–°ç­–ç•¥ã€‚",
     "rationale": "é‡å° OCCC é€æ˜ç´°èƒç™Œã€‚åˆ©ç”¨ PD-1 + anti-VEGF é›™é‡é˜»æ–·æ”¹å–„å…¶ç‰¹æœ‰ä¸”é«˜åº¦å…ç–«æŠ‘åˆ¶ä¹‹å¾®ç’°å¢ƒã€‚",
     "regimen": "Dostarlimab 1000mg Q6W + Bevacizumab 15mg/kg Q3W ç›´è‡³é€²å±•ã€‚"},

{"cancer": "Ovarian", 
        "pos": ["P-MT"], 
        "sub_pos": ["BRCA mutation", "HRD positive (wt)"], "type": "Ongoing",
        "name": "ğŸ“ TroFuse-021 (GOG-3102 / ENGOT-ov85)", "pharma": "MSD (Merck)", "drug": "sac-TMT (MK-2870) Â± Bev", 
        "pop_results": "HRD- æ—ç¾¤ç¶­æŒæ–°è§£ï¼šé‡å° PARPi ç²ç›Šæœ‰é™çš„ HRD é™°æ€§æ—ç¾¤ï¼Œæ¢ç´¢ ADC ç¶­æŒæ²»ç™‚èƒ½å¦å„ªæ–¼æ¨™æº–è§€å¯Ÿæˆ–æ¨™é¶ç¶­æŒã€‚",
        "rationale": "HRD é™°æ€§è…«ç˜¤å° PARPi åæ‡‰å·®ï¼ŒTROP2 ADC æä¾›èˆ‡ä¿®å¾©è·¯å¾‘ç„¡é—œçš„æ®ºå‚·æ©Ÿåˆ¶ï¼Œä¸¦å¯èƒ½èˆ‡ Bevacizumab å…·å‚™å”åŒæŠ—è¡€ç®¡æ•ˆæ‡‰ã€‚",
        "regimen": "Arm A: sac-TMT ç¶­æŒ; Arm B: sac-TMT + Bevacizumab ç¶­æŒ; Arm C: SoC ç¶­æŒ (Bev æˆ– è§€å¯Ÿ)ã€‚",
        "inclusion": ["æ–°è¨ºæ–·æ™šæœŸä¸Šçš®æ€§åµå·¢ç™Œ/è¼¸åµç®¡ç™Œï¼Œå®Œæˆä¸€ç·šå«é‰‘æ²»ç™‚å¾Œæœªé€²å±•è€…",
            "ç¶“æª¢æ¸¬è­‰å¯¦ç‚º HRD-negative",
            "ECOG 0-1"],
        "exclusion": ["å…ˆå‰æ¥å—é TROP2 ADC æˆ–å…¶ä»– Topo-I ADC æ²»ç™‚è€…",
            "ç„¡æ³•è€å—ç¶­æŒæœŸç”¨è—¥å®‰å…¨æ€§è¦æ±‚"],
        "outcomes": "é€²è¡Œä¸­ (Ongoing)ï¼›æ—¨åœ¨å¡«è£œ HRD é™°æ€§æ—ç¾¤åœ¨ä¸€ç·šç¶­æŒæ²»ç™‚ä¸Šçš„è‡¨åºŠéœ€æ±‚ç©ºç™½ã€‚"},

    {"cancer": "Ovarian", 
        "pos": ["R-MT"], 
        "sub_pos": ["ADC/other Maint"], "type": "Ongoing",
        "name": "ğŸ“ TroFuse-022 (GOG-3103 / ENGOT-ov84)", "pharma": "MSD (Merck)", "drug": "sac-TMT (MK-2870) Â± Bev", 
        "pop_results": "PSOC ç¶­æŒæ²»ç™‚æ–°æ©Ÿåˆ¶ï¼šé‡å°å«é‰‘æ•æ„Ÿå¾©ç™¼ä¸”å®ŒæˆåŒ–ç™‚å¾Œï¼Œæ¢ç´¢ TROP2 ADC ä½œç‚ºéé‰‘é¡æ©Ÿåˆ¶ç¶­æŒæ²»ç™‚çš„æ½›åŠ›ã€‚",
        "rationale": "PSOC åœ¨å«é‰‘æ²»ç™‚å¾Œçš„å¾®å°ç—…ç¶æœŸï¼Œåˆ©ç”¨ä¸åŒæ–¼é‰‘é¡çš„ ADC è¼‰è· (Payload) é”æˆæ›´æ·±å±¤çš„ç´°èƒæ¯’æ®ºï¼Œå»¶ç·©å¾©ç™¼ã€‚",
        "regimen": "Arm A: sac-TMT ç¶­æŒ; Arm B: sac-TMT + Bevacizumab ç¶­æŒ; Arm C: SoC ç¶­æŒ (Bev æˆ– è§€å¯Ÿ)ã€‚",
        "inclusion": ["é‰‘é¡æ•æ„Ÿå¾©ç™¼ (PSOC) ä¹‹åµå·¢/è¼¸åµç®¡/åŸç™¼è…¹è†œç™Œ",
            "å®Œæˆå«é‰‘æ²»ç™‚å¾Œé€²å…¥ç¶­æŒæœŸ",
            "ECOG 0-1"],
        "outcomes": "é€²è¡Œä¸­ (Ongoing)ï¼›æ­¤è©¦é©—æ—¨åœ¨ç¢ºèª sac-TMT æ˜¯å¦èƒ½æä¾›å„ªæ–¼ç¾æœ‰ Bevacizumab æˆ– PARPi ç¶­æŒçš„è‡¨åºŠç²ç›Šã€‚"},

{"cancer": "Ovarian", 
        "pos": ["R-TX"], 
        "sub_pos": ["PROC (Resistant Recur)"], "type": "Ongoing",
        "name": "ğŸ“ REJOICE-Ovarian01 (R-DXd)", "pharma": "Daiichi Sankyo / MSD", "drug": "Raludotatug Deruxtecan (R-DXd)", 
        "pop_results": "PROC æ•‘æ˜Ÿï¼šé‡å°é‰‘é¡æŠ—è—¥å¾©ç™¼ï¼ŒPhase II å¯¦è­‰ ORR é«˜é” 50.5% (DCR 77.6%)ï¼Œæ‰“ç ´ä»¥å¾€å–®è—¥åŒ–ç™‚åƒ… 10-15% çš„ç“¶é ¸ã€‚",
        "rationale": "é‡å°ä¸Šçš®æ€§åµå·¢ç™Œé«˜åº¦è¡¨ç¾çš„ CDH6 æ¨™é¶ï¼Œåˆ©ç”¨ DXd è¼‰è·é”æˆå¼·æ•ˆç´°èƒæ®ºå‚·ï¼Œç‚º PROC æä¾›å…¨æ–°çš„ç²¾æº–æ‰“æ“Šæ–¹æ¡ˆã€‚",
        "regimen": "Phase III åŠ‘é‡: 5.6 mg/kg Q3W (å°æ¯”é†«å¸«é¸æ“‡åŒ–ç™‚ TPC: Pacli, PLD, Gem, Topo)ã€‚",
        "inclusion": ["é‰‘é¡æŠ—è—¥å¾©ç™¼ (PROC) é«˜æƒ¡æ€§åº¦åµå·¢ç™Œ",
            "å…ˆå‰æ¥å—é 1-3 ç·šæ²»ç™‚",
            "é«˜ FRÎ± æ‚£è€…é€šå¸¸éœ€æ›¾ç”¨é Mirvetuximab"],
        "outcomes": "Phase II Confirmed ORR: 50.5%; 5.6mg/kg åŠ‘é‡çµ„ ORR äº¦é” 50.0%ï¼›éœ€è­¦æƒ• ILD/Pneumonitis (ç´„ 3.7%) é¢¨éšªã€‚"},
    
    {"cancer": "Ovarian", "name": "ğŸ“ DESTINY-Ovarian01/DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd", "pos": "P-MT", "sub_pos": ["BRCA mutation", "HRD positive (wt)"], "type": "Ongoing",
     "pop_results": "ç”¨ **HER2-ADCï¼ˆT-DXdï¼‰**åœ¨ä¸€ç·šæ²»ç™‚å¾Œåšç¶­æŒï¼Œä¸¦åˆä½µ bevacizumabï¼Œç„æº–ã€ŒHER2 è¡¨ç¾çš„åµå·¢ç™Œäºç¾¤ç¼ºä¹æ˜ç¢ºçš„æ¨™é¶ç¶­æŒæ¨™æº–ã€ä»æ˜“å¾©ç™¼ã€é€™å€‹ unmet needï¼Œå¸Œæœ›å»¶é•·ç¶­æŒæœŸæ§åˆ¶èˆ‡å­˜æ´»ã€‚",
     "rationale": "æ¨™é¶ HER2 ADC ç”¨æ–¼ç¶­æŒã€‚åˆ©ç”¨ T-DXd æ¥µé«˜ DAR (8) å„ªå‹¢æ¸…é™¤åŒ–ç™‚å¾Œæ®˜é¤˜ä¹‹ HER2 è¡¨ç¾å¾®å°ç—…ç¶ã€‚",
     "regimen": "Trastuzumab deruxtecan 5.4mg/kg IV Q3W ç¶­æŒè‡³é€²å±•ã€‚"},    
]

# --- 3. AI æ¨¡å‹å·¡é‚èˆ‡è¯å‹•åŠŸèƒ½ ---
def get_gemini_model():
    try:
        available_models = [m.name for m in genai.list_models() if 'generateContent' in m.supported_generation_methods]
        target_model = next((m for m in available_models if 'gemini-1.5-flash' in m), None)
        if not target_model: target_model = next((m for m in available_models if 'gemini-pro' in m), None)
        if target_model: return genai.GenerativeModel(target_model)
    except: return None

# --- 4. å´é‚Šæ¬„ï¼šæ±ºç­–åŠ©ç† (è¤‡è£½åŠŸèƒ½èˆ‡æ’ç‰ˆå„ªåŒ–ç‰ˆ) ---
with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å¯¦è­‰åª’åˆåŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    
    with st.expander("âœ¨ æ‚£è€…ç—…æ­·æ•¸æ“šæ·±åº¦åˆ†æ", expanded=True):
        p_notes = st.text_area("è¼¸å…¥æ‘˜è¦ (å«åˆ†æœŸ/ç´°èƒ/æ¨™è¨˜)", placeholder="ä¾‹å¦‚ï¼šEC Stage III, dMMR, p53 mutation...", height=200)
        
        if st.button("ğŸš€ é–‹å§‹åª’åˆåˆ†æ", use_container_width=True):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = get_gemini_model()
                    
                    # --- [å„ªåŒ– Prompt] é™åˆ¶ AI ä¸è¦è¼¸å‡ºéå¤š Markdown ç¬¦è™Ÿ ---
                    prompt = f"""
                    è«‹ä½œç‚ºå°ˆæ¥­å©¦ç™Œå°ˆå®¶åˆ†æä»¥ä¸‹ç—…æ­·ï¼š{p_notes}ã€‚
                    åƒè€ƒå¯¦è­‰åº«ï¼š{all_trials_db}ã€‚
                    
                    ã€è¼¸å‡ºè¦æ±‚ã€‘ï¼š
                    1. è«‹ä½¿ç”¨ã€ç´”æ–‡å­—ã€å°ˆæ¥­é†«ç™‚å ±å‘Šæ ¼å¼ã€‚
                    2. åš´ç¦ä½¿ç”¨éå¤šçš„æ˜Ÿè™Ÿ(**)æˆ–äº•å­—è™Ÿ(###)ã€‚
                    3. ä½¿ç”¨ç°¡å–®çš„æ¨™é¡Œèˆ‡é»åˆ—å¼(â€¢)å³å¯ã€‚
                    4. å…§å®¹éœ€åŒ…å«ï¼šç—…æ­·æ‘˜è¦ã€æ¨è–¦è©¦é©—ã€æ¨è–¦ç†ç”±èˆ‡ Decision Tree æ­¥é©Ÿã€‚
                    """
                    
                    response = model.generate_content(prompt)
                    # å°‡çµæœå­˜å…¥æš«å­˜
                    st.session_state['ai_matching_report'] = response.text
                except Exception as e: 
                    st.error(f"AI ç•°å¸¸: {e}")
            else:
                st.warning("è«‹è¼¸å…¥ Key èˆ‡ç—…æ­·æ‘˜è¦")

        # --- [é‡é»ï¼šç©©å®šè¤‡è£½å€å¡Š] ---
        if 'ai_matching_report' in st.session_state:
            st.markdown("---")
            st.info("ğŸ“‹ **åˆ†æå®Œæˆï¼é»æ“Šä¸‹æ–¹æ–¹æ¡†å³ä¸Šè§’åœ–ç¤ºå³å¯ã€ä¸€éµè¤‡è£½ã€ï¼š**")
            
            # ä½¿ç”¨ st.code é¡¯ç¤ºï¼Œå³ä¸Šè§’æœƒè‡ªå‹•å‡ºç¾ä¸€å€‹å®˜æ–¹çš„è¤‡è£½æŒ‰éˆ•ï¼Œä¿è­‰ 100% æˆåŠŸ
            st.code(st.session_state['ai_matching_report'], language=None)
            
            # æä¾›æ¸…ç©ºæŒ‰éˆ•ï¼Œæ–¹ä¾¿ä¸‹ä¸€æ¬¡åˆ†æ
            if st.button("ğŸ—‘ï¸ æ¸…ç©ºç›®å‰çš„åˆ†æå…§å®¹", use_container_width=True):
                del st.session_state['ai_matching_report']
                st.rerun()

# --- 5. ä¸»é é¢ï¼šå°èˆªåœ°åœ–ä½ˆå±€ ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠå°èˆªå„€è¡¨æ¿ (2026 æ——è‰¦æœ€çµ‚æ¥µé‡æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical", "Uterine Sarcoma"], horizontal=True)

cols = st.columns(len(guidelines_nested[cancer_type]))
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            
            # åˆä½µå¯¦è­‰æ¸²æŸ“æŒ‰éˆ•
            rel_trials = [t for t in all_trials_db if t["cancer"] == cancer_type and stage["id"] in t["pos"] and any(s in sub["title"] for s in t["sub_pos"])]
            
            for t in rel_trials:
                label = f"{t.get('pharma', 'N/A')} | {t['name']} | {t['drug']}"
                with st.popover(label, use_container_width=True):
                    # å±•ç¤ºç°¡å–®ç™‚æ•ˆå°çµè«– (åœ–ä¸‰ä¿®å¾©)
                    st.success(f"**æ ¸å¿ƒçµè«–æ‘˜è¦:** {t.get('pop_results', 'æ‹›å‹Ÿä¸­/è©³è¦‹æ·±åº¦çœ‹æ¿')}")
                    # åŒæ­¥è¯å‹•é‚è¼¯ï¼šé»æ“Šè§¸ç™¼ rerun åŒæ­¥çœ‹æ¿
                    unique_key = f"sync_{t['name']}_{cancer_type}_{stage['id']}_{sub['title'].replace(' ', '')}"
                    if st.button("ğŸ“Š åŒæ­¥çœ‹æ¿ç´°ç¯€", key=unique_key):
                        st.session_state.selected_trial = t['name']
                        st.rerun() 
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 6. æ·±åº¦æ•¸æ“šçœ‹æ¿ (æ¥µé‡åŒ–è³‡è¨Šå±•ç¤ºå€) ---
st.divider()
st.subheader("ğŸ“‹ è‡¨åºŠç ”ç©¶æ¥µé‡åŒ–æ•¸æ“šåº« (Published Milestones & Ongoing Trials)")
filtered_names = [t["name"] for t in all_trials_db if t["cancer"] == cancer_type]

if not filtered_names:
    st.info("è©²ç™Œç—‡é¡åˆ¥ä¸‹ç›®å‰ç„¡é©ç”¨å¯¦è­‰æˆ–è¨ˆç•«ã€‚")
else:
    try: curr_idx = filtered_names.index(st.session_state.selected_trial)
    except: curr_idx = 0

    selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿé¸æ“‡ç ”ç©¶è¨ˆç•«ä»¥æŸ¥é–±åˆ†çµ„èˆ‡æ•¸æ“šï¼š", filtered_names, index=curr_idx, key="trial_selector")
    st.session_state.selected_trial = selected_name
    t_obj = next(it for it in all_trials_db if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t_obj['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1, r2 = st.columns([1.3, 1])
    with r1:
        st.markdown("<div style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Rationale & Regimen (æ©Ÿè½‰èˆ‡åˆ†çµ„çµ¦è—¥)</b></div>", unsafe_allow_html=True)
        st.write(f"**è—¥å» :** {t_obj.get('pharma', 'N/A')} | **æ ¸å¿ƒé…æ–¹:** {t_obj['drug']}")
        
        # æ¥µé‡åŒ–çµ¦è—¥æ–¹æ¡ˆ (Dosing Protocol) - è£œé½Šåˆ†çµ„ç´°ç¯€
        st.markdown("<div class='regimen-box'><b>åˆ†çµ„çµ¦è—¥æ–¹å¼ (Regimen per Arm):</b><br>" + t_obj.get('regimen', 'æ­£åœ¨è£œé½Šåˆ†çµ„çµ¦è—¥ç´°ç¯€ã€‚') + "</div>", unsafe_allow_html=True)
        
        st.success(f"**ç§‘å­¸ç†æ“š (Scientific Rationale):** {t_obj.get('rationale', 'æ—¨åœ¨æŒ‘æˆ° SoC ç“¶é ¸æå‡ç²ç›Šã€‚')}")

    with r2:
        st.markdown("<div style='background:#FFF8E1; border-left:8px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ“ˆ Key Outcomes (æœ€æ–°ç”Ÿå­˜èˆ‡ç·©è§£æŒ‡æ¨™)</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:12px;'>
                <div style='font-size: 14px; color: #795548; font-weight:700; margin-bottom:5px;'>Survival Metrics (PFS/OS/HR/ORR)</div>
                <div class='hr-big-val'>{t_obj.get('outcomes', t_obj.get('results_short', 'Ongoing Recruitment'))}</div>
            </div>
        """, unsafe_allow_html=True)
        

    st.divider()
    r3, r4 = st.columns(2)
    with r3:
        st.markdown("<div style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (é—œéµç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t_obj.get('inclusion', ['ç¬¦åˆåˆ†å­æ¨™è¨˜åˆ†å‹èˆ‡å‰ç·šè¦å®šã€‚']): st.write(f"â€¢ **{inc}**")
    with r4:
        st.markdown("<div style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px;'><b>âŒ Exclusion Criteria (é—œéµæ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t_obj.get('exclusion', ['æ’é™¤è‡Ÿå™¨åŠŸèƒ½ç•°å¸¸æˆ–æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚']): st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
